WO1994029309A1 - Spiro-substituted azacycles as neurokinin antagonists - Google Patents

Spiro-substituted azacycles as neurokinin antagonists Download PDF

Info

Publication number
WO1994029309A1
WO1994029309A1 PCT/US1994/005545 US9405545W WO9429309A1 WO 1994029309 A1 WO1994029309 A1 WO 1994029309A1 US 9405545 W US9405545 W US 9405545W WO 9429309 A1 WO9429309 A1 WO 9429309A1
Authority
WO
WIPO (PCT)
Prior art keywords
spiro
piperidine
dichlorophenyl
methylamino
butyl
Prior art date
Application number
PCT/US1994/005545
Other languages
French (fr)
Inventor
Malcolm Maccoss
Sander G. Mills
Shrenik K. Shah
Yuan-Ching P. Chiang
Patrick T. Dunn
Hiroo Koyama
Paul E. Finke
Hongbo Qi
Albert J. Robichaud
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to JP7501802A priority Critical patent/JPH08511522A/en
Priority to AU72011/94A priority patent/AU680020B2/en
Priority to EP95901979A priority patent/EP0702681A1/en
Publication of WO1994029309A1 publication Critical patent/WO1994029309A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Definitions

  • the invention disclosed herein is directed to certain spiro- substituted azacycles useful as tachykinin receptor antagonists.
  • the compounds disclosed herein are neurokinin receptor antagonists.
  • tachykinins substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), are structurally similar members of a family of neuropeptides. Each of these is an agonist of the receptor types, neurokinin-1 receptor (NK-1), neuorokinin-2 receptor (NK-2) and neuorokinin-3 receptor (NK-3), which are so defined according to their relative abilities to bind tachykinins with high affinity and to be activated by the natural agonists SP, NKA and NKB respectively.
  • SP substance P
  • NKA neurokinin A
  • NKB neurokinin B
  • NK-3 neurokinin-3 receptor
  • the tachykinins are distinguished by a conserved carboxyl- terminal sequence Phe-X-Gly-Leu-Met-NH2. More specifically, substance P is a pharmacologically-active neuropeptide that is produced in mammals and possesses a characteristic amino acid sequence:
  • Neurokinin A possesses the following amino acid sequence:
  • Neurokinin B possesses the following amino acid sequence:
  • the neurokinin receptors are widely distributed throughout the mammalian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are involved in regulating a number of diverse biological processes. This includes sensory perception of olfaction, vision, audition and pain, movement control, gastric motility, vasodilation, salivation, and micturition (B. Pernow, Pharmacol. Rev., 1983, 35, 85- 141).
  • the NK1 and NK2 receptor subtypes are implicated in synaptic transmission (Laneuville et al, Life Sci., 42: 1295-1305 (1988)).
  • Substance P acts as a vasodilator, a depressant, stimulates salivation and produces increased capillary permeability. It is also capable of producing both analgesia and hyperalgesia in animals, depending on dose and pain responsiveness of the animal (see R.C.A. Frederickson et al, Science, 199, 1359 (1978); P. Oehme et al, Science, 208, 305 (1980)) and plays a role in sensory transmission and pain perception (T.M. Jessell, Advan. Biochem. Psychopharmacol. 28, 189 (1981)). In particular, substance P has been shown to be involved in the transmission of pain in migraine (see B.E.B. Sandberg et al, Journal of Medicinal Chemistry, 25, 1009 (1982)), and in arthritis (Levine et al Science, (1984) 226, 547-549).
  • NK1 receptors are associated with microvascular leakage and mucus secretion, while NK2 receptors regulate smooth muscle contraction.
  • substance P and neurokinin A are effective in inducing airway constriction and edema. Based on such findings, it is believed that substance P and neurokinin A may be involved in the pathogenesis of neurogenic inflammation, including allergic diseases such as asthma. (Frossard et al, Life Sci., 49, 1941-1953 (1991); Advenier, et al, Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
  • sensory neuropeptides especially tachykinins such as substance P and neurokinin A
  • tachykinins such as substance P and neurokinin A
  • Neurokinin A is a very potent constrictor of human airways in vitro
  • substance P causes mucus secretion in the airways.
  • bradykinin causes bronchoconstriction in asthmatic patients but not in normal subjects.
  • Inhalation of bradykinin causes bronchoconstriction in asthmatic patients but not in normal subjects.
  • bradykinin-induced bronchoconstriction is partly opposed by anticholinergic agents and since bradykinin is only a weak constrictor of human airways in vitro, it has been suggested that the bronchoconstrictor response is partly mediated by a neural reflex. Bradykinin stimulates vagal afferent C fibers and causes broncho ⁇ constriction in dogs.
  • bradykinin causes a bronchoconstrictor response by way of cholinergic and sensory-nerve-mediated mechanisms.
  • Bradykinin-induced bronchoconstriction in human airways may therefore be due partly to tachykinin released from sensory nerve terminals via axon reflex mechanisms.
  • a dual NK-l/NK-2 antagonist such as FK-224 protects against bradykinin induced bronchocontriction in asthmatic patients. (Ichinoe, M. et al, Lancet, , vol. 340, pp 1248-1251 (1992)).
  • tachykinins have also been implicated in gastro ⁇ intestinal (GI) disorders and diseases of the GI tract, such as inflammatory bowel disease, ulcerative colitis and Crohn's disease, etc. (see Mantyh et al, Neuroscience, 25 (3), 817-37 (1988) and D. Regoli in "Trends in Cluster Headache” Ed. F. Sicuteri et al, Elsevier Scientific Publishers, Amsterdam, 1987, pp. 85-95).
  • GI gastro ⁇ intestinal
  • tachykinin antagonists are believed to be useful are allergic conditions (Hamelet et al, Can. J. Pharmacol. Physiol. (1988) 66, 1361-7), immunoregulation (Lotz et al, Science (1988) 241, 1218-21, Kimball et al, J. Immunol. (1988) 141 (10) 3564-9 and A. Perianin, et al, Biochem. Biophys. Res. Commun.
  • Antagonists selective for the substance P and/or the neurokinin A receptor may be useful in the treatment of asthmatic disease (Frossard et al, Life Sci., 49, 1941-1953 (1991); Advenier, et al, Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
  • This invention is directed to compounds of formula I.
  • the invention is also concerned with pharmaceutical formulations with these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders.
  • the compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine and asthma.
  • This invention is directed to compounds of formula I.
  • Rl is selected from a group consisting of: (1) hydrogen, (2) linear or branched C ⁇ _8 alkyl, linear or branched C2-8 alkenyl, or linear or branched C2-8 alkynyl, wherein the Cl-8 alkyl, C2-8 alkenyl or C2-8 alkynyl is optionally mono, di, tri or tetra substituted, the substitutents independently selected from: (a) hydroxy,
  • halogen which is defined to include Br, CI, I, and F,
  • R6 and R7 are 10 independently selected from:
  • heteroaryl wherein heteroaryl is selected from the group consisting of:
  • heteroaryl wherein heteroaryl is selected from the group consisting of:
  • Rl 2(g) is optionally quatemized with Cl-4alkyl or phenylCl-4alkyl or is optionally present as the N-oxide (N+0-);
  • W is selected from the group consisting of
  • X is selected from the group consisting of (1) a covalent bond
  • said ring being an phenyl, naphthyl or heteroaryl group, with the heteroaryls selected from the group consisting of:
  • heteroaryl wherein heteroaryl is selected from the
  • One subclass of this invention consists of structures tabulated below linked to Rl (as detailed immediately above) via the broken bond, and optionally substituted at the positions indicated by numbers 1-8 with
  • the above compounds may be co-administered with a ⁇ 2-agonist such as Bambuterol, US 4,419,364 issued to Draco on 12/6/83; Bitolterol mesylate, US 4,138,581 issued to Sterling 2/6 79; Carbuterol, US 3,763,232 issued to SmithKline 10/2/73; Clenbuterol, US 3,536,712 issued to Boehringer Ingelheim 10/27/70; Dopexamine, US 4,645,768 issued to Fisons 2/24/87; Formoterol, US 3,994,974 issued to Yamanouchi 11/30/76; Mabuterol, US 4,119,710 issued to Boehringer Ingelheim 10/10/78; Pirbuterol hydrochloride US 3,700,681 issued to Pfizer 10/24 72; Procaterol hydrochloride US 4,026,897 issued to Otsuka 5/31/77; Ritodrine hydrochloride US
  • the compounds of formula I are particularly useful in the treatment of diseases or conditions that are advantageously treated by concomitant antagonism of both NKl and NK2 receptors or NKl, NK2 and NK3 receptors.
  • diseases include neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
  • the compounds of formula I may be co-administered with another NKl or NK2 antagonist such as those described in
  • EP-347802 filed 20-Jun-88, Pub. 27-Dec-89; Appln No. EP-412542, filed 10-Aug-89, Pub. 13-Feb-91; Appln No. WO9005729, filed 23- Nov-88, Pub. 31- May-90; Appln No. WO9005525, filed 23-Nov-88, Pub. 31- May-90; Appln No. EP-436334, filed 04-Jan-90, Pub. 10-Jul- 91; Appln No. W09118878, filed 31- May-90, Pub. 12-Dec-91; Appln No. W09118899, filed Ol-Jun-90, Pub. 12-Dec-91; Appln No.
  • the compounds of formula I are useful in the prevention and treatment of a wide variety of clinical conditions (as detailed in this specification) which are characterized by overstimulation of the tachykinin receptors, in particular NKl, NK2 and NK3.
  • These conditions may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic or peripheral neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy, and neuralgia; respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, bronchospasm and asthma; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis,
  • the compounds of the present invention are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example: neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
  • compounds of Formula I may be administered orally, topically, parenterally, ICV, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracistemal injection or infusion techniques.
  • the compounds of the invention are effective in the treatment of humans.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethyl- cellulose, sodium alginate, polyvinyl- pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbit
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol
  • the pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1 ,3-butane diol.
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of formula I may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • topical use creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
  • an appropriate dosage level will generally be about 0.001 to 50 mg per kg patient body weight per day which can be administered in single or multiple doses.
  • the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day.
  • a suitable dosage level may be about 0.001 to 25 mg/kg per day, about 0.005 to 10 mg/kg per day, or about 0.005 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • the compounds of this invention are useful for antagonizing tachykinins, in particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain or migraine and asthma in a mammal in need of such treatment. This activity can be demonstrated by the following assay.
  • the cDNA for the human NK1R was cloned into the expression vector pCDM9 which was derived from pCDM8 (INVITROGEN) by inserting the ampicillin resistance gene (nucleotide 1973 to 2964 from BLUESCRIPT SK+) into the Sac II site.
  • Transfection of 20 ⁇ g of the plasmid DNA into 10 million COS cells was achieved by electroporation in 800 ⁇ l of transfection buffer (135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 0.6 mM KH2PO4, 10 mM glucose, 10 mM HEPES pH 7.4) at 260 V and 950 uF using the IBI GENEZAPPER (IBI, New Haven, CT).
  • the cells were incubated in 10% fetal calf serum, 2 mM glutamine, lOOU/ml penicillin- streptomycin, and 90% DMEM media (GIBCO, Grand Island, NY) in 5% C02 at 37°C for three days before the binding assay. Similar methods were used to express the NK2 receptor.
  • the cDNA was subcloned into the vector pRcCMV (INVITROGEN).
  • Transfection of 20 ⁇ g of the plasmid DNA into CHO cells was achieved by electroporation in 800 ⁇ l of transfection buffer suplemented with 0.625 mg/ml Herring sperm DNA at 300 V and 950 uF using the IBI GENEZAPPER (IBI).
  • the transfected cells were incubated in CHO media (10% fetal calf serum, 100 U/ml pennicilin- streptomycin, 2 mM glutamine, 1/500 hypoxanthine-thymidine (ATCC), 90% IMDM media (JRH BIOSCIENCES, Lenexa, KS), 0.7 mg/ml G418 (GIBCO)) in 5% C ⁇ 2 at 37°C until colonies were visible. Each colony was separated and propagated. The cell clone with the highest number of human NK1R was selected for subsequent applications such as drug screening. Similar methods were used to express the human NK2 receptor.
  • CHO media 10% fetal calf serum, 100 U/ml pennicilin- streptomycin, 2 mM glutamine, 1/500 hypoxanthine-thymidine (ATCC), 90% IMDM media (JRH BIOSCIENCES, Lenexa, KS), 0.7 mg/ml G418 (GIBCO)
  • the binding assay of human NK1R expressed in either COS or CHO cells is based on the use of - ⁇ I-substance P ( ⁇ - ⁇ I-SP, from DU PONT, Boston, MA) as a radioactively labeled ligand which competes with unlabeled substance P or any other ligand for binding to the human NK1R.
  • - ⁇ I-substance P ⁇ - ⁇ I-SP, from DU PONT, Boston, MA
  • Monolayer cell cultures of COS or CHO were dissociated by the non-enzymatic solution (SPECIALTY MEDIA, Lavallette, NJ) and resuspended in appropriate volume of the binding buffer (50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl, 0.04 mg/ml bacitracin, 0.004 mg/ml leupeptin, 0.02 mg/ml BSA, 0.01 mM phosphoramidon) such that 200 ⁇ l of the cell suspension would give rise to about 10,000 cpm of specific ⁇ I-SP binding (approximately 50,000 to 200,000 cells).
  • the binding buffer 50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl, 0.04 mg/ml bacitracin, 0.004 mg/ml leupeptin, 0.02 mg/ml BSA, 0.01 mM phosphoramidon
  • the activation of phospholipase C by NK1R may also be measured in CHO cells expressing the human NK1R by determining the accumulation of inositol monophosphate which is a degradation product of IP3.
  • CHO cells are seeded in 12- well plate at 250,000 cells per well. After incubating in CHO media for 4 days, cells are loaded with 0.025 uCi/ml of ⁇ H-myoinositol by overnight incubation. The extracellular radioactivity is removed by washing with phosphate buffered saline. LiCl is added to the well at final concentration of 0.1 mM with or without the test compound, and incubation is continued at 37°C for 15 min.
  • Substance P is added to the well at final concentration of 0.3 nM to activate the human NK1R. After 30 min of incubation at 37°C, the media is removed and 0.1 N HCI is added. Each well is sonicated at 4°C and extracted with CHCl3/methanol (1:1). The aqueous phase is applied to a 1 ml Dowex AG 1X8 ion exchange column. The column is washed with 0.1 N formic acid followed by 0.025 M ammonium formate-0.1 N formic acid. The inositol monophosphate is eluted with 0.2 M ammonium formate-0.1 N formic acid and quantitated by beta counter. Similar methods were used to assess antagonism at the NK2 receptor, except NKA was used as the stimulating agonist.
  • the compounds of of Formula I as Exemplified in the EXAMPLES below have been found to displace radioactive ligand for the NK-1 receptor at a concentration range of 0.01 nM to 1.0 ⁇ M, for the NK-2 receptor, 0.01 nM to 5 ⁇ M, and for the NK-3 receptor, 1.0 nM to 10 ⁇ M.
  • the required azacycle starting materials are prepared using methods described in the literature; such as described in Ong, H. H. et al, Journal of Medicinal Chemistry, 1983,26, 981-986, and Nargund, R. et al, USSN 08/147,226 (November 3, 1993), EP 93309867.5 hereby encorporated by reference. None of the compounds in these references are claimed to be neurokinin antagonists.
  • the aldehyde needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention the preparation of a representative aldehyde is described in Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322.
  • the alkyl halide or alkyl sulfonate needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be reduced to an alcohol with sodium borohydride, diisobutylaluminum hydride or lithium aluminum hydride, and the product alcohol converted to either the alkyl halide using methods described in March J.
  • a strong reducing agent e.g. diborane including borane dimethylsulfide; and, lithium aluminum hydride
  • the product amide can in and of itself be a neurokinin antagonist or can be reduced with a strong reducing agent, such as diborane or lithium aluminum hydride, to give the ter
  • compound 1 formed in the alkylation step may be further modified in subsequent reactions.
  • the aldehyde fragment contained a t-butoxycarbonylamino group (Example 2).
  • the t-butoxycarbonyl protecting group is removed by treatment with a strong acid such as trifluoroacetic acid or formic acid and the resulting amine is acylated to furnish the desired compounds (Example 3).
  • the protecting group may also be present in the azacycle portion as illustrated with a benzyloxycarbonyl group in Example 6.
  • the allyl acid 2 (described in Hale et al, see above) can be converted into the N-methyl methoxy amide 3, which is then treated with an alkyl or aryl metal reagent, for example methyllithium or butyllithium, to provide the ketone 4 (Scheme 2).
  • the ketone can be converted into an imine which can then be reduced to secondary amine 5 chemically, (e.g using sodium cyanoborohydride or sodium borohydride), or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst).
  • secondary amine 5 chemically, (e.g using sodium cyanoborohydride or sodium borohydride), or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst).
  • the allyl group in 6 can be oxidatively cleaved to aldehyde 7 with osmium tetroxide followed by sodium periodate or with ozone at low temperature. Reductive amination of aldehyde 7 with azacycle 1 can then be carried out under the conditions described above.
  • Substituted spiro(indoline-3,4'-piperidine) derivatives can be prepared as shown in Scheme 3 starting from the appropriately substituted phenylhydrazines. Following the Fischer indole reaction and reduction of the intermediate imine with a mild reducing agent such as sodium borohydride, the indoline nitrogen can be reacted with an electrophile such as an acyl chloride or a sulfonyl chloride.
  • the protecting group on the piperidine nitrogen for example a benzyloxycarbonyl group, can be removed by treatment with hydrogen in the presence of palladium on carbon or by exposure to trimethylsilyl iodide, to give the deprotected substituted spiro(indoline-3,4'- piperidine).
  • Displacement of the chloride with functionalized 2-bromothiophenol provides the allylic sulfide, which can be cyclized under radical conditions to give the illustrated spiro(2,3-dihydrobenzothio ⁇ hene-3,4'- piperidine).
  • Spiro(2,3-dihydrobenzofuran-3 ,4'-piperidine) derivatives can be prepared as illustrated in Scheme 5.
  • Treatment of an appropiately substituted ester of 2-fluorophenylacetate with mechlorethamine hydrochloride under basic conditions provides the piperidine product, which on treatment with a strong reducing agent such as lithium aluminum hydride produces the corresponding 4- (hydroxymethyl) compound.
  • Cyclization with base provides the benzofuran derivative, and cleavage of the N-methyl group can then be carried out using 1 -chloroethyl chloroformate or other suitable N- demethylating agents.
  • ketone derivatives can be prepared by an extension of the chemistry given above, as shown in Scheme 7.
  • a second Amdt-Eistert chain extension provides the illustrated heptenoic acid derivative, which after conversion into its N-methoxy-N-methyl amide, can be reacted with an aryl organometalhc reagent, such as an aryl magnesium bromide, to provide the ketone.
  • Routine oxidative cleavage then gives the desired aldehyde, which can be coupled with a spiro-piperidine derivative as described above.
  • Alcohol containing antagonists can be prepared according to procedures given in Scheme 8. Formation of the N-methyl-N- methoxy amide of the indicated acid followed by oxidative cleavage of the olefin provides the intermediate aldehyde. Coupling with a spiro(indoline-3,4'-piperidine) derivative followed by addition of an organometalhc reagent to the amide provides the illustrated ketone. Treatment with a hydride reducing agent, such as sodium borohydride, then yields the desired alcohol derivatives.
  • a hydride reducing agent such as sodium borohydride
  • heterocycle substituted antagonists can be carried out according to the procedure given in Scheme 9 for substituted imidazoles.
  • Reduction of the allyl acid with a strong reducing agent such as lithium aluminum hydride followed by in situ formation of the trifluoromethanesulfonate of the formed alcohol allows for displacement of the triflate with a nucleophile such as 2- phenylimidazole.
  • Oxidative cleavage under standard conditions provides the indicated aldehyde which can then be coupled under the conditions described above to the appropriate spiro derivative.
  • Spiro(2-oxo-l,2,3,4-tetrahydroquinoline-4,4'-piperidine) and spiro( 1-oxo-l, 2,3 ,4-tetrahydroisoquinoline-4,4'-piperidine) can be prepared as shown in Scheme 10.
  • Scheme 10 Starting from the indicated spiro(2- oxoindane-3,4'-pi ⁇ eridine) (described in Claremon, D.A. et al, European Patent 0 431 943 943 A2. Evans, B.E. et al U.S. Patent 5.091.387. Davis, L. et al, U.S. Patent 4.420.485.
  • deprotection of the piperidine nitrogen is carried out by treatment with acid, for example trifluoroacetic acid, followed by protection as the trifluoroacetamide, and the product is exposed to hydrazoic acid in the presence of sulfuric acid. Heating of this mixture effects a Schmidt rearrangement, to provide both the tetrahydroquinoline and the tetrahydroisoquinoline derivatives.
  • Neurokinin antagonists with ether substituents can also be prepared by the route shown in Scheme 11.
  • the allyl acid discussed earlier can be reduced to the corresponding alcohol with, for example, lithium aluminum hydride.
  • This alcohol can be alkylated by a Williamson ether synthesis, by deprotonation with a strong base such as sodium hydride or sodium hexamethyldisilazide followed by reaction with a benzyl halide such as benzyl bromide.
  • the product can be processed through the oxidative cleavage steps described earlier to provide the aldehyde, which can then be coupled with a spirocycle ismer reductive amination conditions or else by reduction to the corresponding alcohol and conversion to the bromide, the bromide can then be used to alkylate a spirocycle under the conditions detailed above.
  • the invention encompasses a process of making compounds of formula I
  • a suitable solvent such as acetonitrile or dimethylacetamide with a compound of formula Rl-Xl wherein Xl is a leaving group such as bromo, chloro, tosyl or mesyl optionally in the presence of a suitable base such as trialkylamine; or
  • Step A l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-l- methanesulfonyl-spirofindoline-S ⁇ '-piperidine)
  • Step B l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfony 1- spiroCindoline-3 ⁇ '-piperidine
  • Mass Spectmm 200, 202, 228, 230, 279, 308, 310, 494, 496, 670, 672
  • the yellow oil was dissolved in 800 mL of 1,2- dichloroethane and cooled in ice bath as 50 mL (463 mmol) of 1- chloroethyl chloroformate keeping the temperature below 10°C. The resulting solution was heated to reflux. Gas evolution was noticed when the reaction temperature reached 70-75 °C. After 1 h the solution was cooled, concentrated to ca. 250 mL in vacuo and 700 mL of methanol was added. The mixture was refluxed for 1.5 h and gas evolution was observed. The reaction was cooled to room temperature and concentrated in vacuo to a wet solid. The solid was slurried with cold methanol, the solid was filtered, washed with cold methanol and dried.
  • the filtrate was concentrated to a thick oil and the oil was dissolved in 40 mL of EtOH.
  • Acetic acid (3 mL) and 0.8 g of 10% Pd/C were added to the solution and the resulting mixture was hydrogenated on a Parr apparatus for 3 h.
  • the catalyst was filtered and washed with EtOAc and the combined filtrate was concentrated.
  • the residue was partitioned between CH2CI2 and water and 2N NaOH was added to this mixture until the aqueous layer was basic.
  • the layers were separated and the aqueous layer was extracted with CH2CI2.
  • the combined organic layer was washed with brine, dried over Na2S ⁇ 4 and the filtrate was concentrated to give 2.93 g (77%) of the title compound sufficiently pure for use in the next reaction.
  • Step 1 N-Methoxy-N-methyl-2-(S)-(3,4-dichlorophenyl)-4- pentenamide
  • Step 2 3-(S - .4-dichlorophenylV5-hexen-2-one
  • Step 3 N-Methyl 3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(RS)- amine
  • Step 4 N-Methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-
  • Step 5 N-Methyl-N-t-butoxycarbonyl-3-(S)-(3 ,4-dichlorophenyl)-
  • Step 6 l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(t-butoxy- carbonyl)(methylamino))pentyl)- 1 -methanesulfonyl- spiro(indoline-3 ,4'-piperidine
  • Step 7 l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)- fmethylamino ⁇ pentyl 1 -methanesulfonyl-spirofindoline- 3.4'-piperidine
  • Step 8 l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3-methyl- benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl- spirofindoline-3.4'-piperidine
  • the title compound was prepared from l'-(3-(S)-(3,4- dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine) (from Step 7 above) using a procedure identical to Example 3, Step (b), substituting m-toluoyl chloride for 3,5-dimethylbenzoyl chloride.
  • the title compound was prepared from l'-(3-(S)-(3,4- dichlorophenyl)-4-(R or S)-(methylamino)pentyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3 Step (b), substituting 3,5- bis(trifluoromethyl)benzoyl chloride for 3,5-dimethylbenzoyl chloride.
  • the filtrate was concentrated and the residue which was a mixture of the desired acid and the aldehyde was dissolved in 3 mL of acetone.
  • the solution was treated with 6 N Jones reagent until the orange color persisted. After stirring for 20 min the excess reagent was destroyed by adding few drops of i-PrOH.
  • the solution was diluted with water and extracted with CH2CI2.
  • the CH2CI2 layer was washed with brine, dried and the filtrate was concentrated.
  • the residue was purified by prep TLC using 0.5:30:69.5 of HOAc:EtOAc:hexane to isolate 0.14 g (45 %) of 3-bromo-5-methylbenzoic acid.
  • Step B l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5- methy lbenzoyl)(methylamino))buty 1)- 1 -methanesulf onyl- spiro(indoline-3.4'-piperidine
  • Step A 1.r-Dimethyl-spiro( ⁇ ndol-2-one-3.4'-piperidine)
  • Step B l-Methyl-spiro( ' indol-2-one-3.4'-piperidine
  • Step C l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-methyl-spiro(indol-2-one-
  • Step A 1 '-Trifluoroacetyl-spirod -indanone-3.4'-piperidine
  • Step B l'-Trifluoroactyl-spiro-(2-oxo- 1,2,3, 4-tetrahydro- quinoline-4,4'-piperidine) and r-trifluoroactyl-spiro-(l- oxo-1.2.3.4-tetrahydroisoquinoline-4.4'-piperidine
  • a mixture of 1.09 g (16.8 mmol) of Sodium azide in 1.2 mL of water and 6.6 mL of CHCI3 was added 0.46 mL of concentrated H2SO4 (36 N) keeping the temperature between 0-5°C.
  • Step C Spiro-(2-oxo-1.2.3.4-tetrahydroquinoline-4.4'-piperidine
  • Step D l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydro-
  • Step A 1 -Methy l-spiro-(2-oxo-l ,2,3,4-tetrahydroquinoline-4,4'- piperidine
  • Step B l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro- benzoy l)(methylamino))buty 1)- 1 -methyl-spiro(2-oxo- tetrahydroquinoline-4.4'-piperidine
  • Step A 3-(S)-(4-Fluorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)methylamino)butanol.
  • Step B 4-Bromo-2-(S)-(4-fluorophenyl)-l-(N-(3,5- bistrifluoromethylbenzoyl)methylamino)butane.
  • Example 22 The compounds in Examples 22-26 were prepared as in Example 21 from the requisite bromide, prepared from the corresponding phenylacetic acid as described in Example 20, and the required 1- substituted-spiro(indoline-3,4'-piperidine).
  • the title compound was prepared as in Example 21 from 4-bromo-2- (S)-(4-chlorophenyl)-l -(N-(3,5- bistrifluoromethylbenzoyl)methylamino)butane and spiro(2,3- dihydrobenzothiophene-3,4'-piperidine) hydrochloride except that 3 eq. of diisopropylethylamine were used.
  • the title compound was prepared from 3-(S)-(4-pyridyl)-4-(N-(3,5- bistrifluoromethyl-benzoyl)methylamino)butanal (prepared from 4- pyridylacetic acid as described by J. Hale et. al., Bioorganic & Medicinal Chemistry Letters 1993,5, 319-322) by reductive amination as described in Example 2.
  • Step A 4-Bromo-2-(S)-(3 ,4-dichlorophenyl)- 1 -(N-(3 ,5- dimethylbenzoyl)methylamino)butane.
  • the title compound was prepared as in Example 20, Steps A and B, from 3-(S)-(3,4-dichlorophenyl)-4-(N-(3,5-dimethyl- benzoyl)ethylamino)butanal (prepared from 3,4-dichlorophenylacetic acid as described by J. Hale et. al., (Bioorganic & Medicinal Chemistry Letters 1993,5, 319-322) using ethylamine rather than methylamine to form the intermediate amide).
  • Step B 1 '-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5- dimethylbenzoyl)-(ethylamino))butyl)- 1 -methanesulfonyl- spiro(indoline-3 ,4'-piperidine).
  • the title compound was prepared from the bromide prepared in Step A and l-acetyl-spiro(indoline-3,4'-piperidine) as described in Example 21.
  • Step 2) 4-(2,5-Difluorophenyl)-4-hydroxymethyl-l -methylpiperidine
  • EtOH (5.1 mL, 86 mmol) was added to 0.5 M LiAlH4 in glyme (82 mL, 41 mmol) at 0°C.
  • 4-(2,5-difluorophenyl)-4-methoxycarbonyl-l- methylpiperidine (3.45 g, 12.8 mmol) in glyme (4 mL) was added.
  • Saturated aqueous sodium potassium tartrate (50 mL) was added along with Celite (10 g), and the mixture was mechanically stirred 1 h at room temp. The slurry was filtered, and the organic layer was extracted with IN HCI. The HCI was washed with EtOAc and then basified with 3N NaOH.
  • n-Butyl lithium (9.57 mL, 2.45M in hexane, 23.7 mmol) was added to a -78°C solution of diisopropylamine (3.32 mL, 23.7 mmol) in THF (15 mL). After 30 min at -78°C, methyl phenyl sulfoxide (3.32 g, 23.7 mmol) in THF (4 mL) was added. The solution was warmed to 0°C and cooled back down to -78°C. l-t-butoxycarbonyl-4-piperidinone (4.69 g, 23.7 mmol) in THF (20 mL) was added.
  • Step 2) 1 -t-Butoxycarbonyl-3,4-didehydro-4-(chloromethyl)piperidine
  • the allylic chloride (330 mg, 1.43 mmole) was dissolved in acetone (10 mL) and 2-bromothiophenol (172 ml, 1.43 mmole) and K2CO3 (390 mg, 2.86 mmole) were added.
  • the reaction mixture was heated to 60°C for 1 h and then filtered though silica gel ( ether).
  • the organic layer was concentrated in vacuo and purified by column chromatography (silica gel 60, hexanes/ethyl acetate 10/1) to give the title compound in 84% yield (460 mg).
  • Step 4) 1 '-t-Butoxycarbonyl-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine).
  • the intermediate adduct from step 3 above 450 mg, 1.17 mmole was dissolved in benzene (60 mL) and AIBN (10 mg) and tributyltin hydride (644 mL, 2.39 mmole) were added. This mixmre was refluxed for 2 h and concentrated. The residue was dissolved in Et2 ⁇ and Br2 was added until the reaction solution turned to a brownish color. To this brownish solution at room temp was added DBU (650 mL) dropwise.
  • the title compound was prepared by oxidizing l'-(3-((S)-(3,4- dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)- spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) as described in Example 47 above, and then removing the BOC group and N- benzoylating according to the procedures given in Example 3, Steps A and B.
  • the title compound was prepared by the oxone oxidation method described in Example 53.
  • the title compound was prepared by the oxone oxidation method described in Example 51.
  • Substituted indoline spiropiperidine derivatives were obtained by employing substituted phenyl hydrazines and 1- benzyloxycarbonylpiperidine-4-carboxyaldehyde in the Fisher indole synthesis. When regioisomers were formed, they were separated as the 1 '-benzyloxy carbonyl- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperidine) derivative by chromatography (silica gel 60, THF/hexane). Preparation of a representative substituted spiro(indoline-3,4'-piperidinium) hydrochloride is described below:
  • Step 1) 1 '-Benzyloxycarbonyl-5-fluoro-l -methanesulf onyl- spiro(indoline-3 ,4'-piperidine)
  • N-Napthoyl- methylamino derivatives (Examples 91 -101 ) were prepared by analogy to the benzoyl derivatives, employing commercially available 1-napthoyl chlorides in place of benzoyl chlorides:
  • Benzylamine derivatives could be synthesized by reducing the benzamide of the 1 -methanesulfony l-spiro(indoline-3,4'-piperidine) derivatives described in some of the Examples.
  • the methanesulfonyl group could be removed by heating with HBr/acetic acid/phenol and then be replaced with an acetyl group by treating with acetic anhydride/pyridine. Representative procedures and compounds are given in Examples 102 and 103 below:
  • Step 1) l-Bromo-4-fluoro-3,5-dimethylbenzene
  • 4-Bromo-2,6-dimethylaniline 8.3 g, 42 mmol
  • H2 ⁇ 50 mL
  • cone H2SO4 6.25 mL
  • NaN ⁇ 2 4.1 g
  • Water (30 mL) was added to make the mixture homogeneous.
  • HBF4 50%, 13.7 g was added dropwise with stirring.
  • the resultant white precipitate was collected by vacuum filtration, washed with H2 ⁇ (30 mL), MeOH (30 mL), and Et2 ⁇ (60 mL), and dried over P2O5 under vacuum for 16 h. The solid was then heated in a glass flask with an open flame until all the solid had decomposed. The remaining liquid was diluted with Et2 ⁇ (50 mL) and 0.5 M NaOH (30 mL).

Abstract

Disclosed are spiro-substituted azacycles of formula (I), tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma. In particular compounds of formula (I) are shown to be neurokinin antagonists.

Description

TITLE OF THE INVENTION
SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ
ANTAGONISTS
BACKGROUND OF THE INVENTION
The invention disclosed herein is directed to certain spiro- substituted azacycles useful as tachykinin receptor antagonists. In particular, the compounds disclosed herein are neurokinin receptor antagonists.
The tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), are structurally similar members of a family of neuropeptides. Each of these is an agonist of the receptor types, neurokinin-1 receptor (NK-1), neuorokinin-2 receptor (NK-2) and neuorokinin-3 receptor (NK-3), which are so defined according to their relative abilities to bind tachykinins with high affinity and to be activated by the natural agonists SP, NKA and NKB respectively.
The tachykinins are distinguished by a conserved carboxyl- terminal sequence Phe-X-Gly-Leu-Met-NH2. More specifically, substance P is a pharmacologically-active neuropeptide that is produced in mammals and possesses a characteristic amino acid sequence:
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
Neurokinin A possesses the following amino acid sequence:
His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2.
Neurokinin B possesses the following amino acid sequence:
Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2-
(Chang et al, Nature New Biol. 232, 86 (1971); D.F. Veber et al, U.S. Patent No. 4,680,283). The neurokinin receptors are widely distributed throughout the mammalian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are involved in regulating a number of diverse biological processes. This includes sensory perception of olfaction, vision, audition and pain, movement control, gastric motility, vasodilation, salivation, and micturition (B. Pernow, Pharmacol. Rev., 1983, 35, 85- 141). The NK1 and NK2 receptor subtypes are implicated in synaptic transmission (Laneuville et al, Life Sci., 42: 1295-1305 (1988)).
Substance P acts as a vasodilator, a depressant, stimulates salivation and produces increased capillary permeability. It is also capable of producing both analgesia and hyperalgesia in animals, depending on dose and pain responsiveness of the animal (see R.C.A. Frederickson et al, Science, 199, 1359 (1978); P. Oehme et al, Science, 208, 305 (1980)) and plays a role in sensory transmission and pain perception (T.M. Jessell, Advan. Biochem. Psychopharmacol. 28, 189 (1981)). In particular, substance P has been shown to be involved in the transmission of pain in migraine (see B.E.B. Sandberg et al, Journal of Medicinal Chemistry, 25, 1009 (1982)), and in arthritis (Levine et al Science, (1984) 226, 547-549).
In the airways, it has been indicated that NK1 receptors are associated with microvascular leakage and mucus secretion, while NK2 receptors regulate smooth muscle contraction. Also, it has been shown that both substance P and neurokinin A are effective in inducing airway constriction and edema. Based on such findings, it is believed that substance P and neurokinin A may be involved in the pathogenesis of neurogenic inflammation, including allergic diseases such as asthma. (Frossard et al, Life Sci., 49, 1941-1953 (1991); Advenier, et al, Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
In experimental studies, sensory neuropeptides, especially tachykinins such as substance P and neurokinin A, can bring about many of the pathophysiological features of asthma. Neurokinin A is a very potent constrictor of human airways in vitro, and substance P causes mucus secretion in the airways. (Barnes P.J., Lancet, pp 242-44 (1986); Rogers D.R., Aursudkij B., Barnes P.J., Euro. J. Pharmacol, 174, 283- 86 (1989)).
Inhalation of bradykinin causes bronchoconstriction in asthmatic patients but not in normal subjects. (Fuller R.W., Dixon C.M.S., Cuss F.M.C., Barnes PJ., Am Rev Respir Dis, 135, 176-80 (1987)). Since the bradykinin-induced bronchoconstriction is partly opposed by anticholinergic agents and since bradykinin is only a weak constrictor of human airways in vitro, it has been suggested that the bronchoconstrictor response is partly mediated by a neural reflex. Bradykinin stimulates vagal afferent C fibers and causes broncho¬ constriction in dogs. (Kaufman M.P., Coleridge H.M., Coleridge J.C.G., Baker D.G., J. Appl. Physio., 48, 511-17 (1980)). In guinea-pig airways, bradykinin causes a bronchoconstrictor response by way of cholinergic and sensory-nerve-mediated mechanisms. (Ichinoe M., Belvisi M.G., Barnes P.J., J. Pharmacol. Exp. Ther., 253, 594-99 (1990). Bradykinin-induced bronchoconstriction in human airways may therefore be due partly to tachykinin released from sensory nerve terminals via axon reflex mechanisms. Clinical trials have shown that a dual NK-l/NK-2 antagonist (such as FK-224) protects against bradykinin induced bronchocontriction in asthmatic patients. (Ichinoe, M. et al, Lancet, , vol. 340, pp 1248-1251 (1992)).
The tachykinins have also been implicated in gastro¬ intestinal (GI) disorders and diseases of the GI tract, such as inflammatory bowel disease, ulcerative colitis and Crohn's disease, etc. (see Mantyh et al, Neuroscience, 25 (3), 817-37 (1988) and D. Regoli in "Trends in Cluster Headache" Ed. F. Sicuteri et al, Elsevier Scientific Publishers, Amsterdam, 1987, pp. 85-95).
It is also hypothesized that there is a neurogenic mechanism for arthritis in which substance P may play a role (Kidd et al, "A Neurogenic Mechanism for Symmetric Arthritis" in The Lancet, 11 November 1989 and Gronblad et al, "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in J. Rheumatol. (1988) 15(12) 1807-10). Therefore, substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid arthritis and osteoarthritis (O 'Byrne et al, in Arthritis and Rheumatism (1990) 33, 1023-8). Other disease areas where tachykinin antagonists are believed to be useful are allergic conditions (Hamelet et al, Can. J. Pharmacol. Physiol. (1988) 66, 1361-7), immunoregulation (Lotz et al, Science (1988) 241, 1218-21, Kimball et al, J. Immunol. (1988) 141 (10) 3564-9 and A. Perianin, et al, Biochem. Biophys. Res. Commun. 161, 520 (1989)) vasodilation, bronchospasm, reflex or neuronal control of the viscera (Mantyh et al, PNAS (1988) 85, 3235-9) and, possibly by arresting or slowing β-amyloid-mediated neurodegenerative changes (Yankner et al, Science, (1990) 250, 279-82) in senile dementia of the Alzheimer type, Alzheimer's disease and Downs Syndrome. Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis (J. Luber-Narod et al, poster presented at C.I.N.P. XVTHth Congress, 28th June-2nd July, 1992). Antagonists selective for the substance P and/or the neurokinin A receptor may be useful in the treatment of asthmatic disease (Frossard et al, Life Sci., 49, 1941-1953 (1991); Advenier, et al, Biochem. Biophys. Res. Comm., 184(3), 1418-1424 (1992)).
SUMMARY OF THE INVENTION
This invention is directed to compounds of formula I.
Figure imgf000006_0001
I The invention is also concerned with pharmaceutical formulations with these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine and asthma.
DETAILED DESCRIPTION OF THE INVENTION
This invention is directed to compounds of formula I.
Figure imgf000007_0001
R
I or a pharmaceutically acceptable salt thereof, wherein the nitrogen expressly shown above is optionally quatemized with Cι_4alkyl or phenylCi-4alkyl or is optionally present as the N- oxide (N+0-), and wherein: 1 and m are each independently 0, 1 , 2, 3, 4, or 5, with the proviso that 1 + m is equal to 1, 2, 3, 4, or 5;
Rl is selected from a group consisting of: (1) hydrogen, (2) linear or branched Cι_8 alkyl, linear or branched C2-8 alkenyl, or linear or branched C2-8 alkynyl, wherein the Cl-8 alkyl, C2-8 alkenyl or C2-8 alkynyl is optionally mono, di, tri or tetra substituted, the substitutents independently selected from: (a) hydroxy,
(b) oxo,
(c) cyano,
(d) halogen which is defined to include Br, CI, I, and F,
(e) trifluoromethyl, (f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from
(1) phenyl,
(2) hydroxy,
5 (3) Cl-3alkyl,
(4) cyano,
(5) halogen,
(6) trifluoromethyl,
(7) -NR6COR7, wherein R6 and R7 are 10 independently selected from:
(a) hydrogen,
(b) Cl-6 alkyl, or mono or disubstituted Cl-6 alkyl, the substitutents independently selected from
15 (1) phenyl,unsubstituted or substituted with hydroxy, Cl-3alkyl, cyano, halogen, trifluoromethyl or Cl-4alkoxy, (2) hydroxy, 20 (3) oxo,
(4) cyano,
(5) halogen,
(6) trifluoromethyl,
(c) phenyl, pyridinyl or thiophene or mono, di or
25 trisubstituted phenyl , pyridinyl or thiophene , the substitutents independently selected from
(1) hydroxy,
(2) Ci-4alkyl,
(3) cyano,
30 (4) halogen,
(5) trifluoromethyl,
(d) Cl-3alkyloxy, or R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is 5 unsubstituted or mono or disubstituted, the substituents independently selected from
(a) hydroxy,
(b) oxo,
(c) cyano, 10 (d) halogen,
(e) trifluoromethyl,
(8) -NR6C02R7,
(9) -NR6CONHR7,
(10) -NR6S(0)jR7, wherein j is 1 or 2,
15 (11) -CONR6R7,
(12) -COR6,
(13) -CO2R6,
(14) -OR6,
(15) -S(0)kR6 wherein k is 0, 1 or 2,
20 (16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) benzimidazolyl,
(2) benzofuranyl,
(3) benzoxazolyl,
25 (4) furanyl,
(5) imidazolyl,
(6) indolyl,
(7) isoxazolyl,
(8) isothiazolyl,
30 (9) oxadiazolyl,
(10) oxazolyl,
(11 ) pyrazinyl,
(12) pyrazolyl,
(13) pyridyl, (14) pyrimidyl,
(15) pyrrolyl,
(16) quinolyl,
(17) tetrazolyl,
5 (18) thiadiazolyl,
(19) thiazolyl,
(20) thienyl, and
(21) triazolyl, wherein the heteroaryl is unsubstituted or mono, di 10 or trisubstituted, the substituents independently selected from,
(a) hydroxy,
(b) oxo,
(c) cyano, 15 (d) halogen,
(e) trifluoromethyl,
(g) -NR6R7,
(h) -NR6COR7,
(i) -NR6C02R7, 20 (j) -NR6CONHR7,
(k) -NR6S(0)jR7,
(1) -CONR6R7,
(m) -COR6,
(n) -CO2R6, 25 (0) -OR6,
(p) -S(0)kR6,
(q) heteroaryl, wherein heteroaryl is selected from the group consisting of:
( 1 ) benzimidazolyl, 30 (2) benzofuranyl,
(3) benzoxazolyl,
(4) furanyl,
(5) imidazolyl,
(6) indolyl, (7) isoxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl,
(io: ) oxazolyl, or ) pyrazinyl,
(12: ) pyrazolyl,
(i3: ) pyridyl,
(i4: ) pyrimidyl,
(i5: ) pyrrolyl,
(i6: ) quinolyl,
(i7: ) tetrazolyl, as: ) thiadiazolyl,
(i9: ) thiazolyl,
(2o; ) thienyl,
(2i : ) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstitu ted, the substituents independently selected from
(1) phenyl,
(2) hydroxy,
(3) oxo,
(4) cyano,
(5) halogen,
(6) trifluoromethyl,
wherein the nitrogen of definition Rl 2(g) as defined above is optionally quatemized with Cl-4alkyl or phenylCl-4alkyl or is optionally present as the N-oxide (N+0-); W is selected from the group consisting of
(1) a covalent bond
(2) Cl-3 alkyl, unsubstituted or substituted with
(a) oxo,
(b) hydroxy
(c) OR6, (d) halogen,
(e) trifluoromethyl,
(f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) hydroxy,
(2) cyano,
(3) halogen,
(4) trifluoromethyl, (3) S(0)k, (4) (Cl-3 alkyl)-S(0)k,
(5) S(0)k-(Cl-2 alkyl),
(6) S(0)k-NH,
(7) S(0)j-NH(Cl-2 alkyl),
(8) S(0)j-NR6, (9) S(0)j-NR6-(Cl-2 alkyl),
(10) CONH,
(11) CONH-(Ci-2 alkyl),
(12) CONR6,
(13) CONR6-(C 1-2 alkyl), (14) C02,
(15) Cθ2-(Cl-2 alkyl); Q = NR2, O, S, S(O), or S02, with the proviso that when W is a covalent bond and X is Ci-3alkyl, then Q must be NR2; R2 is selected from a group consisting of: (1) hydrogen,
(2) Cl-8 linear or branched alkyl, unsubstituted, monosubstituted or multiply substituted with
(a) -OR6,
(b) = 0, (c) -NHCOR6,
(d) -NR6R7,
(e) -CN,
(f) -halogen,
(g) -CF3, (h) -phenyl, unsubstituted or substituted, wherein the substitutents are selected from the group consisting of
(1) hydroxy, (2) cyano,
(3) halogen,
(4) trifluoromethyl,
(3) S(0)R8, wherein R8 is Cl-6 linear or branched alkyl, unsubstituted, mono di or trisubstituted with (a) hydroxy,
(b) oxo,
(c) cyano,
(d) -OR6,
(e) -NR6R7, (f) -NR6COR7,
(g) -halogen,
(h) -CF3,
(i) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (1) hydroxy,
(2) oxo,
(3) cyano,
(4) -NHR6,
(5) -NR6R7, (6) -NR6COR7,
(7) -halogen,
(8) -CF3, and
(9) Cl-3 alkyl,
(4) S02R8, (5) C0R8,
(6) C02R8;
(7) CONR7R8;
X is selected from the group consisting of (1) a covalent bond
(2) Ci-3 alkyl, unsubstituted or substituted with
(a) oxo,
(b) 0R6, (c) halogen,
(d) trifluoromethyl,
(e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) 0R6, (2) halogen, and
(3) trifluoromethyl,
(3) S(0)k,
(4) (Cl-3 alkyl)S(0)k,
(5) S(0)k(Cl-2 alkyl), (6) NHS(0)j,
(7) NH(Cl-2 alkyl)S(0)j,
(8) S(0)jNR6,
(9) S(0)j-NR6-(Ci-2 alkyl),
(10) NHCO, (11 ) NHC0-(Cl-2 alkyl),
(12) NR6C0,
(13) NR6-(Ci-2 alkyl)CO,
(14) 0(CO), and
(15) (Ci-2 alkyl)0(C0),
Y-Z considered together are 2 adjoining atoms of the ring
said ring being an phenyl, naphthyl or heteroaryl group, with the heteroaryls selected from the group consisting of:
( 1 ) benzimidazolyl,
(2) benzofuranyl,
(3) benzoxazolyl, (4) furanyl,
(5) imidazolyl,
(6) indolyl,
(7) isoxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl,
(io; ) oxazolyl, di; ) pyrazinyl,
(12; ) pyrazolyl,
(13; ) pyridyl,
(14; ) pyrimidyl,
(i5; ) pyrrolyl,
(16; ) quinolyl,
(i7 ) tetrazolyl,
(is: ) thiadiazolyl,
(i : ) thiazolyl,
(2o; ) thienyl,
(2i; ) triazolyl, and wherein the aryl or heteroaryl group is unsubstituted,
, di or tri substituted, the substitutents selected from:
(a) hydrogen,
(b) Cl-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy,
(c) oxo
(d) OR6, wherein R6 is as defined immediately above,
(e) halogen,
(f) trifluoromethyl,
(g) nitro,
(h) cyano,
(i) .NHR6,
G) NR6R7,
(k) NHCOR6,
0) NR6COR7, (m) NHC02R6,
(n) NR6CO2R7,
(o) NHS(0)jR6,
(P) NR6S(0)jR7,
(q) CONR6R7,
(r) C0R6,
(s) CO2R6,
(t) S(0)jR6,
( ) heteroaryl, wherein heteroaryl is selected from the
10 group consisting of:
(a) benzimidazolyl,
(b) benzofuranyl,
(c) benzoxazolyl,
(d) furanyl,
15 (e) imidazolyl,
(f) indolyl,
(g) isoxazolyl,
(h) isothiazolyl,
G) oxadiazolyl,
20
G) oxazolyl,
(k) pyrazinyl,
(1) pyrazolyl,
(m) pyridyl,
(n) pyrimidyl,
25 (o) pyrrolyl,
(P) quinolyl,
(q) tetrazolyl,
(r) thiadiazolyl,
(s) thiazolyl,
30
(t) thienyl,
(u) triazolyl, and wherein the heteroaryl is unsubstituted mono or di substituted, the substitutents selected from
(1) hydrogen, (2) Cl-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy,
(3) oxo,
(4) OR6,
(5) trifluoromethyl,
(6) nitro,
(7) cyano,
(8) NHR6,
(9) NR6R7,
(10) NHCOR6,
(I D NR6COR7,
(12) NHCO2R6,
(13) NR6CO2R7,
(14) NHS(0)jR6,
(15) NR6S(0)jR7,
(16) CONR6R7,
(17) COR6,
(18) CO2R6,
(19) S(0)jR6, and
(20) phenyl.
One subclass of this invention consists of structures tabulated below linked to Rl (as detailed immediately above) via the broken bond, and optionally substituted at the positions indicated by numbers 1-8 with
(a) hydroxy,
(b) oxo,
(c) cyano,
(d) -NR6R7,
(e) -NHCOR6R7,
(f) -halogen,
(g) -CF3, (h) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from (a) through (g) and Cl-3 alkyl; the tabulated structures being
10
15
20
25
30
Figure imgf000019_0001
Figure imgf000019_0002
25
30
Figure imgf000019_0003
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000021_0002
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000024_0002
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000034_0002
Figure imgf000035_0001
Figure imgf000035_0002
Figure imgf000036_0001
Figure imgf000036_0002
As is clear from the examples and schemes, the designation:
Figure imgf000037_0001
in formula I is interchangeable with (CH2)l or (CH2)m respectively. As appreciated by those of skill in the art, halo as used herein are intended to include chloro, fluoro, bromo and iodo. Exemplifying the invention are the compounds of the examples including the group consisting of
(a) 1 '-(3-(S)-(3 ,4-dichlorophenyl)-4-(t-butoxy carbonyl
(methylamino)) butyl)- 1 -methanesulf onyl-spiro(indoline-3, 4'- piperidine); (b) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'- piperidine);
(c) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N- (benzoyl)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'- piperidine);
(d) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine);
(e) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- methylbenzoy l)(methylamino))buty 1)- 1 -methanesulf onyl-spiro(indo line- 3,4'-piperidine);
(f) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- chlorobenzoyl)(methylamino))butyl)-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine); (g) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- trifluoromethyl-benzoyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro (indoline- 3 ,4 ' -piperidine) ;
(h) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro- benzoy l)(methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'- piperidine); (i) l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- trifluoromethyl-phenylacetyl)(methylamino))butyl)-l-methanesulfonyl- spiro(indoline-3 ,4'-piperidine) ;
(j) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- isopropyloxy-phenylacetyl)(methylamino))butyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine);
(k) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N- (benzenesulfonyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro(indoline-3 ,4'-piperidine) ; (1) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-benzyoxycarbonyl-spiro(indoline-3,4'- piperidine);
(m) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-spiro(indoline-3,4'-piperidine);
(n) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-propionyl-spiro(indoline-3,4'- piperidine);
(o) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino)) butyl)- 1 -formyl-spiro(indoline-3,4'- piperidine);
(p) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-f-butylcarbonyl-spiro(indoline-3,4'- piperidine);
(q) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoy l)(methylamino))butyl)- 1 -methy laminocarbonyl-spiro(indoline- 3,4'-piperidine);
(r) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-ethoxycarbonyl-spiro(indoline-3,4'- piperidine);
(s) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-ethanesulfonyl-spiro(indoline-3,4'- piperidine); (t) l '(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methy lamino))butyl)- 1 -/-propanesulf onyl-spiro(indoline-3 ,4'- piperidine);
(u) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)- 1 '-methyl- 1 -methanesulf onyl-spiro- indoline-3 ,4'-piperidinium iodide;
(v) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3- methylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine);
(w) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5- bis(trifluoromethyl)benzoyl)(methylamino))pentyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine);
(x) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5- dimethylbenzoy l)(methylamino))pentyl)- 1 -methanesulfony 1-spiro- (indoline-3,4'-piρeridine);
(y) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5- dichlorobenzoy l)(methylamino))penty 1)- 1 -methanesulf ony 1-spiro- (indoline-3,4'-piρeridine);
(aa) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- difluorobenzoyl)(methylamino))butyl)- 1 -methanesulfony 1-spiro- (indoline-3,4'-piperidine);
(ab) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-f uoro-5- (trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine);
(ac) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(l-naphthoyl)- (methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'- piperidine);
(ad) l'-(2-((S)-(3,4-dichlorophenyl))-l-(N-(2-chloro- phenylsulfonyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro- (indoline-3 ,4'-piρeridine); (ae) l'-(2-((S)-(3,4-dichlorophenyl))-l-(N-(3-chloro- phenylsulf onyl)-(methylamino))-4-butyl)- 1 -methylsulf onyl-spiro- (indoline-3 ,4'-piperidine);
(af) l'-(2-((S)-(3,4-dichlorophenyl))-l-(N-(4-chloro- phenylsulf onyl)-(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro-
(indoline-3 ,4'-piperidine);
(ag) l'-(2-((S)-(3,4-dichlorophenyl))-l-(N-(3,5-dichloro- phenylsulfonyl)-(methylamino))-4-butyl)-l -methy lsulfonyl-spiro- (indoline-3,4'-piperidine); (ah) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5-
(trifluoromethyl)benzoyl)(methylamino))butyl)-l-acetyl-spiro(indoline- 3,4'-piperidine);
(ai) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine).
(aj) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5- methylbenzoyl)(methylamino))butyl)-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine);
(ak) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)- 1 -(2-aminoacetyl)-spiro- (indoline-3 ,4'-piperidine);
(al) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-l-methyl-spiro(indol-2-one- 3,4'-piperidine);
(am) l"-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one- 3,4'-piperidine);
(an) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydroquinoline-4,4'- piperidine); and
(ao) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro- benzoyl)(methylamino))butyl)-l-methyl-spiro(2-oxo-tetrahydro- quinoline-4,4'-piperidine). In an alternative embodiment the above compounds may be co-administered with a β2-agonist such as Bambuterol, US 4,419,364 issued to Draco on 12/6/83; Bitolterol mesylate, US 4,138,581 issued to Sterling 2/6 79; Carbuterol, US 3,763,232 issued to SmithKline 10/2/73; Clenbuterol, US 3,536,712 issued to Boehringer Ingelheim 10/27/70; Dopexamine, US 4,645,768 issued to Fisons 2/24/87; Formoterol, US 3,994,974 issued to Yamanouchi 11/30/76; Mabuterol, US 4,119,710 issued to Boehringer Ingelheim 10/10/78; Pirbuterol hydrochloride US 3,700,681 issued to Pfizer 10/24 72; Procaterol hydrochloride US 4,026,897 issued to Otsuka 5/31/77; Ritodrine hydrochloride US
3,410,944 issued to North American Philips 11/12/68; Brosaterol, US 4,276,299 issued to Zambon 6/30/81 and US 4,520,200 issued to Zambon 5/28/85; Cimaterol, US 4,407,819 issued to American Cyanamid 10/4/83; Docarpamine, US 4,228,183 issued to Tanabe 10/14/80; Salmeterol, US 4,992,474 issued to Glaxo 2/21/91 and US 5,091,422 issued to Glaxo 2/25/92.
The compounds of formula I are particularly useful in the treatment of diseases or conditions that are advantageously treated by concomitant antagonism of both NKl and NK2 receptors or NKl, NK2 and NK3 receptors. These diseases include neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
In a second alternative embodiment the compounds of formula I may be co-administered with another NKl or NK2 antagonist such as those described in
Appln No. DO-139125, filed 08-Jun-78, Pub. 12-Dec-79; Appln No. EP-82568, filed 22-Dec-81, Pub. 29-Jun-83; Appln No. EP-490379, filed 13-Dec-90, Pub. 17-Jun-92; Appln No. EP-353732, filed 05-Aug- 88, Pub. 07-Feb-90; Appln No. EP-161007, filed 13-Jan-84, Pub. 13- Nov-85; Appln No. EP-385-43, filed 28-Feb-89, Pub. 05-Sep-90; Appln No. WO8301251, filed 09-Oct-81, Pub. 14-Apr-83; Appln No. BE- 894602, filed 09-Oct-81, Pub. 31-Jan-83; Appln No. DE3205991, filed 19-Feb-82, Pub. 01-Sep-83; Appln No. EP-327009, filed 02-Feb-88, Pub. 09-Aug-89; Appln No. EP-336230, filed 05-Apr-88, Pub. 11-Oct- 89; Appln No. 394989, filed 28-Apr-89, Pub. 31-Oct-90; Appln No. AU9068010, filed 22-Dec-89, Pub. 27-Jun-91; Appln No. EP-482539, filed 24-Oct-90, Pub. 29-Apr-92; Appln No. EP-443132, filed 10-Dec-
90, Pub. 28-Aug-91; Appln No. EP-498069, filed 21-Dec-90, Pub. 12- Aug-92; Appln No. W09222569, filed 19-Jun-91 , Pub. 23-Dec-92;
Appln No. J04297492, filed 24-Oct-91, Pub. 21-Oct-92; Appln No. US4997853, filed 02-Dec-88, Pub. 05-Mar-91 ; Appln No. EP-272929, filed 24-Dec-86, Pub. 29-Jun-88; Appln No. EP-360390, filed 25-Jul- 88, Pub. 28-Mar-90; Appln No. US3862114, filed 22-Nov-71 , Pub. 21- Jan-75; Appln No. EP-219258, filed 30-Sep-85, Pub. 22-Apr-87, Appln No. US4742156, filed 30-Sep-85, Pub. 03-May-88; Appln No. EP- 401177, filed 29-May-89, Pub. 05-Dec-90; Appln No. WO9202546, filed 03-Aug-90, Pub. 20-Feb-92; Appln No. EP-176436, filed 26-Sep- 84, Pub. 02-Apr-86; Appln No. US4680283, filed 26-Sep-84, Pub. 14- Jul-87; Appln No. WO9220661, filed 22-May-91, Pub. 26-Nov-92; Appln No. EP-520555, filed 24-Jun-91, Pub. 30-Dec-92; Appln No. EP-347802, filed 20-Jun-88, Pub. 27-Dec-89; Appln No. EP-412542, filed 10-Aug-89, Pub. 13-Feb-91; Appln No. WO9005729, filed 23- Nov-88, Pub. 31-May-90; Appln No. WO9005525, filed 23-Nov-88, Pub. 31-May-90; Appln No. EP-436334, filed 04-Jan-90, Pub. 10-Jul- 91; Appln No. W09118878, filed 31-May-90, Pub. 12-Dec-91; Appln No. W09118899, filed Ol-Jun-90, Pub. 12-Dec-91; Appln No. WO9201688, filed 23-Jul-90, Pub. 06-Feb-92; Appln No. WO9206079, filed 28-Sep-90, Pub. 16-Apr-92; Appln No. W09212152, filed 03-Jan-
91 , Pub. 23-Jul-92; Appln No. W09212151 , filed 10-Jan-91, Pub. 23- Jul-92; W09215585, filed Ol-Mar-91, Pub. 29-Apr-92; Appln No. WO022-676, filed 22-May-91, Pub. 26-Nov-92; Appln No. W09221677, filed 31-May-91 , Pub. 10-Dec-92; Appln No. WO9300331, filed 20-Jun-91 , Pub. 07-Jun-93; Appln No. WO9300330, filed 21-Jun-91, Pub. 07-Jan-93; Appln No. WO9109844, filed 11-Jul- 91 , Pub. l l-Jul-91 ; Appln No. EP-429366, filed 23-Nov-89, Pub. 29- May-91; Appln No. EP-430771, filed 23-Nov-89, Pub. 05-Jun-91; Appln No. EP-514274, filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-514276, filed 17-May-91 , Pub. 19-Nov-92; Appln No. EP-514275, filed 17-May-91, Pub. 19-Nov-92; Appln No. EP-514273, filed 17- May-91, Pub. 19-Nov-92; Appln No. EP-428434, filed 06-Nov-89, Pub. 22-May-91 ; Appln No. EP-474561 , filed 09-May-90, Pub. l l-Mar-92; Appln No. EP-512901, filed 03-May-91 , Pub. l l-Nov-92; Appln No. EP-512902, filed 03-May-91 , Pub. l l-Nov-92; Appln No. EP-515240, filed 03-May-91, Pub. 25-Nov-92; Appln No. US4472305, filed 17- May-83, Pub. 18-Sep-84; Appln No. US4839465, filed 20-Jan-87, Pub. 13-Jun-89; Appln No. EP-101929, filed 28-M-82, Pub. 07-Mar-84; Appln No. WO9102745, filed 16-Aug-89, Pub. 07-Mar-91 ; Appln No. US3912711, filed 03-M-72, Pub. 14-Oct-75; Appln No. US4059693, filed l l-Jun-76, Pub. 22-Nov-77; Appln No. US4481139, filed 13-Apr- 83, Pub. 06-Nov-84; Appln No. US7358073, filed 24-Oct-88, Pub. 19- Dec-89; Appln No. US7261627, filed 24-Oct-88, Pub. 07-Mar-89, which are hereby incorporated by reference.
The compounds of formula I are useful in the prevention and treatment of a wide variety of clinical conditions (as detailed in this specification) which are characterized by overstimulation of the tachykinin receptors, in particular NKl, NK2 and NK3.
These conditions may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; neurodegenerative disorders such as AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis and other neuropathological disorders such as diabetic or peripheral neuropathy, AIDS related neuropathy, chemotherapy-induced neuropathy, and neuralgia; respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, bronchospasm and asthma; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders such as alcholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosis; gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease and incontinence; disorders of bladder function; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that is attributable to or associated with any of the foregoing conditions especially the transmission of pain in migraine. Hence, these compounds are readily adapted to therapeutic use for the treatment of physiological disorders associated with the overstimulation of the tachykinin receptors, in particular NKl, NK2 and NK3.
The compounds of the present invention are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example: neuropathy, such as diabetic or peripheral neuropathy and chemotherapy-induced neuropathy; asthma; osteoarthritis; rheumatoid arthritis; and migraine.
For the treatment of any of these diseases compounds of Formula I may be administered orally, topically, parenterally, ICV, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracistemal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compounds of the invention are effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethyl- cellulose, sodium alginate, polyvinyl- pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1 ,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of formula I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
In the treatment of a condition associated with an excess of tachykinins, an appropriate dosage level will generally be about 0.001 to 50 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day. A suitable dosage level may be about 0.001 to 25 mg/kg per day, about 0.005 to 10 mg/kg per day, or about 0.005 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
TACHYKININ ANTAGONISM ASSAY
The compounds of this invention are useful for antagonizing tachykinins, in particular substance P and neurokinin A in the treatment of gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain or migraine and asthma in a mammal in need of such treatment. This activity can be demonstrated by the following assay.
A. Receptor Expression in COS
To express the cloned human neurokinin- 1 receptor (NK1R) transiently in COS, the cDNA for the human NK1R was cloned into the expression vector pCDM9 which was derived from pCDM8 (INVITROGEN) by inserting the ampicillin resistance gene (nucleotide 1973 to 2964 from BLUESCRIPT SK+) into the Sac II site. Transfection of 20 μg of the plasmid DNA into 10 million COS cells was achieved by electroporation in 800 μl of transfection buffer (135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 0.6 mM KH2PO4, 10 mM glucose, 10 mM HEPES pH 7.4) at 260 V and 950 uF using the IBI GENEZAPPER (IBI, New Haven, CT). The cells were incubated in 10% fetal calf serum, 2 mM glutamine, lOOU/ml penicillin- streptomycin, and 90% DMEM media (GIBCO, Grand Island, NY) in 5% C02 at 37°C for three days before the binding assay. Similar methods were used to express the NK2 receptor. B. Stable Expression in CHO
To establish a stable cell line expressing the cloned human NK1R, the cDNA was subcloned into the vector pRcCMV (INVITROGEN). Transfection of 20 μg of the plasmid DNA into CHO cells was achieved by electroporation in 800 μl of transfection buffer suplemented with 0.625 mg/ml Herring sperm DNA at 300 V and 950 uF using the IBI GENEZAPPER (IBI). The transfected cells were incubated in CHO media (10% fetal calf serum, 100 U/ml pennicilin- streptomycin, 2 mM glutamine, 1/500 hypoxanthine-thymidine (ATCC), 90% IMDM media (JRH BIOSCIENCES, Lenexa, KS), 0.7 mg/ml G418 (GIBCO)) in 5% Cθ2 at 37°C until colonies were visible. Each colony was separated and propagated. The cell clone with the highest number of human NK1R was selected for subsequent applications such as drug screening. Similar methods were used to express the human NK2 receptor.
C. Assay Protocol using COS or CHO
The binding assay of human NK1R expressed in either COS or CHO cells is based on the use of -^I-substance P (^-^I-SP, from DU PONT, Boston, MA) as a radioactively labeled ligand which competes with unlabeled substance P or any other ligand for binding to the human NK1R. Monolayer cell cultures of COS or CHO were dissociated by the non-enzymatic solution (SPECIALTY MEDIA, Lavallette, NJ) and resuspended in appropriate volume of the binding buffer (50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl, 0.04 mg/ml bacitracin, 0.004 mg/ml leupeptin, 0.02 mg/ml BSA, 0.01 mM phosphoramidon) such that 200 μl of the cell suspension would give rise to about 10,000 cpm of specific ^^I-SP binding (approximately 50,000 to 200,000 cells). In the binding assay, 500 ul of cells were added to a tube containing 20 μl of 1.5 to 0.25 nM of 125I-SP and 5 μl of unlabeled substance P or any other test compound in DMSO. The tubes were incubated at 4°C or at room temperature for 1 hour with gentle shaking. The bound radioactivity was separated from unbound radioactivity by GF/C filter (BRANDEL, Gaithersburg, MD) which was pre-wetted with 0.1% polyethylenimine. The filter was washed with 3 ml of wash buffer (50 mM Tris pH 7.5, 5 mM MnCl2, 150 mM NaCl) three times and its radioactivity was determined by gamma counter. A similar assay was used for NK2 except 125I-NKA was used as the ligand.
The activation of phospholipase C by NK1R may also be measured in CHO cells expressing the human NK1R by determining the accumulation of inositol monophosphate which is a degradation product of IP3. CHO cells are seeded in 12- well plate at 250,000 cells per well. After incubating in CHO media for 4 days, cells are loaded with 0.025 uCi/ml of ^H-myoinositol by overnight incubation. The extracellular radioactivity is removed by washing with phosphate buffered saline. LiCl is added to the well at final concentration of 0.1 mM with or without the test compound, and incubation is continued at 37°C for 15 min. Substance P is added to the well at final concentration of 0.3 nM to activate the human NK1R. After 30 min of incubation at 37°C, the media is removed and 0.1 N HCI is added. Each well is sonicated at 4°C and extracted with CHCl3/methanol (1:1). The aqueous phase is applied to a 1 ml Dowex AG 1X8 ion exchange column. The column is washed with 0.1 N formic acid followed by 0.025 M ammonium formate-0.1 N formic acid. The inositol monophosphate is eluted with 0.2 M ammonium formate-0.1 N formic acid and quantitated by beta counter. Similar methods were used to assess antagonism at the NK2 receptor, except NKA was used as the stimulating agonist.
The compounds of of Formula I as Exemplified in the EXAMPLES below have been found to displace radioactive ligand for the NK-1 receptor at a concentration range of 0.01 nM to 1.0 μM, for the NK-2 receptor, 0.01 nM to 5 μM, and for the NK-3 receptor, 1.0 nM to 10 μM.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples.
The compounds of the present invention are prepared by alkylating azacycle 1, in which Rl = H, under appropriate conditions (Scheme 1). The required azacycle starting materials are prepared using methods described in the literature; such as described in Ong, H. H. et al, Journal of Medicinal Chemistry, 1983,26, 981-986, and Nargund, R. et al, USSN 08/147,226 (November 3, 1993), EP 93309867.5 hereby encorporated by reference. None of the compounds in these references are claimed to be neurokinin antagonists.
Thus, azacycle 1 (Ri=H) is combined with the appropriate aldehyde and the intermediate imine is reduced to the tertiary amine chemically (e.g. using sodium cyanoborohydride) or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst) (Scheme 1). The aldehyde needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention the preparation of a representative aldehyde is described in Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322.
In an alternative embodiment of the present invention, azacycle 1 (Rl=H) can be alkylated with an alkyl halide or alkyl sulfonate ester (with or without an added base to neutralize the mineral acid or sulfonic acid by-product) to give the desired compound (Scheme 1). The alkyl halide or alkyl sulfonate needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be reduced to an alcohol with sodium borohydride, diisobutylaluminum hydride or lithium aluminum hydride, and the product alcohol converted to either the alkyl halide using methods described in March J. "Advanced Organic Chemistry", 3rd ed., John Wiley & Sons, New York, pp. 382-384 (1985), or alkyl sulfonate ester using methods described in March J. "Advanced Organic Chemistry", 3rd ed., John Wiley & Sons, New York, p. 444 (1985).
In an alternative embodiment of the present invention, 1 (Rl = H) can be acylated to give the tertiary amide and subsequent reduction with a strong reducing agent (e.g. diborane including borane dimethylsulfide; and, lithium aluminum hydride) will give the desired compound (Scheme 1). The acylating agent needed for this reaction can be prepared by methods generally known in the chemical literature; for the purposes of the present invention an aldehyde, prepared as described above, can be oxidized using such commonly used reagents as permanganate in acid or silver oxide, and the resulting acid activated as an acid chloride or mixed anhydride which can be used to acylate I (Rl = H). The product amide can in and of itself be a neurokinin antagonist or can be reduced with a strong reducing agent, such as diborane or lithium aluminum hydride, to give the tertiary amine.
Optionally, compound 1 formed in the alkylation step may be further modified in subsequent reactions. In one illustration of such an approach,the aldehyde fragment contained a t-butoxycarbonylamino group (Example 2). After reductive animation, the t-butoxycarbonyl protecting group is removed by treatment with a strong acid such as trifluoroacetic acid or formic acid and the resulting amine is acylated to furnish the desired compounds (Example 3). Alternatively, the protecting group may also be present in the azacycle portion as illustrated with a benzyloxycarbonyl group in Example 6. Thus an azacycle containing a benzyloxycarbonylindoline (prepared in Example 4) is alkylated with an aldehyde in the presence of a reducing agent. Next, the protecting group is removed to liberate a free amine (Example 7) and the amine is further reacted to provide additional analogs (Example 8).
SCHEME 1
RCHO, [H]
Figure imgf000053_0001
Strong [H]
Figure imgf000053_0002
In an alternative embodiment of the present invention, the allyl acid 2 (described in Hale et al, see above) can be converted into the N-methyl methoxy amide 3, which is then treated with an alkyl or aryl metal reagent, for example methyllithium or butyllithium, to provide the ketone 4 (Scheme 2). The ketone can be converted into an imine which can then be reduced to secondary amine 5 chemically, (e.g using sodium cyanoborohydride or sodium borohydride), or catalytically (e.g. using hydrogen and palladium on carbon or Raney nickel catalyst). Acylation under standard conditions, for example with an acid chloride, provides amide 6. The allyl group in 6 can be oxidatively cleaved to aldehyde 7 with osmium tetroxide followed by sodium periodate or with ozone at low temperature. Reductive amination of aldehyde 7 with azacycle 1 can then be carried out under the conditions described above.
Substituted spiro(indoline-3,4'-piperidine) derivatives can be prepared as shown in Scheme 3 starting from the appropriately substituted phenylhydrazines. Following the Fischer indole reaction and reduction of the intermediate imine with a mild reducing agent such as sodium borohydride, the indoline nitrogen can be reacted with an electrophile such as an acyl chloride or a sulfonyl chloride. The protecting group on the piperidine nitrogen, for example a benzyloxycarbonyl group, can be removed by treatment with hydrogen in the presence of palladium on carbon or by exposure to trimethylsilyl iodide, to give the deprotected substituted spiro(indoline-3,4'- piperidine).
SCHEME2
Figure imgf000055_0001
1) 0s04
Figure imgf000055_0002
CF3C02H anisole, CH2CI2
Figure imgf000055_0003
SCHEME 3
Figure imgf000056_0001
OBn
Figure imgf000056_0002
Preparation of spiro(2,3-dihydrobenzothiophene-3,4'- piperidine) derivatives is shown in Scheme 4. Reaction of N-Boc protected 4-piperidone with the lithium salt of methyl phenyl sulfoxide followed by base-mediated elimination-rearrangement and basic cleavage provides the indicated allylic alcohol. The alcohol can be converted to the rearranged allylic chloride with thionyl chloride in toluene in the presence of 2,6-lutidine as a proton scavenger. Displacement of the chloride with functionalized 2-bromothiophenol provides the allylic sulfide, which can be cyclized under radical conditions to give the illustrated spiro(2,3-dihydrobenzothioρhene-3,4'- piperidine). Cleavage of the t-butoxycarbonyl group under standard conditions, such as trifluoroacetic acid, then provides the desired spirocycle.
SCHEME 4
Figure imgf000057_0001
Spiro(2,3-dihydrobenzofuran-3 ,4'-piperidine) derivatives can be prepared as illustrated in Scheme 5. Treatment of an appropiately substituted ester of 2-fluorophenylacetate with mechlorethamine hydrochloride under basic conditions provides the piperidine product, which on treatment with a strong reducing agent such as lithium aluminum hydride produces the corresponding 4- (hydroxymethyl) compound. Cyclization with base provides the benzofuran derivative, and cleavage of the N-methyl group can then be carried out using 1 -chloroethyl chloroformate or other suitable N- demethylating agents.
SCHEME 5
Figure imgf000059_0001
Compounds with alternate arrangements of the amide bond can be prepared as shown in Scheme 6. The illustrated acid can be homologated under Amdt-Eistert conditions to give the chain-extended acid, which can be derivatized under standard acylating conditions with, for example, an aniline derivative, to give the corresponding amide. Oxidative cleavage of the olefin with osmium tetroxide or ozone then provides the aldehyde intermediate suitable for coupling as described earlier.
SCHEME 6
Figure imgf000061_0001
In addition, ketone derivatives can be prepared by an extension of the chemistry given above, as shown in Scheme 7. A second Amdt-Eistert chain extension provides the illustrated heptenoic acid derivative, which after conversion into its N-methoxy-N-methyl amide, can be reacted with an aryl organometalhc reagent, such as an aryl magnesium bromide, to provide the ketone. Routine oxidative cleavage then gives the desired aldehyde, which can be coupled with a spiro-piperidine derivative as described above.
SCHEME 7
Figure imgf000063_0001
Figure imgf000064_0001
Alcohol containing antagonists can be prepared according to procedures given in Scheme 8. Formation of the N-methyl-N- methoxy amide of the indicated acid followed by oxidative cleavage of the olefin provides the intermediate aldehyde. Coupling with a spiro(indoline-3,4'-piperidine) derivative followed by addition of an organometalhc reagent to the amide provides the illustrated ketone. Treatment with a hydride reducing agent, such as sodium borohydride, then yields the desired alcohol derivatives.
SCHEME8
10
15
20
25
30
Figure imgf000067_0001
Formation of heterocycle substituted antagonists can be carried out according to the procedure given in Scheme 9 for substituted imidazoles. Reduction of the allyl acid with a strong reducing agent such as lithium aluminum hydride followed by in situ formation of the trifluoromethanesulfonate of the formed alcohol allows for displacement of the triflate with a nucleophile such as 2- phenylimidazole. Oxidative cleavage under standard conditions provides the indicated aldehyde which can then be coupled under the conditions described above to the appropriate spiro derivative.
SCHEME 9
LiAIH, -0H (CF3S02)0
THF 2,6-lutidine
Figure imgf000069_0002
Figure imgf000069_0001
ide
Figure imgf000069_0003
Spiro(2-oxo-l,2,3,4-tetrahydroquinoline-4,4'-piperidine) and spiro( 1-oxo-l, 2,3 ,4-tetrahydroisoquinoline-4,4'-piperidine) can be prepared as shown in Scheme 10. Starting from the indicated spiro(2- oxoindane-3,4'-piρeridine) (described in Claremon, D.A. et al, European Patent 0 431 943 943 A2. Evans, B.E. et al U.S. Patent 5.091.387. Davis, L. et al, U.S. Patent 4.420.485. all of which are incorporated by reference, and Parham et al, Journal of Organic Chemistry. 41. 2628 (1976)), deprotection of the piperidine nitrogen is carried out by treatment with acid, for example trifluoroacetic acid, followed by protection as the trifluoroacetamide, and the product is exposed to hydrazoic acid in the presence of sulfuric acid. Heating of this mixture effects a Schmidt rearrangement, to provide both the tetrahydroquinoline and the tetrahydroisoquinoline derivatives. These spiro compounds can then be separated and coupled to functionalized aldehydes by the methodology given above.
SCHEME 10
Figure imgf000070_0001
Neurokinin antagonists with ether substituents can also be prepared by the route shown in Scheme 11. Thus, the allyl acid discussed earlier can be reduced to the corresponding alcohol with, for example, lithium aluminum hydride. This alcohol can be alkylated by a Williamson ether synthesis, by deprotonation with a strong base such as sodium hydride or sodium hexamethyldisilazide followed by reaction with a benzyl halide such as benzyl bromide. The product can be processed through the oxidative cleavage steps described earlier to provide the aldehyde, which can then be coupled with a spirocycle kunder reductive amination conditions or else by reduction to the corresponding alcohol and conversion to the bromide, the bromide can then be used to alkylate a spirocycle under the conditions detailed above.
SCHEME 11
ide
Figure imgf000071_0001
Accordingly in another aspect the invention encompasses a process of making compounds of formula I
Figure imgf000072_0001
I as defined above, comprising the steps of: (a) reacting a compound of formula A
Figure imgf000072_0002
H
in a suitable solvent such as acetonitrile or dimethylacetamide with a compound of formula Rl-Xl wherein Xl is a leaving group such as bromo, chloro, tosyl or mesyl optionally in the presence of a suitable base such as trialkylamine; or
(b) reacting a compound of formula A in a second suitable solvent such as methanol or ethanol with a compound of the formula R-CH(O), wherein R-CH2 is Rl as defined above, in the presence of a reducing agent such as sodium cyanoborohydride or hydrogen and a palladium on carbon catalyst; or
(c) reacting a compound of formula A in a halocarbon solvent such as methylene chloride with a compound of the formula R-C(0)X2 wherein X2 is a suitable leaving group such as bromo or chloro in the presence of a suitable base such as trialkylamine, to yield a compound of formula I.
EXAMPLE 1
S-fS^-CS -DichlorophenvD^-fN-Ct-butoxycarbonvπmethylamino butanal
A solution of 10 g (41 mmol) of 3-(S)-(3,4-dichloro- phenyl)-4-methylamino-l-pentene in 100 mL of CH2CI2 was cooled in an ice bath and treated with 5.8 mL (41 mmol) of triethylamine (Et3N) and 9 g (41 mmol) of di-t-butyl dicarbonate. The cold bath was removed after 5 min and the stirring was continued for 1 h. The reaction mixture was diluted with CH2CI2 and washed with water, 1.2 N HCI, saturated NaHCθ3 and brine. The solution was dried over Na2Sθ4 and concentrated to give 14.58 g of residual oil. lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.36 (s, 9H), 2.33 (m, 2H), 2.60 & 2.70 (2s, 3H), 2.8-3.6 (m, 3H), 4.94 (m, 2H), 5.59 (m, IH), 6.9-7.4 (m, 3H).
The residue was dissolved in 80 mL of acetone, 40 mL of t- butanol and 40 mL of water. To this solution 1 mL of osmium tetroxide (4% solution in water) and 5.15 g (44 mmol) of 4- methylmorpholine N-oxide were added. After stirring for 26 h, the reaction was quenched with approximately 5 g of Na2Sθ3 and concentrated to 25% of the original volume. The residue was partitioned between water and 1:1 ether (Et2θ), ethyl acetate (EtOAc), the layers were separated and the aqueous layer was extracted with Et2θ:EtOAc. Each organic layer was washed with water, brine and dried by filtering through Na2S04. The filtrate was concentrated to afford the crude diol.
A solution of the diol in 120 mL of tetrahydrofuran (THF) and 40 mL of water was treated with 9.42 g (44 mmol) of sodium periodate. After stirring for 2 h, the reaction was diluted with
Et2θ:EtOAc and washed with water and brine. The organic layer was dried (Na2Sθ4) and the filtrate was concentrated. The residue was purified by prepLC using 30% EtOAc/hexane to furnish 11.74 g (83% yield for three steps) of the title compound as a thick oil. lH NMR (CDC13, ppm ranges are given because of amide rotomers and line broadening) δ 1.38 (s, 9H), 2.69 & 2.75 (2s, 3H), 2.6-3.65 (m, 5H), 6.95-7.4 (m, 3H), 9.67 (s, IH).
EXAMPLE 2
l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(t- bi]toxycarbonyl¥methylamino butv -l -methanesulf onyl- spirof indoline-3.4'-piperidine
To a solution of 0.76 g (2.2 mmol) of 3-(S)-(3,4- dichlorophenyl)-4-(N-(t-butoxycarbonyl)methylamino)butanal ( from Example 1) in 4 mL of methanol were added 0.608 g (2 mmol) of 1- methane-sulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride and 0.6 g of powdered 4 A molecular sieves. After 15 min a solution of 0.554 g (8.8 mmol) of NaCNBH3 in 8 mL of THF was dropwise added. Some gas evolution was observed. After 2 h, when the reaction was complete by TLC, the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with methanol. The filtrate was concentrated to approximately 5 ml and the residue was partitioned between saturated NaHCθ3 and Et2θ:EtOAc. The organic layer was washed with water, brine and dried over Na2S04- The filtrate was concentrated and the residue was chromatographed on a flash column using a gradient of 49:49:2 to 74:24:2 EtOAc:hexane: triethylamine to furnish 0.94 g (72%) of the title compound as a foam. lH NMR (CDC13, ppm ranges are given because of amide rotomers and line broadening) δ 1.37 (s, 9H), 1.6-3.6 (m, 15H), 2.61 & 2.72 (2s, 3H), 2.86 (s, 3H), 3.74 (s, 2H), 6.95-7.4 (m, 7H).
EXAMPLE 3 l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino)) butyl)- 1 -methanesulf onyl - piroCindoline-S^'-piperidine
Step A: l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-l- methanesulfonyl-spirofindoline-S^'-piperidine)
Cold trifluoroacetic acid (TFA, 4 mL) and 0.2 mL of anisole were added to 0.94 g (1.57 mmol) of l'-(3-(S)-(3,4- dichlorophenyl)-4-(N-(t-butoxycarbonyl)(methylamino))butyl)-l- methanesulfonyl-spiro(indoline-3,4'-piperidine) and the mixture was stirred in an ice bath until all the foam dissolved. After stirring the resulting solution at room temperature for 30 min, it was concentrated in vacuo. The residue was partitioned between 0.5 N NaOH and CH2CI2 and the layers were separated. The organic layer was washed with brine, dried over Na2Sθ4 and concentrated to give 0.7 g of foam which was used in the next step without purification. lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.7-2.7 (m, 10H), 2.64 (s, 3H), 2.88 (s, 3H), 2.9-3.4 (m, 5H), 3.70 (s, 2H), 6.8-7.4 (m, 7H).
Step B: l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfony 1- spiroCindoline-3 ^'-piperidine
A solution of 0.12 g (0.52 mmol) of 3,5-dimethylbenzoic acid in 2 mL of CH2CI2 containing 1 drop of DMF was treated with 85 ul of oxalyl chloride. (Caution-gas evolution!) After 20 min the solution was concentrated in vacuo and the residue was mixed with 0.2 g (0.4 mmol) of l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)- l-methane-sulfonyl-spiro(indoline-3,4'-piperidine) obtained from Step A, and 0.14 mL (1 mmol) of Et3N in 2 mL of CH2CI2. After 1 h the reaction mixture was diluted with CH2CI2 and washed with saturated NaHC03, water, and brine. The CH2CI2 solution was dried over Na2S04, filtered and concentrated. Purification of the residue by prep TLC using 2% Et3N/EtOAc afforded 0.238 g (93% yield) of the title compound as a foam. lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.6-2.4 (m, 10H), 2.27 (s, 6 H), 2.6-3.9 (m, 10H), 2.86 (s, 3H), 6.6-7.5 (m, 10H).
The following compounds were prepared by substituting the required acid chloride for 3,5-dimethylbenzoyl chloride in Step B. l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)(methylamino)) butyl)-
1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum (FAB) 602 (37Q + 35C1 isotope), 600 (35C1 + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulf ony 1- spiro(indoline-3,4'-piperidine)
Mass Spectrum (FAB) 738 (37C1 + 35C1 isotope), 736 (35C1 + 35C1 isotope).
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)
(methylamino))-butyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine) lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.6-2.4 (m, 10H), 2.32 (s, 3H), 2.6-3.9 (m, 10H),
2.86 (s, 3H), 6.75-7.5 (m, 11H).
Mass Spectrum (FAB) 616 (37C1 + 35C1 isotope), 614 (35C1 + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)
(methylamino))-butyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine) lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.6-2.4 (m, 10H), 2.6-3.9 (m, 10H), 2.86 (s, 3H),
6.75-7.5 (m, 11H). Mass Spectrum (FAB) 635 (37C1 + 35C1 isotope), 633 (35C1 + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-trifluoromethylbenzoyl)
(methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'- piperidine)
Mass Spectrum (FAB) 669 (37d + 35ci isotope), 667 (35d + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)
(methylamino))-butyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine) lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.6-2.4 (m, 10H), 2.6-3.9 (m, 10H), 2.86 (s, 3H),
6.75-7.5 (m, 10H).
Mass Spectrum (FAB) 671 (37C1 + 35ci isotope), 669 (35C1 + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-trifluoromethylphenylacetyl) (methylamino))butyl)-l-methanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 684 (37C1 + 35C1 isotope), 682 (35d + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-isopropyloxyphenylacetyl)
(methyl-amino))butyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine)
1 '-(3-((S)-(3 ,4-Dichloropheny l))-4-(N-(benzenesulf ony 1)
(methylamino))-butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'- piperidine) lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.65 (m, 3H), 1.8-2.3 (m, 7H), 2.62 (s, 3H), 2.7-3.05
(m, 4H), 2.86 (s, 3H), 3.3 (m, 2H), 3.74 (s, 2H), 7.0-7.7 (m, 12H). Mass Spectrum (FAB) 637 (37ci + 35C1 isotope), 635 (35d + 35d isotope).
The following compounds were also prepared by using the appropriate acid chloride under the conditions given in Step B above: l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-difluorobenzoyl)(methyl- amino))butyl)-l -methanesulf onyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 638(37d + 35d isotope), 636(35d + 35d isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)- benzoyl)(methylamino))butyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine)
Mass Spectrum (CI) 688 (37C1 + 35C1 isotope), 686 (35d + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(l-naphthoyl)(methylamino))- butyl)-l-methanesulfonyl-spiro(indoline-3,4'-piperidine) lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) d
Mass Spectrum (FAB) (37C1 + 35C1 isotope), (35C1 + 35d isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(2-chlorophenylsulfonyl)- (methylamino))butyl)-l-methylsulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectmm: 200, 202, 228, 230, 279, 308, 310, 494, 496, 670, 672 (cluster).
l'-(3-((S)-(3,4-Dichlorophenyl))-l-(N-(3-chlorophenylsulfonyl)-
(methylamino))-4-butyl)- 1 -methylsulfonyl-spiro(indoline-3 ,4'- piperidine)
Mass Spectmm: 200, 202, 228, 230, 279, 308, 310, 494, 496, 670, 672
(cluster). l'.(3.((S)-(3,4-Dichlorophenyl))-4-(N-(4-chlorophenylsulfonyl)- (methylamino))butyl)- 1 -methylsulf onyl-spiro(indoline-3 ,4'-piperidine) Mass Spectrum: 200, 228, 230, 279, 494, 496, 669 (cluster).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorophenylsulfonyl)- (methylamino))butyl)- 1 -methylsulf ony l-spiro(indoline-3 ,4'-piperidine) Mass Spectrum: 228, 230, 279, 494, 496, 703, 705 (cluster).
EXAMPLE 4
l-Benzyloxycarbonyl-spiro(indoline-3.4'-piperidinium) hydrochloride A solution of 99 g (489 mmol) of l'-methylspiro(indoline- 3,4'-piperidine) (prepared according to Ong, H. H. et al, J. Med. Chem., 1983, 26, 981-986) in 1 L of CH2CI2 and 82 mL (539 mmol) of Et3N was cooled to 0-5°C with an ice bath and 77 mL (539 mmol) of benzyl chloroformate was added over 30 min keeping the reaction temperature below 10°C. After stirring for 2 h 19 mL (136 mmol) of Et3N and 15 mL (105 mmol) of benzyl chloroformate were added since the reaction was incomplete and stirred for 2 h. At this time, additional 19 mL (136 mmol) of Et3N and 15 mL (105 mmol) of benzyl chloroformate were added. After 1 h, when a TLC indicated a complete reaction, the solution was concentrated in vacuo and the residue was partitioned between ether and saturated NaHCθ3. The layers were separated, the organic layer was washed with saturated NaHCθ3 and brine, and dried over MgS04. The filtrate was concentrated and the residue was chromatographed on 2 kg of silica gel using 1-5% MeOH/CH2θ2 to obtain 117 g (71 %) of l-benzyloxycarbonyl-l'-methylspiro(indoline- 3,4'-piperidine) as a yellow oil.
The yellow oil was dissolved in 800 mL of 1,2- dichloroethane and cooled in ice bath as 50 mL (463 mmol) of 1- chloroethyl chloroformate keeping the temperature below 10°C. The resulting solution was heated to reflux. Gas evolution was noticed when the reaction temperature reached 70-75 °C. After 1 h the solution was cooled, concentrated to ca. 250 mL in vacuo and 700 mL of methanol was added. The mixture was refluxed for 1.5 h and gas evolution was observed. The reaction was cooled to room temperature and concentrated in vacuo to a wet solid. The solid was slurried with cold methanol, the solid was filtered, washed with cold methanol and dried. The filtrates and the washing were combined and concentrated to a brown foam. The brown foam and the filtered solid were suspended in CH2CI2, washed with 2.5 N NaOH and the CH2CI2 solution was dried. The residue was chromatographed on 2 kg of silica gel using a gradient of 94:5:1 to 89:10:1 CH2CI2, methanol, NH4OH to isolate 91.3 g of free base as a brown oil. The oil was dissolved in 1 L of EtOAc by adding methanol (ca. 10 mL) and HCI gas was passed through the solution. After stirring the acidic solution for 10 min, it was concentrated to a foam. The foam was triturated with ether and the solid was filtered, washed with more ether and dried to furnish 91.5 g (73%) of title compound as a light yellow solid.
EXAMPLE 5
3-((S)-(3,4-Dichlorophenyl))-4-((3,5-dimethylbenzoyl)methylamino)- butanal
The title compound was prepared using the procedures described in Example 1 by substituting 3,5-dimethylbenzoyl chloride for di-t-butyl dicarbonate. lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 2.27 (s, 6H), 2.6-3.9 (m, 8H), 6.5-7.5 (m, 6H), 9.73 (s, IH).
EXAMPLE 6
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methyl-
Figure imgf000080_0001
The title compound was prepared from 3-((S)-(3,4- dichlorophenyl))-4-((3,5-dimethylbenzoyl)methylamino)butanal (Example 5) and l-benzyloxycarbonyl-spiro(indoline-3,4'- piperidinium) hydrochloride (Example 4) following the procedure of
Example 2. lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.6-2.35 (m, 10H), 2.27 (s, 6H), 2.6-3.9 (m, 10H),
5.23 & 5.3 (2 s, 2H), 6.6-7.6 (m, 15H).
Mass Spectrum (FAB) 686 (37C1 + 35d isotope), 684 (35d + 35C1 isotope).
EXAMPLE 7
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) methylamino) )butyl spiro('indoline-3.4'-piperidineN)
To a solution of 1.23 g (1.8 mmol) of l'-(3-((S)-(3,4- dichlorophenyl))-4-(3,5-dimethylbenzoyl(methylamino))butyl)-l- benzyoxycarbonyl-spiro(indoline-3,4'-piperidine) (Example 6) in 10 mL of ethanol and 0.8 mL of acetic acid (HO Ac) was added 0.15 g of 10% Pd/C. The resulting mixture was hydrogenated on a Pan- apparatus for 20 h. The catalyst was filtered and washed with EtOH. The combined filtrate was concentrated in vacuo and the residue was dissolved in CH2CI2. The CH2CI2 solution was washed with dilute (ca 0.5 N) NaOH and brine, and dried by filtering through Na2Sθ4. The filtrate was concentrated to furnish 1.03 g (quantitative) of the title compound as a foam which was used in the next reaction without purification. lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.6-2.45 (m, 10H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 6.5-7.5 (m, 10H).
Mass Spectrum (FAB) 552 (37C1 + 35d isotope), 550 (35C1 + 35d isotope).
EXAMPLE 8
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) methylamino^butyl l-acetyl-spiroCindoline-S^'-piperidine Acetyl chloride (16 uL) was added to a solution of 0.1 g (0.18 mmol) of l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-spiro(indoline-3,4'-piperidine) (Example 7) in 4 mL of CH2CI2 containing 30 mL of pyridine. After stirring for 2 h, the reaction mixture was diluted with CH2CI2 and washed with saturated NaHC03, water, brine and dried. The residue after concentration of the filtrate was purified by prep TLC using 5% Et3N/EtOAc as an eluent to afford 90 mg (84%) of the title compound. lH NMR (CDCI3, ppm ranges are given because of amide rotomers and line broadening) δ 1.55-2.5 (m, 10H), 2.22 (s, 3H), 2.27 (s, 6H), 2.6-3.9 (m, 10H), 6.6-7.5 (m, 9H), 8.17 (d, IH, J = 12Hz). Mass Spectrum (FAB) 594 (37ci + 35C1 isotope), 592 (35d + 35d isotope).
The following analogs were prepared by substituting the appropriate acylation reagent for acetyl chloride in the above procedure. l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methyl- amino))butyl)-l-propionyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 608 (37d + 35d isotope), 606 (35d + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)-l -formyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 580 (37d + 35C1 isotope), 578 (35d + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)- l- -butylcarbonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 636 (37d + 35C1 isotope), 634 (35d + 35d isotope). l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)
(methylamino)) butyl)-l -methylaminocarbonyl-spiro(indoline-3,4'- piperidine)
Mass Spectmm (FAB) 609 (M+H, 37d + 35d isotope), 607 (M+H,
35C1 + 35C1 isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)- l-ethoxycarbonyl-spiro(indoline-3,4'-piperi dine) Mass Spectrum (FAB) 624 (37C1 + 35C1 isotope), 622 (35d + 35ci isotope).
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl) (methylamino)) butyl)- l-ethanesulfonyl-spiro(indoline-3,4'-piperidine) Mass Spectrum (FAB) 643 (37C1 + 35C1 isotope), 641 (35d + 35d isotope).
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)
(methylamino)) butyl)-l- -propanesulfonyl-spiro(indoline-3,4'- piperidine)
Mass Spectrum (FAB) 657 (37C1 + 35C1 isotope), 655 (35d + 35C1 isotope).
The following compound can also be prepared under the conditions given above: l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-fluoro-5-(trifluoromethyl)- benzoyl)(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine) Mass Spectmm (FAB) (CI) 652 (37d + 35ci isotope), 650 (35d +35C1 isotope).
An alternative method (method B) is given below: l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methyl- amino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine)
1 - Acetyl-spiro(indoline-3 ,4'-piperidine) Acetyl chloride (1.4 mL, 19.9 mmol) was added to a solution of 5.35 g (16.6 mmol) of l'-benzyloxycarbonyl-spiro(indoline- 3,4'-piperidine) in 33 mL of CH2CI2 and 3.2 mL (23.2 mmol) of Et3N keeping the temperature between 0-5°C by cooling in ice bath. After 10 min the cold bath was removed and reaction was stirred for 30 min at which time a TLC indicated complete reaction. The solution was diluted with CH2CI2 and washed with water, brine and dried over Na2S04. The filtrate was concentrated to a thick oil and the oil was dissolved in 40 mL of EtOH. Acetic acid (3 mL) and 0.8 g of 10% Pd/C were added to the solution and the resulting mixture was hydrogenated on a Parr apparatus for 3 h. The catalyst was filtered and washed with EtOAc and the combined filtrate was concentrated. The residue was partitioned between CH2CI2 and water and 2N NaOH was added to this mixture until the aqueous layer was basic. The layers were separated and the aqueous layer was extracted with CH2CI2. The combined organic layer was washed with brine, dried over Na2Sθ4 and the filtrate was concentrated to give 2.93 g (77%) of the title compound sufficiently pure for use in the next reaction.
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methyl- amino butylVl -acetyl-spiro('indoline-3.4'-piperidines)
To a solution of 0.284 g (0.75 mmol)of 3-((S)-(3,4- dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))butanal (Example 5) in 2 mL of MeOH were added 0.166 g (0.72 mmol) of 1- acetyl-spiro(indoline-3,4'-piperidine), 0.5 g of powdered 4 A molecular sieves and 10 drops (ca. 0.1 mL) of acetic acid. After stirring the mixture for 1.5 h a solution of 0.189 g (3 mmol) of NaCNBH3 in 3 mL of THF was added. Some gas evolution was observed. After 30 min when the reaction was complete by TLC the mixture was filtered through a pad of celite, the reaction flask and the pad were rinsed with MeOH. The filtrate was concentrated to approximately 3 mL and the residue was diluted with EtOAc. The EtOAc solution was washed with water, brine and dried over Na2S04. The filtrate was concentrated and the residue was chromatographed on a flash column using 50% EtOAc- hexane followed by 2% Et3N-EtOAc and finally 93:5:2 EtOAc: MeOH: Et3N to isolate 0.317 g (74%) of the title compound as a white foam.
EXAMPLE 9
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(3,5- dimethylbenzoyl(methylamino)) butyl)- 1 '-methyl- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidinium) iodide
A solution of 53 mg (0.084 mmol) of l'-(3-((S)-(3,4- dichlorophenyl))-4-(3 ,5-dimethylbenzoyl (methy lamino))butyl)-l- methanesulfonyl-spiro(indoline-3,4'-piperidine) in 5 drops of MeOH was diluted with 1 mL of ether and 0.5 mL of methyl iodide was added. The reaction mixture was stirred overnight while a solid was formed. The yellowish solid was allowed to settle and the supematent was removed. The solid was washed with ether and dried to furnish 51 mg (78%) of the title compound.
EXAMPLE 10
l'_(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3-methylbenzoyl) (methyl-amino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'- piperidine
Step 1 : N-Methoxy-N-methyl-2-(S)-(3,4-dichlorophenyl)-4- pentenamide
A mixture of 306 mg (1.25 mmol) of (2S)-(3,4- dichlorophenyl)-4-pentenoic acid (prepared according to the procedure of Hale, J.J.; Finke, P.E.; MacCoss, M. Bioorganic & Medicinal Chemistry Letters 1993,3, 319-322) and 202 mg (1.50 mmol) of 1- hydroxybenzotriazole hydrate in 10 mL of methylene chloride was cooled to 0°C and treated with 287 mg (1.50 mmol) of l-(3-dimethyl- aminopropyl)-3-ethylcarbodiimide. The cooling bath was removed and after 45 min. a solution of 365 mg (3.75 mmol) of N,0-dimethyl- hydroxylamine hydrochloride and 522 μl (3.75 mmol) of triethylamine in 10 mL of methylene chloride was added via cannula. The mixture was then stirred at 22°C for 4 hours and then quenched with 10 mL of water and diluted with 8 mL of methylene chloride. The layers were separated and the aqueous layer was extracted with methylene chloride (2 x 10 mL). The combined organic layers were washed with 10 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 75 g of silica gel using 1:9 v/v ethyl acetate/ hexane as the eluant afforded 319 mg (89%) of the title compound as a clear oil. lH NMR (400 MHz, CDCI3) δ 2.40 (pentet, IH), 2.75 (pentet, IH), 3.13 (s, 3H), 3.52 (s, 3H), 3.99-4.01 (m, IH), 4.96-5.05 (m, 2H), 5.63-5.70 (m, IH), 7.15 (dd, IH), 7.35 (d, IH), 7.41 (d, IH). Mass Spectmm (FAB): m/z 290 (M+H, 37C1 + 35d isotope, 50%), 288 (M+H, 37C1 + 37C1 isotope, 100%).
Step 2: 3-(S - .4-dichlorophenylV5-hexen-2-one
A solution of 319 mg (1.11 mmoL) of N-methoxy-N- methyl-2-(S)-(3,4-dichlorophenyl)-4-pentenamide (from Step 1 above) in 10 mL of dry tetrahydrofuran was cooled to -70°C and treated with 1.0 mL (1.40 mmol) of methyllithium and stirred between -70°C to -40°C. After 3 hours, the reaction was quenched with 5 mL of water, and diluted with 10 mL of ethyl acetate. The layers were separated and the organic layer was washed with water (3 x 10 mL). The aqueous layers were extracted with 10 mL of ethyl acetate. The combined organic layers were washed with 10 mL of saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 44 g of silica gel using 1 :3 v/v ethyl acetate/hexane as the eluant afforded 250 mg (93%) of the title compound as a clear oil. lH NMR (400 MHz, CDCI3) δ 2.07 (s, 3H), 2.36 (pentet, IH), 2.72 (pentet, IH), 3.64 (t, IH), 4.95-5.01 (m, 2H), 5.55-5.65 (m, IH), 7.03 (dd, IH), 7.30 (d, IH), 7.39 (d, IH). Mass Spectmm (FAB): m/z 245 (M+H, 37C1 + 35d isotope, 30%), 243 (M+H, 37C1 + 37C1 isotope, 50%), 155 (60%), 119 (100%).
Step 3: N-Methyl 3-(S)-(3,4-dichlorophenyl)-5-hexen-2-(RS)- amine
A mixture of 102 mg (0.42 mmol) of 3-(S)-(3,4- dichlorophenyl)-5-hexen-2-one (from Step 2 above), 170 mg (2.52 mmol) of methylamine hydrochloride, and 234 μl (1.68 mmol) of triethylamine in 4.0 mL of methanol was treated with 16 mg (0.25 mmol) of sodium cyanoborohydride and stirred at 22°C for 20 hours. Saturated aqueous sodium bicarbonate solution (1.0 mL) was added and the resulting milky mixture was diluted with 5.0 mL of ethyl acetate and 5.0 mL of water. The layers were separated and the organic layer was washed with water (3 x 5 mL). The aqueous layers were extracted with 10 mL of ethyl acetate. The combined organic layers were washed with 10 mL of saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 42 g of silica gel using 10:1 v/v ether/ hexane as the eluant afforded 64 mg of the higher Rf isomer (Isomer A) and 22 mg of a lower Rf isomer (Isomer B) both as yellow oils. lH NMR (400 MHz, CDCI3); Isomer A: δ 1.04 (d, 3 H), 2.29-2.35 (m, 4 H), 2.50-2.68 (m, 3H), 4.86-4.95 (m, 2H), 5.48-5.56 (m, IH), 7.01 (dd, IH), 7.26 (d, IH), 7.34 (d, IH); Isomer B: δ 0.86 (d, 3H), 2.32- 2.50 (m, 4H), 2.51-2.53 (m, IH), 2.68-2.73 (m, 2H), 4.88-4.98 (m, 2H), 5.54-5.61 (m, IH), 6.97 (dd, IH), 7.22 (d, IH), 7.33 (d, IH). Mass Spectrum (Isomer A) (FAB): m/z 260 (M+H, 37C1 + 35d isotope, 70%), 258 (M+H, 35d + 35C1 isotope, 100%).
Step 4: N-Methyl-N-t-butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-
5-hexen-2-CRS -amine
A solution of 1.1 g (4.1 mmol) of N-methyl-(3-(S)-(3,4- dichlorophenyl)-5-hexen-2-(R or S)-amine (Isomer B from Step 3 above) in 10 mL of dry methylene chloride was cooled to 0°C and treated with 690 μl (5.0 mmol) of triethylamine and 1.2 g (5.3 mmol) of di-tert-butyl dicarbonate. The cooling bath was removed and the reaction was stirred at 22°C for 20 hours. The reaction was quenched with 10 mL of water and diluted with 25 mL of methylene chloride. The layers were separated and the aqueous layer was extracted with methylene chloride (2 x 10 mL). The combined organic layers were washed with 15 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 72 g of silica gel using 1:3 v/v ethyl acetate/ hexane as the eluant afforded 1.4 g (95%) of the title compound as a yellow oil. lH NMR (400 MHz, CDCI3, ranges are given due to amide rotamers and line broadening) δ 1.24-5.70 (22H), 6.88-7.40 (3H), 1.50 (s, 3H, N- CH3).
Mass Spectmm (FAB): m/z 358 (M+H, 37d + 35C1 isotope, 30%), 302 (100%).
Step 5: N-Methyl-N-t-butoxycarbonyl-3-(S)-(3 ,4-dichlorophenyl)-
4-fRSVamino-pentanal
A solution of 1.4 g (3.9 mmol) of N-methyl-N-t-butoxy- carbonyl-3-(S)-(3 ,4-dichlorophenyl)-5-hexen-2-(RS)-amine (from Step 4 above) in 20 mL of 2:1 :1 v/v/v acetone/t-butanol/water was treated with 30 mg (0.12 mmol) of osmium tetroxide. After 5 min., 691 mg (5.90 mmol) of N-methylmorpholine N-oxide was added and the resulting mixture was stirred at 22°C for 4 hours. The reaction was quenched with 491 mg of sodium bisulfite and concentrated in vacuo to 25% of the original volume. The residue was partitioned between 20 mL of methylene chloride and 10 mL of water and the layers were separated. The aqueous layer was extracted with methylene chloride (2 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. A solution of the crude diol in 24 mL of 3:1 v/v tetrahydrofuran/water was treated with 1.1 g (5.1 mmol) of sodium periodate and stirred at 22°C for 20 hours. The reaction mixture was partitioned between 20 mL of ethyl ether and 10 mL of water and the layers were separated. The organic layer was washed with water (2 x 15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 68 g of silica gel using 4:1 v/v ethyl ether/hexane as the eluant afforded 372 mg of the higher Rf isomer (Isomer A) and 879 mg of a lower Rf isomer (Isomer B) both as yellow oils. lH NMR (400 MHz, CDCI3) Isomer B: δ 1.19-1.34 (m, 13H), 2.45 (s,
3H, N-CH3), 2.68-2.81 (m, 2H), 3.28-3.34 (m, IH), 4.20-4.50 (m, IH),
6.98-7.32 (m, 3H), 9.60 (s, IH, -CHO).
Mass Spectrum (Isomer B) (FAB): m/z 360 (M+H, 37ci + 35C1 isotope, 20%), 242 (100%).
Step 6: l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(t-butoxy- carbonyl)(methylamino))pentyl)- 1 -methanesulfonyl- spiro(indoline-3 ,4'-piperidine
A mixture of 217 mg (0.60 mmol) of N-methyl-N-t- butoxycarbonyl-3-(S)-(3,4-dichlorophenyl)-4-(RS)-amino-pentanal (from Step 5 above) and 262 mg (0.86 mmol) of 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine) hydrochloride in 13 mL of methanol was treated with 115 mg (1.83 mmol) of sodium cyanoborohydride and stirred at 22°C for 20 hours. Saturated sodium bicarbonate solution (1.0 ml) was added and the resulting milky mixture was concentrated to 50% of its original volume. The residue was partitioned between 25 mL of ethyl acetate and 15 mL of water and the layers were separated. The organic layer was washed with water (3 x 10 mL). The aqueous layers were extracted with 20 mL of ethyl acetate. The combined organic layers were washed with 15 mL of brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromato¬ graphy on 42 g of silica gel using 5:95 v/v methanol/methylene chloride as the eluant afforded 329 mg (89%) of the title compound as a white foam. lH NMR (400 MHz, CDCI3, ranges are given due to amide rotamers and line broadening) δ 1.20-2.90 (31H), 3.74 (s, 3H, N-SO2CH3), 7.05- 7.41 (m, 8H). Mass Spectmm (FAB): m/z 612 (M+H, 37C1 + 35C1 isotope, 70%), 610 (M+H, 37C1 + 37C1 isotope, 100%).
Step 7: l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)- fmethylamino^pentyl 1 -methanesulfonyl-spirofindoline- 3.4'-piperidine
To a solution of 329 mg (0.54 mmol) of l'-(3-(S)-(3,4- dichlorophenyl)-4-N((R or S)-(t-butoxycarbonyl) (methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'- piperidine) (from Step 6 above) in 8.0 mL of dry methylene chloride at 0°C was added 117 μl (1.1 mmol) of anisole and 2.0 mL of trifluoroacetic acid. The cooling bath was removed and the reaction was stirred at 22°C for 20 minutes. The reaction was concentrated in vacuo. The residue was partitioned between 10 mL of methylene chloride and 5.0 mL of water. The organic layer was washed with 2N NaOH (3 x 5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography on 42 g of silica gel using 5:95:0.5 v/v/v methanol/methylene chloride/ammonium hydroxide as the eluant afforded 221 mg (80%) of the title compound as a clear oil.
IH NMR (400 MHz, CDCI3) δ 1.05 (d, 3H, J = 6.2Hz), 1.62-2.85 (m, 17H), 2.30 (s, 3H, N-CH3), (7.03-7.37 (m, 7H).
Mass Spectmm (FAB): m/z 512 (M+H, 37d + 35d isotope, 70%), 510 (M+H, 37C1 + 37C1 isotope, 100%).
Step 8: l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3-methyl- benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl- spirofindoline-3.4'-piperidine
The title compound was prepared from l'-(3-(S)-(3,4- dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine) (from Step 7 above) using a procedure identical to Example 3, Step (b), substituting m-toluoyl chloride for 3,5-dimethylbenzoyl chloride. lH NMR (400 MHz, CDCI3, ranges are given due to amide rotamers and line broadening) δ 1.42 (δ, 3H, J = 6.7Hz), 1.60-2.30 (16H), 2.54 (s, 3H, Ph-CH3), 2.87 (s, 3H, N-CH3), 3.74 (s, 3H, N-SO2CH3), 7.05- 7.79 (m, 11H).
Mass Spectmm (FAB): m/z 630 (M+H, 37C1 + 35d isotope, 70%), 628 (M+H, 37C1 + 37C1 isotope, 100%).
EXAMPLE 11
l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(R or S)-(3,5-bis(trifluoromethyl)- benzoyl)(methylamino))pentyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'- piperidine)
The title compound was prepared from l'-(3-(S)-(3,4- dichlorophenyl)-4-(R or S)-(methylamino)pentyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3 Step (b), substituting 3,5- bis(trifluoromethyl)benzoyl chloride for 3,5-dimethylbenzoyl chloride. lH NMR (400 MHz, CDCI3, ranges are given due to amide rotamers and line broadening) δ 1.38-3.00 (22H), 3.74 (s, 3H, N-SO2CH3), 6.40- 7.41 (m, 10H).
Mass Spectmm (FAB): m/z 752 (M+H, 37C1 + 35d isotope, 40%), 750 (M+H, 37C1 + 37C1 isotope, 60%), 241 (100%).
EXAMPLE 12
l'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(3,5- dimethylbenzoyl(methyl-amino )pentyl)- 1 -methanesulfonyl- spiroCindoline-S .4'-piperidine
The title compound was prepared from l'-(3-(S)-(3,4- dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-l -methanesulfonyl- spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3, Step (b). lH NMR (400 MHz, CDCI3, ranges are given due to amide rotamers and line broadening) δ 1.37-2.86 (28H), 3.74 (s, 3H, N-SO2CH3), 6.24-
7.41 (m, 10H).
Mass Spectmm (FAB): m/z 642 (M+H, 37d + 35C1 isotope, 70%), 644 (M+H, 37C1 + 37C1 isotope, 100%).
EXAMPLE 13
(l'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(3,5-dichlorobenzoyl- (methy lamino))pentyl)- 1 -methanesulf ony l-spiro(indoline-3 ,4'- piperidine)
The title compound was prepared from l'-(3-(S)-(3,4- dichlorophenyl)-4-(R or S)-(methylamino)pentyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine) (from Example 1, Step 7 above) using a procedure identical to Example 3, Step (b), substituting 3,5-dichloro- benzoyl chloride for 3,5-dimethylbenzoyl chloride. lH NMR (400 MHz, CDCI3, ranges are given due to amide rotamers and line broadening) δ 1.38-2.93 (22H), 3.73 (s, 3H, N-SO2CH3), 6.53-
7.42 (m, 10H).
Mass Spectmm (FAB): m/z 684 (M+H, 37d + 35d isotope, 70%), 686 (M+H, 37C1 + 37C1 isotope, 100%).
EXAMPLE 14 l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5-methylbenzoyl)- (methylamino butylVl-methanesulfonyl-spiro(indoline-3.4'-piperidine
Step A: 3-Bromo-5-methylbenzoic acid
To a solution of 0.38 g (1.44 mmol) of 3-bromo-5-methyl- benzyl bromide (prepared by NBS bromination of 3,5-dimethyl- bromobenzene) in 22 mL of MeCN and 50 mL of water was added 7.8 mL (28.8 mmol) of aqueous sodium hypochlorite (13% active CI). The mixture was allowed to stand in an ultrasonic cleaning bath for 14 h. The reaction was acidified with HCI to pH 3 and extracted with CH2CI2. The organic layer was washed with water, brine and dried with Na2Sθ4. The filtrate was concentrated and the residue which was a mixture of the desired acid and the aldehyde was dissolved in 3 mL of acetone. The solution was treated with 6 N Jones reagent until the orange color persisted. After stirring for 20 min the excess reagent was destroyed by adding few drops of i-PrOH. The solution was diluted with water and extracted with CH2CI2. The CH2CI2 layer was washed with brine, dried and the filtrate was concentrated. The residue was purified by prep TLC using 0.5:30:69.5 of HOAc:EtOAc:hexane to isolate 0.14 g (45 %) of 3-bromo-5-methylbenzoic acid.
Step B: l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5- methy lbenzoyl)(methylamino))buty 1)- 1 -methanesulf onyl- spiro(indoline-3.4'-piperidine
3-Bromo-5-methylbenzoic acid was used in the acylation reaction according to the procedure of Example 3, Step B to obtain the title compound.
Mass Spectrum (CI) 696 (37d + 35d isotope), 694 (35d + 35ci isotope).
EXAMPLE 15
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino^butylVl-^-aminoacetylVspiro indoline-S^'-piperidine
A solution of 65 mg (0.31 mmol) of carbobenzyl- oxyglycine in 3 mL of CH2CI2 was treated with 82 mg (0.41 mmol) of l-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 56 mg (0.41 mmol) of 1 -hydroxybenzotriazole and 42 mg (0.41 mmol) of N- methylmorpholine. After 10 min 123 mg (0.21 mmol) of l'-(3-((S)- (3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)(methylamino))- butyl)-spiro(indoline-3,4'-piperidine) (Example 7) was added and the reaction was stirred for 2 h. The mixmre was diluted with CH2CI2 and washed with water, brine, dried and concentrated to give 0.184 g of residue. The residue in 10 drops of HO Ac was dissolved in 3 mL of EtOH and the solution was hydrogenated on a Parr apparatus for 16 h. The catalyst was filtered and washed with EtOAc. The filtrate was washed with 10% Na2Cθ3, brine and concentrated. The residue was purified by prep TLC using 30% MeOH-EtOAc to give 80 mg (59%) of the title compound. Mass Spectrum (CI) 651 (37d + 35d isotope), 649 (35d + 35ci isotope).
EXAMPLE 16
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- fmethylamino) butylVl-methyl-spiro('indol-2-one-3.4'-piperidines)
Step A: 1.r-Dimethyl-spiro(ιndol-2-one-3.4'-piperidine)
A solution of 0.1 g (0.68 mmol) of N-methyl-2-oxo-indole in 2 mL of THF was added to a well stirred suspension of 0.14 g (3.4 mmol) of NaH in 2 mL of THF with cooling in ice bath. After the gas evolution had stopped the cold bath was removed and the mixmre was heated in a 50°C bath for another 15 min. The reaction was allowed to cool to room temperature and 0.68 mL of DMSO was added and more gas evolution was observed. After stirring for 10 min, the reaction mixture was cooled in ice bath and 0.144 g of mechlorethamine hydro¬ chloride was added. The mixture was warmed to room temperature and stirred overnight. Next morning, the reaction was quenched with water and extracted with EtOAc. The EtOAc extact was washed with brine, dried with Na2Sθ4 and filtered. The filtrate was concentrated and the residue was purified by prep TLC using 89:10:1 EtOAc:MeOH:Et3N to furnish 25 mg (15%) of the title compound.
Step B: l-Methyl-spiro('indol-2-one-3.4'-piperidine
A solution of 25 mg (0.11 mmol) of l ,l'-dimethyl- spiro(indol-2-one-3,4'-piperidine) (from Step A above) in 1 mL of dry dichloroethane was treated with 0.023 mL (0.22 mmol) of 1-chloroethyl chloroformate (ACEC1) under a dry N2 atmosphere. After 30 min at room temperature, the solution was kept in a 50°C bath for 30 min. The reaction mixture was cooled to room temperature, 2 mL of MeOH was added and reheated to 60°C. After 30 min the solution was cooled and concentrated in vacuo. The residue was partitioned between water and EtOAc and the aqueous phase was adjusted to pH 9 by adding IN NaOH. The layers were separated and the combined EtOAc solution was washed with brine and dried. The filtrate upon concentration gave 34 mg of a residue which was a mixture of the desired compound and the starting material, but was sufficiently pure to be used in the next reaction.
Step C: l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-methyl-spiro(indol-2-one-
3.4'-piperidine
A reaction of 49 mg (0.13 mmol) of 3-((S)-(3,4-dichloro- phenyl))-4-(N-(3,5-dimethylbenzoyl)methylamino)butanal (Example 5) with 34 mg of impure 1 -methy l-spiro(indol-2-one-3,4'-piperidine) (from Step B) according to the procedure of Example 8, method B furnished 32 mg of the title compound after purification by prep TLC. Mass Spectrum (CI) 580 (37C1 + 35C1 isotope), 578 (35d + 35d isotope).
EXAMPLE 17
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichloro
Figure imgf000095_0001
Mass Spectrum (CI) 622 (37C1 + 35d isotope), 620 (35d + 35d isotope).
EXAMPLE 18
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino^butvD-spiroC2-oxo-tetrahvdroquinoline-4.4'-piperidines)
Step A: 1 '-Trifluoroacetyl-spirod -indanone-3.4'-piperidine
Cold trifluoroacetic acid (15 mL) and 0.6 mL of anisole were added to 2 g (6.6 mmol) of l'-t-butoxycarbonyl-spiro(l-indanone- 3, 4 '-piperidine) and the resulting solution was stirred in ice bath for lh. The reaction mixture was concentrated in vacuo and the residue was partitioned between CH2CI2 and 0.5 N NaOH. The organic layer was washed with brine, dried with Na2Sθ4 and concentrated. The residual orange oil was dissolved in 10 mL of CH2CI2 and 1.92 mL (13.7 mmol) of Et3N, 1 mL (7.1 mmol) of trifluoroacetic anhydride and 3 crystals of DMAP were added. After stirring for 4 h, the reaction mixmre was diluted with CH2CI2 and washed with water, brine and dried. The solution was filtered and the filtrate was concentrated to yield 2.0 g (quantitative) of the desired product as a solid. lH NMR (CDCI3) δ 1.65 (d, 2H, J=14Hz), 2.05 (m, 2H), 2.67 (ABq, 2H), 2.89 (m, IH), 3.28 (m, IH), 4.1 l(d, IH, J=14Hz), 4.67 (dt, IH, J=14 and 2Hz), 7.5-7.8 (m, 4H).
Step B: l'-Trifluoroactyl-spiro-(2-oxo- 1,2,3, 4-tetrahydro- quinoline-4,4'-piperidine) and r-trifluoroactyl-spiro-(l- oxo-1.2.3.4-tetrahydroisoquinoline-4.4'-piperidine To a mixture of 1.09 g (16.8 mmol) of Sodium azide in 1.2 mL of water and 6.6 mL of CHCI3 was added 0.46 mL of concentrated H2SO4 (36 N) keeping the temperature between 0-5°C. (Caution!) After 10 min the cold bath was removed and the reaction was stirred for 3 h, at which time the CHCI3 layer was separated from the aqueous layer. The CHCI3 layer containing HN3 was dried and the filtrate was added to a solution of 2 g (6.7 mmol) of -trifluoroacetyl-spiro(l- indanone-3,4'-piperidine) (from Step A) in 7 mL of CHCI3.
Concentrated H2SO4 (1.8 mL) was added to this solution and the reaction was allowed to age for 30 min. The mixture was heated in a 45°C bath for 45 min and then stirred at room temperature for 16 h. Next morning, the reaction mixture was poured into ice and the layers were separated. The aqueous layer was neutralized with aq. NaOH and extracted with EtOAc. The combined organic phases were washed with brine, dried and concentrated. The residue was chromatographed using 50-80% EtOAc-CH2Cl2 to isolate 0.34 g (16%) of l'-trifluoroactyl- spiro(2-oxo-l, 2,3, 4-tetrahydroquinoline-4,4'-piperi dine) and 0.13 g of 1 '-trifluoroactyl-spiro( 1 -oxo- 1 ,23 ,4-tetrahydroisoquinoline-4,4'- piperidine). In addition, 0.72 g (36%) of the starting indanone was recovered. lH NMR (CDC13) Isomer A: δ 1.82 (m, 2H), 1.96 (m, 2H), 2.75 (ABq,
2 H, J=14Hz), 3.16 (t, IH), 3.46 (t, IH), 3.9 (d, IH), 4.42 (d, IH), 6.8-
7.3 (m, 4H), 8.49 (br s, IH); Isomer B: δ 1.9-2.1 (m, 4H), 3.09 (t, IH), 3.42 (m, IH), 3.61 (ABq, 2H), 3.94 (d, IH), 4.45 (d, IH), 6.72 (br s, IH), 7.3-7.6 (m, 3H), 8.11 (d, IH).
Step C: Spiro-(2-oxo-1.2.3.4-tetrahydroquinoline-4.4'-piperidine
To a solution of 0.3 g (0.97 mmol) of l'-trifluoroacetyl- spiro-(2-oxo-l ,2,3,4-tetrahydroquinoline-4,4'-piperidine) (from Step B) in 4 mL of MeOH was added 0.16 g (2.9 mmol) of KOH in 1 mL of water. After stirring the reaction for 16 H the solution was concentrated and the residue was partitioned between EtOAc and water. The EtOAc layer was washed with brine, dried with Na2S04 and concentrated to give 0.16 g (76%) of the title compound as a white solid. lH NMR (CDC13) δ 1.6-2.0 (m, 4H), 2.72 (s, 2H), 2.95 (m, 4H), 6.7-
7.4 (m, 4H), 8.4 (br s, IH).
Step D: l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-spiro(2-oxo-tetrahydro-
Figure imgf000097_0001
The title compound was obtained by reductive amination of 3-((S)-(3,4-dichlorophenyl))-4-((3,5-dimethylbenzoyl)methylamino)- butanal (Example 5) by spiro-(2-oxo-l ,2,3,4-tetrahydroquinoline-4,4'- piperidine) obtained in Step C according to the procedure of Example 8, method B. Mass Spectmm (CI) 580 (37d + 35d isotope), 578(35d + 35ci isotope). EX AMPLE 19
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)(methyl- amino))butyl)- 1 -methyl-spiro(2-oxo-tetrahydroquinoline-4,4'- piperidine)
Step A: 1 -Methy l-spiro-(2-oxo-l ,2,3,4-tetrahydroquinoline-4,4'- piperidine
To a solution of 0.15 g (0.48 mmol) of l'-trifluoroacetyl- spiro-(2-oxo-l ,2,3,4-tetrahydroquinoline-4,4'-piperidine) (from Example 18, Step B) in 1.7 mL of DMF was added 19 mg (0.77 mmol) of 95% NaH at 0°C. After 15 min 0.063 mL (1 mmol) of methyl iodide was added and the reaction was allowed to warm to room temperature. After stirring for 16 H the reaction was not complete, so an additional 0.015 mL of methyl iodide was added and the solution was heated in a 45°C bath. After 2 H the reaction was cooled to room temperature and partitioned between EtOAc and water. The EtOAc layer was washed with brine, dried and the filtrate was concentrated. The residue was purified by prep TLC using 33% EtOAc-hexane to provide 1-methyl- l '-trifluoroacetyl-spiro-(2-oxo- 1 ,2,3, 4-tetrahydroquinoline-4,4'- piperidine). Hydrolysis of this trifluoroacetamide as described in Example 55, Step C furnished 71 mg (64%) of the title compound. lH NMR (CDC13) δ 1.61 (d, 2H), 1.92 (m, 2H), 2.74 (s, 2H), 2.98 (m, 4H), 3.36 (s, 3H), 7.0-7.4 (m, 4H).
Step B: l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro- benzoy l)(methylamino))buty 1)- 1 -methyl-spiro(2-oxo- tetrahydroquinoline-4.4'-piperidine
The title compound was prepared by reaction of the amine from Step A and 3-((S)-(3,4-dichlorophenyl))-4-((3,5-dichlorobenzoyl)- methylamino)butanal as described in Example 18, Step D.
Mass Spectrum (CI) 636 (37d + 35C1 isotope), 634 (35d + 35d isotope).
EXAMPLE 20 4-Bromo-2-(S)-(4-fluorophenyl)-l-(N-(3,5- bistrifluoromethylbenzoyl)methylamino)butane.
Step A: 3-(S)-(4-Fluorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)methylamino)butanol.
A solution of 1.67 g (3.84 mmol) of 3-((S)-(4-fluorophenyl)-4-(N-(3,5- (bistrifluoromethyl)benzoyl)(methylamino))butanal (prepared from 4- fluorophenylacetic acid as described by J. Hale et. al., Bioorganic & Medicinal Chemistry Letters 1993,5, 319-322) in 16 mL of absolute ethanol at 0 °C was treated with 172 mg (4.55 mmol) of sodium borohydride. After stirring for 1 h at room temperature, the reaction was quenched with saturated NH4CI and extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried (MgS04) and evaporated to give 1.59 of residual oil. Purification on a silica gel flash column (30:70 then 50:50 ethyl acetate:hexanes) provided 1.21 g (72%) of the title compound as a viscous oil.
Mass Spectrum (CI/NH3) M+H= 438.
Step B: 4-Bromo-2-(S)-(4-fluorophenyl)-l-(N-(3,5- bistrifluoromethylbenzoyl)methylamino)butane.
To a solution of 1.19 g (2.72 mmol) of 3-(S)-(4-fluorophenyl)-4-(N- (3,5-bistrifluoromethylbenzoyl)methylamino)butanol in 20 mL of acetonitrile was added 1.49 g (3.53 mmol) of triphenylphosphine dibromide. After 1.5 h the reaction was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgS04) and concentrated to give 2.33 g of cmde white solid. Purification on a silica gel flash column (30:70 ethyl acetate:hexanes) gave 944 mg. (69%) of the desired bromide as a viscous oil.
Mass Spectrum (CI/NH3) M+H=500, 502 (79,8 lβr isotope).
EXAMPLE 21 l'-(3-(S)-(4-Fluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)- (methylamino))butyl)-l-acetyl-spiro(indoline-3,4'-piperidine).
To 40 mg (0.08 mmol) of the bromide prepared in Example 20, Step B and 0.21 ul (0.12 mmol) of N,N-diisopropylethylamine in 0.5 mL of acetonitrile was added 37 mg (0.16 mmol) of 1 -acetyl-spiro(indoline- 3,4'-piperidine). The resultant mixture was heated in a tightly capped vial at 50 °C for four days. The solvent was evaporated and the residue was purified on a 1000 micron silica gel prep plate (93:5:2 ethyl acetate:methanol:triethylamine) to furnish 46.6 mg (90%) of the title compound as a white foam.
Mass Spectrum (CI/ H3) M+H=650.
The compounds in Examples 22-26 were prepared as in Example 21 from the requisite bromide, prepared from the corresponding phenylacetic acid as described in Example 20, and the required 1- substituted-spiro(indoline-3,4'-piperidine).
EXAMPLE 22
l'-(3-(S)-(3-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)- (methylamino))butyl)-l-acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 666, 668 (35,37d-isotope).
EXAMPLE 23 l'-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)- (methylamino))butyl)-l-acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 666, 668 (35,37d-isotope).
EXAMPLE 24
l'-(3-(S)-(3,4-Difluorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)- (methylamino))butyl)-l-acetyl-spiro(indoline-3,4'-piperidine).
Mass Spectrum (CI/NH3) M+H= 668.
EXAMPLE 25
l'-(3-(S)-(3,4-Methylenedioxyphenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)-(methylamino))butyl)-l-methanesulfonyl- spiro(indoline-3 ,4'-piperidine).
Mass Spectrum (CI/NH3) M+H=712.
EXAMPLE 26
l'-(3-(RS)-(3,5-Dichlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-
(methylamino))butyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine).
Mass Spectrum (CI/NH3) M+H=736, 738 (35,37d-isotope). EXAMPLE 27
l'-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)-
(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine).
The title compound was prepared as in Example 21 from 4-bromo-2- (S)-(4-chlorophenyl)-l -(N-(3,5- bistrifluoromethylbenzoyl)methylamino)butane and spiro(2,3- dihydrobenzothiophene-3,4'-piperidine) hydrochloride except that 3 eq. of diisopropylethylamine were used.
Mass Spectmm (CI/NH3) M+H=641,643 (35,37ci-isotope).
EXAMPLE 28
l'-(3-(RS)-(4-Pyridyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)- (methylamino))butyl)-l-acetyl-spiro(indoline-3,4'-piperidine).
The title compound was prepared from 3-(S)-(4-pyridyl)-4-(N-(3,5- bistrifluoromethyl-benzoyl)methylamino)butanal (prepared from 4- pyridylacetic acid as described by J. Hale et. al., Bioorganic & Medicinal Chemistry Letters 1993,5, 319-322) by reductive amination as described in Example 2.
Mass Spectrum (CI/NH3) M+H=633.
EXAMPLE 29
l'-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5-dimethylbenzoyl)- (ethylamino))butyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperi dine). Step A: 4-Bromo-2-(S)-(3 ,4-dichlorophenyl)- 1 -(N-(3 ,5- dimethylbenzoyl)methylamino)butane.
The title compound was prepared as in Example 20, Steps A and B, from 3-(S)-(3,4-dichlorophenyl)-4-(N-(3,5-dimethyl- benzoyl)ethylamino)butanal (prepared from 3,4-dichlorophenylacetic acid as described by J. Hale et. al., (Bioorganic & Medicinal Chemistry Letters 1993,5, 319-322) using ethylamine rather than methylamine to form the intermediate amide).
Mass Spectrum (CI/NH3) M = 454, 456 (79,8 lβr isotope).
Step B: 1 '-(3-(S)-(3,4-Dichlorophenyl)-4-(N-(3,5- dimethylbenzoyl)-(ethylamino))butyl)- 1 -methanesulfonyl- spiro(indoline-3 ,4'-piperidine).
The title compound was prepared from the bromide prepared in Step A and l-acetyl-spiro(indoline-3,4'-piperidine) as described in Example 21.
Mass Spectrum (CI/NH3) M+H = 641, 643 (35,37d-isotope).
EXAMPLE 30
5-Fluoro-spiro(2.3-dihvdrobenzofuran-3.4'-piperidine hydrochloride salt
Step 1) 4-(2,5-Difluorophenyl)-4-methoxycarbonyl-l -methylpiperidine
Methyl 2,5-difluorophenylacetate (4.8 g, 26 mmol) and mechlorethamine hydrochloride (5.0 g, 26 mmol) in DMSO (15 mL) and THF (50 mL) at 0°C was carefully treated with NaH (2.5 g, 104 mmol). The reaction was gradually warmed to reflux over 1 h and refluxed further for 1 h. The reaction was cooled to 0°C, and 6N HCI (25 mL) was slowly added. The reaction was diluted with IN HCI (200 mL) and washed with hexane (200 mL). The aqueous layer was cooled to 0°C and adjusted to pH 12 with solid K2CO3. The product was extracted with ethyl acetate (200 mL), washed with brine (100 mL), dried (MgSθ4), and concentrated to 4.1 g (59%) of the title compound as an oil.
lH NMR (400 MHz, CDCI3) δ 7.34 (dq, IH), 6.88 (m, IH) 6.78 (ddd, IH) 6.69 (minor NMe invertomer, dm), 6.59 (minor NMe invertomer, dd), 3.69 (s, 3H), 3.80 (minor invertomer, s), 2.71 (d, 2H), 2.48 (d, 2H), 2.38 (t, 2H), 2.25 (s, 3H), 2.10 (t, 2H) ppm.
Step 2) 4-(2,5-Difluorophenyl)-4-hydroxymethyl-l -methylpiperidine
EtOH (5.1 mL, 86 mmol) was added to 0.5 M LiAlH4 in glyme (82 mL, 41 mmol) at 0°C. 4-(2,5-difluorophenyl)-4-methoxycarbonyl-l- methylpiperidine (3.45 g, 12.8 mmol) in glyme (4 mL) was added. Saturated aqueous sodium potassium tartrate (50 mL) was added along with Celite (10 g), and the mixture was mechanically stirred 1 h at room temp. The slurry was filtered, and the organic layer was extracted with IN HCI. The HCI was washed with EtOAc and then basified with 3N NaOH. The product was extracted with CH2CI2, washed with 20% brine, dried (MgSθ4), and concentrated to a cmde solid, which was recrystallized (EtOAc) to yield 1.46 g (52%) of the title compound as colorless crystals.
lH NMR (400 MHz, CDCI3) δ 7.28 (dt, IH, J =7,9 Hz), 6.88 (ddd, IH, J=3,9,9 Hz), 6.81 (ddd, J=3,9,13 Hz), 3.76 (s, 2H), 2.59 (m, 2H), 2.32- 2.20 (m, 4H), 2.23 (s, 3H), 1.96 (t, 2H, J=5 Hz) ppm. Step 3) 5-Fluoro-l '-methyl-spiro(2,3-dihydrobenzofuran-3,4'- piperidine)
NaH (158 mg, 6.56 mmol) was added to 4-(2,5-difluorophenyl)-4- hydroxymethyl-1 -methylpiperidine (1.45 g, 6.56 mmol) in DMF (20 mL). The slurry was heated to 90°C for 6 h. The reaction was diluted with hexane (200 mL), washed with water (200 mL), brine (50 mL), dried (MgS04), and concentrated to yield 1.21 g (92%) of the title compound as a white crystalline solid;
lH NMR (400 MHz, CDCI3) δ 6.98 (dd, IH), 6.54 (dt, IH), 6.48 (dd, IH), 4.37 (s, 2H), 2.84 (m, 2H), 2.31 (s, 3H), 1.97 (4H, pentuplet), 1.71 (m, 2H) ppm.
Step 4) 5-Fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride salt
5-fluoro-r-methyl-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) (1.21 g, 5.48 mmol) in 1 ,2-dichloroethane (12 mL) at room temp was treated with 2-chloroethyl chloroformate (1 mL, 9 mmol). A white precipitate formed, and the reaction was refluxed 2 h. MeOH (12 mL) was added and refluxing was continued for 2 h. The reaction was concentrated to a cmde solid, which was triturated with EtOAc (5 mL) and filtered to yield 1.27 g (95%) of the title compound as a white crystalline solid.
lH NMR (400 MHz, d6-DMSO) δ 9.12 (s, IH), 9.04 (s, IH), 7.11 (dd, IH), 7.74-7.66 (m, 2H), 4.53 (s, 2H), 3.26 (d, 2H), 2.95 (t, 2H), 2.08 (t, 2H), 1. 79 (d, 2H) ppm.
Reaction of 5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride with 3-((S)-(3,4-dichlorophenyl))-4-(N-(t- butoxycarbonyl)-(methylamino))butanal according to the procedure given in Example 8, Method B gave l'-(3-((S)-(3,4-dichlorophenyl))-4- (N-(t-butoxycarbonyl)-(methylamino))butyl)-5-fluoro-spiro(2,3- dihydrobenzofuran-3,4'-piperidine). Removal of the BOC group and benzamide formation according to the procedure given in Example 3, Steps A and B afforded the compounds listed in Examples 31-36:
EXAMPLE 31
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)-
(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'- piperidine)
Mass spectrum (CI): m/z = 611.2 (35α + 35ci isotope + H+), 613.2 (37ci + 35ci isotope + H+).
EXAMPLE 32
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)-
(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'- piperidine)
Mass spectrum (CI): m/z = 609.3 (35ci + 35ci isotope + H+), 611.3 (37d + 35ci isotope + H+).
EXAMPLE 33
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-
(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'- piperidine) Mass spectrum (CI): m/z = 575.2 (35ci + 35d isotope + H+), 577.2 (37ci + 35ci isotope + H+), 579.2 (37ci + 37d isotope + H+).
EXAMPLE 34
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'- piperidine)
Mass spectrum (CI): m/z = 569.3 (35ci + 35ci isotope + H+), 571.3 (37ci + 35d isotope + H+).
EXAMPLE 35
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)-
(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'- piperidine)
Mass spectrum (CI): m/z = 555.3 (35ci + 35d isotope + H+), 557.3 (37ci + 35ci isotope + H+).
EXAMPLE 36
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)- 5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 541.3 (35ci + 35ci isotope + H+), 543.3 (37ci + 35d isotope + H+).
Preparation of spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride was carried out by analogy to the procedure given in Example 30, starting with methyl 2-fluorophenylacetate. Reaction of spiro(2,3-dihydrobenzofuran-3,4'-piperidine) hydrochloride with 3-(S)- (3,4-dichlorophenyl)-4-(t-butoxycarbonyl-methylamino)butanal according to the procedure given in Example 8, Step B gave l'-(3-((S)- (3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)- spiro(2,3-dihydrobenzofuran-3,4'-piperidine). Removal of the BOC group and benzamide formation according to the procedure given in Example 3, Steps A and B afforded the compounds listed in Examples 37-43:
EXAMPLE 37
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(benzoyl)-(methylamino))butyl)- spiro(2,3-dihydrobenzofuran-3,4'-piperidine)
Mass spectrum (CI): m/z = 523.1 (35ci + 35ci isotope + H+).
EXAMPLE 38
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 537.2 (35ci + 35ci isotope + H+), 539.2 (37ci + 35ci isotope + H+).
EXAMPLE 39
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine)
Mass spectrum (CI): m/z = 551.2 (35ci + 35ci isotope + H+), 553.2 (37d + 35ci isotope + H+).
EXAMPLE 40
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine)
Mass spectrum (CI): m/z = 557.0 (35ci + 35ci isotope + H+).
EXAMPLE 41
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine)
Mass spectmm (CI): m/z = 591.0 (35ci + 35ci isotope + H+), 593.1 (37ci + 35ci isotope + H+).
EXAMPLE 42 1 *-(3-((S)-(3 ,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine)
Mass spectrum (CI): m/z = 591.3 (35ci + 35ci isotope + H+), 593.2 (37ci + 35ci isotope + H+).
EXAMPLE 44
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)
Step 1) l-t-Butoxycarbonyl-3-hydroxy-4-methylenepiperidine
n-Butyl lithium (9.57 mL, 2.45M in hexane, 23.7 mmol) was added to a -78°C solution of diisopropylamine (3.32 mL, 23.7 mmol) in THF (15 mL). After 30 min at -78°C, methyl phenyl sulfoxide (3.32 g, 23.7 mmol) in THF (4 mL) was added. The solution was warmed to 0°C and cooled back down to -78°C. l-t-butoxycarbonyl-4-piperidinone (4.69 g, 23.7 mmol) in THF (20 mL) was added. The reaction was warmed to room temp, quenched by addition of solid NH4CI, concentrated in vacuo, and partitioned between H2O (100 mL) and EtOAc (100 mL). The organic layer was washed with H2O (50 mL) brine (50 mL), dried (MgSθ4), and concentrated in vacuo. The resultant oil was heated at 80°C in t-butanol (50 mL) with potassium t-butoxide (3.4g, 30 mmol) for 2 h. Solid NH4CI was added, and the reaction was concentrated in vacuo and partitioned between H2O (100 mL) and EtOAc (100 mL). The EtOAc was washed with brine (50 mL), dried (MgS04) , concentrated in vacuo and purified by column chromatography (silica gel 60, 0-50% EtOAc/hexane) to yield 4.47 g (79%) of the title compound as a crystalline solid. lH NMR (400 MHz, DMSO-d6) δ 5.21 (d,lH), 4.96 (s, IH), 4.77 (s, IH), 3.82 (t, 2H), 3.67 (dt, IH), 2.83 (dt, IH), 2.77-2.50 (brd d, IH), 2.26 (dt, IH), 2.01 (ddd, IH), 1.38 (s, 9H) ppm.
Step 2) 1 -t-Butoxycarbonyl-3,4-didehydro-4-(chloromethyl)piperidine
To l-t-butoxycarbonyl-3-hydroxy-4-methylenepiperidine (5.329 g, 25.1 mmol) in toluene (120 mL) and 2,6-lutidine (3.1 mL, 26 mmol) at 0°C was added SOC12 (2.0 mL, 26 mmol). The reaction was heated at 40°C for 30 min, cooled to 0°C, washed with 0°C IN HCI (100 mL), 0.1 N HCI (100 mL), H2O (100 mL), brine (50 mL), dried (MgSθ4), and concentrated in vacuo to afford 5.18 g (89%) of allylic chloride as a yellow oil.
lH NMR (400 MHz, CDCI3) δ 5.78 (s, IH), 4.04 (s, 2H), 3.95 (s, 2H), 3.55 (t, 2H, J=6 Hz), 2.24 (s, 2H), 1.45 (s, 9H) ppm.
Step 3) l-t-Butoxycarbonyl-4-((2-bromophenyl)thio)methyl-l ,2,5,6- tetrahydropyridine
The allylic chloride (330 mg, 1.43 mmole) was dissolved in acetone (10 mL) and 2-bromothiophenol (172 ml, 1.43 mmole) and K2CO3 (390 mg, 2.86 mmole) were added. The reaction mixture was heated to 60°C for 1 h and then filtered though silica gel ( ether). The organic layer was concentrated in vacuo and purified by column chromatography (silica gel 60, hexanes/ethyl acetate 10/1) to give the title compound in 84% yield (460 mg).
Step 4) 1 '-t-Butoxycarbonyl-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine). The intermediate adduct from step 3 above (450 mg, 1.17 mmole) was dissolved in benzene (60 mL) and AIBN (10 mg) and tributyltin hydride (644 mL, 2.39 mmole) were added. This mixmre was refluxed for 2 h and concentrated. The residue was dissolved in Et2θ and Br2 was added until the reaction solution turned to a brownish color. To this brownish solution at room temp was added DBU (650 mL) dropwise. The resulting cloudy solution was filtered though silica gel and washed with Et2θ. The Et2θ solution was concentrated and the residue was purified by radial chromatography (silic gel 60, 10/1 hexanes/EtOAc) to give the title compound (157 mg) in 43% yield.
iH NMR (400 MHz, CDCI3) δ 7.18 (d, 7 Hz, 1 H), 7.12 (t, 7 Hz, 1 H), 7.06 (m, 2 H), 4.1 l(m, 2 H), 3.30 (s, 3 H), 2.89 (m, 2 H), 1.79 (m, 4 H), 1.47 (s, 9 H) ppm.
Removal of the BOC group according to the procedure given in Example 3, Step A followed by reaction with 3-((S)-(3,4- dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butanal according to the procedure given in Example 8, Method B gave l '-(3- ((S)-(3,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine). Removal of the BOC group and benzamide formation according to the procedures described in Example 3, Steps A and B gave the compounds listed in Examples 45-46:
EXAMPLE 45
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) - I l l -
Mass spectmm (CI): m/z = 567.2 (35ci + 35ci isotope + H+), 569.2 (37ci + 35ci isotope + H+).
EXAMPLE 46
l'-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)
Mass spectrum (CI): m/z = 533 (35ci + 35d isotope + H+), 535 (37ci + 35ci isotope + H+).
EXAMPLE 47
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine)-l -oxide.
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) (222 mg, 415 μmol) in CH2CI2 (500 μL) at -78°C was treated with a solution of m-chloroperbenzoic acid (86 mg, 498 μmol) in CH2CI2 (1 mL). The reaction was poured into 0°C saturated aqueous NaHS03. The organic layer was washed with saturated aqueous NaHC03 (1 mL), brine (1 mL), dried (MgSθ4), concentrated in vacuo and purified by column chromatography (silica gel 60, 0-100% acetone/CH2Cl2) to yield 54.3 mg (24%) of the title compound as a white foam.
lH NMR (500 MHz, CDCI3) δ 7.84 (d, IH, J=7.5 Hz), 7.60 (t, IH, J=7.5 Hz), 7.48 (t, IH, J=7.5 Hz), 7.44 (m, IH), 7.39 (dd, IH, J=2.0, 8.5 Hz), 7.32 (m, IH), 7.10-7.04 (rotamer multiplets, IH), 3.6-3.2 (m, 2H), 3.34, 3.32 (two doublets of one diastereomer, IH), 3.16, 3.14 (two doublets of other diastereomer, IH), 3.1 -2.8 (m, 3H), 2.75-2.65 (rotamer singlets, 3H), 2.3-1.7 (m, 10 H), 1.42 (s, 9H) ppm.
EXAMPLE 48
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthylmethyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine)-l -oxide.
The title compound was prepared by oxidizing l'-(3-((S)-(3,4- dichlorophenyl))-4-(N-(t-butoxycarbonyl)-(methylamino))butyl)- spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) as described in Example 47 above, and then removing the BOC group and N- benzoylating according to the procedures given in Example 3, Steps A and B.
Mass spectrum (CI): m/z = 623.1 (35ci + 5ci isotope + H+).
EXAMPLE 49
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(t-butoxycarbonyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine)- 1 , 1 -dioxide.
To 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(t-butoxycarbonyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) (102 mg, 191 μmol) in MeOH (0.8 mL) at 0°C was added Oxone (176 mg, 287 μ) in water (0.4 mL). After 30 min at room temp, the reaction was filtered through a plug of silica gel and concentrated to yield 39.5 mg (36%) of the title compound as a white foam. i H NMR (500 MHz, CDCI3) δ 7.72 (d, IH, J=7.5 Hz), 7.66 (t, IH, J=7.5 Hz), 7.51 (t, IH, J=7.3 Hz), 7.39 (t, IH, J=8.3 Hz), 3.65-3.25 (m, 2H), 3.38 (s, 2H), 3.15-2.85 (m, 3H), 2.76,2.66 (rotamer singlets, 3H), 2.25 (m, 2H), 2.15-1.95 (m, 3H), 1.95-1.65 (m, 5H), 1.40 (s, 9H) ppm.
EXAMPLE 50
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine)- 1 , 1 -dioxide.
The title compound was prepared by removing the BOC group and N- benzoylating (according to the procedures given in Example 3, Steps A and B) the product from Example 49.
Mass spectmm (CI): m/z = 639.1 ( ci + 35ci isotope + H+).
EXAMPLE 51
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine)- 1 , 1 -dioxide.
To l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) (10 mg, 20 μmol) in MeOH (0.1 mL) at 0°C was added 0.4 M aqueous Oxone (75 μL, 30 μmol). The reaction was warmed to room temp and stirred overnight. The reaction was concentrated in vacuo, partitioned between IN NaOH (1 mL) and CH2CI2 (1 mL). The organic layer was concentrated and purified by column chromatography (silica gel 60, 0- 100% acetone/CH2Cl2) to yield 9.0 mg (90%) of the title compound as a clear film.
Mass spectrum (CI): m/z = 599.1 (35d + 35ci isotope + H+), 601.1 (37d + 35ci isotope + H+).
EXAMPLE 52
l'-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine)- 1 , 1 -dioxide.
This compound was prepared according to the procedure given in Example 51 above.
Mass spectmm (CI): m/z = 567 (35ci + 35ci isotope + H+), 565 (37Q + 35ci isotope + H+).
EXAMPLE 53
l'-(3-((S)-(4-Chlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-sρiro(2,3-dihydrobenzothiophene-3,4'- piperidine)-l -oxide.
To l '-(3-((S)-(4-chlorophenyl))-4-(N-(3 ,5-dimethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) (25 mg, 47 μmol) in MeOH (1.0 mL) at 0°C was added a solution of Oxone (38 mg, 61 μmol) in H2O (1.0 mL). The reaction was stirred 2 min and quenched with 10% aqueous sodium bisulfite. The reaction mixture was diluted with H2θ (10 mL), neutralized with sat. aqueous NaHC03 (15 mL), extracted with CH2CI2 (3 x 25 mL), washed with brine (10 mL), dried (Na2S04), concentrated in vacuo, and purified by column chromatography (silica gel 60, 5-8% MeOH/CH2Cl2) to yield 25 mg (99%) of a colorless solid; Mass spectrum (CI): m/z = 549 (35ci + 35ci isotope + H+), 551 (3 d + 35ci isotope + H+).
EXAMPLE 54
l'-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine), 1 -oxide.
The title compound was prepared by the oxone oxidation method described in Example 53.
Mass Spectrum (CI/NH3) M+H=657, 659 (35,37ci-isotope).
EXAMPLE 55
l '-(3-(S)-(4-Chlorophenyl)-4-(N-(3,5-bistrifluoromethylbenzoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine), 1, 1 -dioxide.
The title compound was prepared by the oxone oxidation method described in Example 51.
Mass Spectrum (CI/NH3) M+H=673, 675 (35,37ci-isotope).
Substituted indoline spiropiperidine derivatives were obtained by employing substituted phenyl hydrazines and 1- benzyloxycarbonylpiperidine-4-carboxyaldehyde in the Fisher indole synthesis. When regioisomers were formed, they were separated as the 1 '-benzyloxy carbonyl- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperidine) derivative by chromatography (silica gel 60, THF/hexane). Preparation of a representative substituted spiro(indoline-3,4'-piperidinium) hydrochloride is described below:
EXAMPLE 56
l'-Benzyloxycarbonyl-5-fluoro-spiro(indoline-3,4'-piperidine)
A slurry of 4-fluorophenylhydrazine hydrochloride (6.504 g, 40 mmol), pyridine (6.56 ml, 80 mmol), toluene (360 mL), acetonitrile (40 mL), and N-benzylcarboxy-4-piperidine carboxyaldehyde (9.88g, 40 mmol) was maintained at 0°C for 1 h. Trifluoroacetic acid (18.5 mL, 240 mmol) was added, and the reaction was heated 20 h at 60°C. The reaction was cooled to 0°C, and methanol (40 mL) was added followed by NaBH4 (1.51 g, 40 mmol). The cooling bath was removed and 30% aqueous NH4OH (100 mL) was added. The organic layer was separated, washed with 5% aqueous NH4OH (100 mL) brine (50 mL), dried (MgSθ4), and concentrated to a cmde oil which was purified by column chromatography (SG 60 silica, 0-5% acetone/CH2θ2) to yield 6.48 g (48%) of the title compound as a clear oil.
lH NMR (400 MHz, CDCI3): δ 7.23-7.36 (m, 5H), 6.76-6.71 (m, 2H), 6.58 (dd, IH, J=4.4, 8.0 Hz), 5.14 (s, 2H), 4.12 (br s, 2H), 3.49 (s, 2H), 2.95 (br s, 2H) 1.73 (br s, 4H) ppm.
EXAMPLE 57
Step 1) 1 '-Benzyloxycarbonyl-5-fluoro-l -methanesulf onyl- spiro(indoline-3 ,4'-piperidine)
To a solution of l'-benzyloxycarbonyl-5-fluoro-spiro(indoline-3,4'- piperidine) (6.48 g, 19.0 mmol) in CH2CI2 (19 mL) and pyridine (38 mmol, 3.1 mL) at 0°C was added methanesulfonyl chloride (19 mmol, 1.52 mL). The reaction was warmed to room temp., diluted with ethyl acetate (200 mL), washed with IN aqueous HCI (100 mL) saturated aqeuous NaHC03 (100 mL) brine (50 mL), dried (MgS04), and concentrated to 7.81 g (98%) of the title compound as a red foam.
lH NMR (400MHz, CDCI3) δ 7.35 (m, 5H), 7.32 (dd, IH, J=4.2, 9.0 Hz), 6.90 (dt, IH, J=2.7, 8.8 Hz), 6.81 (IH, dd, J=2.6, 8.2 Hz), 5.14 (s, 2H), 4.22 (br s, 2H), 3.84 (s, 2H), 2.92 (br s, 2H), 2.88 (s, 3H), 1.79 (br s, 2H), 1.69 (d, 2H, 13 Hz) ppm.
Step 2) 5-Fluoro-l-methanesulfonyl-spiro(indoline-3,4'-piperidine) hydrochloride salt
To 1 '-benzyloxycarbonyl-5-fluoro-l -methanesulf onyl-spiro(indoline- 3,4'-piperidine) (7.81 g, 18.7 mmol) in CHCI3 (18 mL) at room temp, was added trimethylsilyl iodide (20.5 mmol, 2.93 ml). After 5 min, the rxn was cooled to 0°C, and a 5M solution of HCI in methanol/methyl acetate is added with vigorous stirring. The HCI solution was prepared by adding acetyl chloride (190 mmol, 14 ml) to methanol (20 mL) at 0°C. 40 ml of EtOAc was added, and the slurry was vigorously stirred at 0°C for 4 h. The solid was filtered off under dry nitrogen, washed with 0°C ethyl acetate (10 mL) and then with hexane (10 mL), and dried under vacuum to yield 4.77 g (80%) of the title compound as a light pink solid.
lH NMR (400 MHz, DMSO-d6) δ 8.85 (br s, IH), 8.77 (br s, IH), 7.26 (dd, IH, J=4.4, 8.8 Hz), 7.1 1 (dt, IH, J=2.8, 8.8 Hz), 7.02 (dd, IH, J=2.8, 8.4 Hz), 3.97 (s, 3H), 3.30 (m, 2H), 3.06 (m, 2H), 3.06 (s, 3H), 2.04 (m, 2H), 1.83 (d 2H, J=14 Hz) ppm. The substituted l-methanesulfonyl-spiro(indoline-3,4'-piperidinium) hydrochlorides could be reductively aminated with 3-(S)-(3,4- dichlorophenyl)-4-(t-butoxycarbonyl-methylamino)butanal according to the procedure described in Example 8, Method B. Removal of the BOC group by the procedure given in Example 3, Step A provided intermediate secondary amine compounds described below which could then be benzoylated under conditions given in Example 3, Step B to give the indicated benzamide derivatives.
EXAMPLE 58
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(methylamino)butyl)-l- methanesulfonyl-5-methoxy-spiro(indoline-3,4'-piperidine)
lH NMR (CDC13, 400 MHz) δ 7.37 (d, IH, J=8.2 Hz), 7.29 (d, IH), 7.25 (d, IH), 7.04 (dd, IH, J=2.1, 8.3 Hz), 6.72 (m, 2H), 3.76 (s, 3H), 3.73 (s, 2H), 2.87 (m, 2H), 2.82 (s, 3H), 2.78 (d, 2H, J=7.1 Hz), 2.41 (s, 3H), 2.32-2.18 (m, 2H), 2.05-1.85 (m, 5H), 1.7 (m, 3H) ppm.
EXAMPLE 59
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(methylamino)butyl)-l- methanesulfonyl-5-methyl-spiro(indoline-3,4'-piperidine)
l H NMR (CDC13, 400 MHz) δ 7.37 (d, IH, J=6.2 Hz), 7.30 (d, IH, J=2.0 Hz), 7.24 (d, IH, J=10 Hz), 7.05 (dd, IH, J=2.0, 8.2 Hz), 7.00 (d, IH, J= 8.8 Hz), 6.95 (s, IH), 3.71 (dd, 2H, J=16, 5.4 Hz), 2.9 (m, 3H), 2.84 (s, 3H), 2.79 (d, 2H, J=7.4 Hz), 2.43 (s, 3H), 2.30 (s, 3H), 2.24 (m, IH), 2.05-1.85 (m, 5H), 1.75-1.60 (m, 3H) ppm.
EXAMPLE 60 5-Chloro-l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-l - methanesulfonyl-spiro^doline-S^'-piperidine)
lH NMR (CDC13, 400 MHz) δ 7.39 (d, IH, J=8.2 Hz), 7.29 (d, IH, J=2.1), 7.24 (s, IH), 7.17 (dd, IH, J=2.2, 8.5 Hz), 7.11 (d, IH, J=2.1 Hz), 7.05 (dd, IH, J=2.0, 8.3 Hz), 3.76 (dd, 2H, J=4.5, 25 Hz), 3.18 (p, IH), 2.10-2.85 (m, 4H), 2.87 (s, 3H), 2.61 (s, 3H), 2.47 (m, IH), 2.34 (m, IH), 2.15 (t, IH), 2.04 (m, 2H), 1.95-1.70 (m, 5H) ppm. 0
EXAMPLE 61
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(methylamino)butyl)-5-fluoro-l- 15 methanesulfonyl-spiro(indoline-3,4'-piperidine)
lH NMR (CDCI3, 400 MHz) δ 7.38 (d, IH), 7.3 (m, 2H), 7.05 (dd, IH),
7.91-7.85 (m, 2H), 3.75 (dd, 2H), 3.0-2.8 (m, 3H), 2.81 (d, 2H), 2.43
(s, 3H), 2.42 (m, IH), 2.34 (m, IH), 2.1-1.8 (m, 5H), 1.7 (m, 3H) ppm. 20
EXAMPLE 62
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(methylamino)butyl)-7-fluoro-l- 25 methanesulfonyl-spiro(indoline-3 ,4'-piperidine)
lH NMR (CDC13, 400 MHz) δ 7.38 (d, IH), 7.29 (d, IH), 7.05 (m, 2H), 6.95 (m, 2H), 3.99 (dd, 2H), 3.25 (s, 3H), 2.9 (m, 2H), 2.81 (t, IH), 2.45 (s, 3H), 2.38 (m, IH), 2.28 (m, IH), 2.1-1.8 (m, 5H), 1.75 (m, 3H)
3 J 0U ppm.
EXAMPLE 63 l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-
(methylamino))butyl)-l-methanesulfonyl-5-methyl-spiro(indoline-3,4'- piperidine)
Mass spectrum (FAB): m/z = 642.0 (35ci + 35d isotope + H+).
EXAMPLE 64
5-Chloro-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)- (methylamino))butyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperidine)
Mass spectrum (FAB): m/z = 648.1 (35ci + 35ci isotope + H+).
EXAMPLE 65
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)- 1 -methanesulfonyl-5-methoxy-spiro(indoline- 3,4'-piperidine)
Mass spectmm (FAB): m/z = 658 (35ci + 35ci isotope + H+).
EXAMPLE 66
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-methylbenzoyl)-
(methy lamino))butyl)-5-fluoro- 1 -methanesulf onyl-spiro(indoline-3 ,4'- piperidine) Mass spectmm (CI): m/z = 632.2 (35ci + 35ci isotope + H+), 634.2 (37ci + 35ci isotope + H+).
EXAMPLE 67
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)- (methylamino))butyl)-5-fluoro-l -methanesulf onyl-spiro(indoline-3 ,4'- piperidine)
Mass spectrum (FAB): m/z = 688.0 (37ci + 35d isotope + 5d + 35ci isotope+ H+).
EXAMPLE 68
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-
( (mmeetthhyyllaammiino))butyl)-5-fluoro-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine)
Mass spectrum (CI): m/z = 646.1 (35ci + 35ci isotope + H+), 648.1 (37ci + 35ci isotope + H+).
EXAMPLE 69
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chlorobenzoyl)-
(methylamino))butyl)-5-fluoro-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine) Mass spectrum (CI): m/z = 652.2 (35ci + 35ci isotope + 35ci + 35ci isotope + H+), 656.2 (37ci + 35ci isotope + 37d + 35ci isotope+ H+), 657.2 (37C1 + 37ci isotope + 37ci + 35ci isotope+ H+),. 658.2 (37d + 37d isotope + 37d + 37ci isotope+ H+).
EXAMPLE 70
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5- bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-5-fluoro- 1 - methanesulfonyl-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 754.1 (35ci + 35ci isotope + H+), 756.1 (37ci + 35d isotope + H+).
EXAMPLE 71
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)-
(methylamino))butyl)-7-fluoro-l-methanesulfonyl-spiro(indoline-3,4' piperidine)
Mass spectrum (CI): m/z = 646.1 (35d + 35d isotope + H+), 648.1, (37ci + 35d isotope + H+).
EXAMPLE 72
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
To 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-t-butoxycarbonyl)- (methylamino))butyl)-5-fluoro-l-methanesulfonyl-spiro(indoline-3,4'- piperidine) (1.32 g 2.15 mmol) in toluene (5 mL) at 0°C was added 3.4M Red-Al/toluene (5.1 mL, 17.2 mmol). After 4 h at room temp, the reaction was cooled to 0°C and quenched by cautious addition of IN aqueous NaOH (2 mL). Cold saturated aqueous sodium potassium tartrate (30 mL) was added, and the biphasic mixmre was mechanically stirred at 0°C for 1 h. The product was extracted with toluene (3 x 10 mL), washed with 50% saturated aqueous sodium potassium tartrate (10 mL), H2θ (10 mL), brine (10 mL), dried (MgSθ4), and concentrated to roughly 5 mL volume, and cooled to 0°C. Pyridine (705 μL, 8.6 mmol) and acetic anhydride (410 μL, 4.3 mmol) were added. After 16 hours at room temp, the reaction was concentrated and purified by column chromatography (silica gel 60, 0-50% acetone/CH2θ2) to yield 830 mg (72%) of the title compound as a white foam.
lH NMR (400 MHz, CDCI3) δ 8.14 (dd, IH), 7.37 (d, IH), 7.28 (m, IH), 7.1-7.0 (m, IH), 6.87 (m, 2H), 3.95, 3.81 (rotamer singlets, 2H), 3.53 (m, IH), 3.36 (m, 2H), 3.22 (m, IH), 3.01 (m, IH), 2.90 (m, IH), 2.82 (m, IH), 2.74, 2.63 (rotamer singlets, 3H), 2.39, 2.20 (rotamer singlets, 3H), 1.89 (m, 4H), 1.65 (m, 4H) ppm.
The corresponding l-acetyl-spiro(indoline-3,4'-piperidine) compounds were obtained by selectively removing the methanesulfonyl group with Red-Al and then treating with acetic anhydride/pyridine at the stage where the methylamino group is protected with BOC; a representative procedure is given in Example 72 above. The BOC group could be removed using the procedure given in Example 3, step A to give intermediate methylamino compounds which were benzoylated according to Example 3, step B to give the compounds in Examples 73- 90:
EXAMPLE 73
l -Acetyl-5-chloro-l'-(3-((S)-(3,4-dichlorophenyl))-4- (methylamino)butyl)-spiro(indoline-3,4'-piperidine) lH NMR (CDC13, 400 MHz) δ 7.83 (d, IH, J=6.6 Hz), 7.12 (d, IH, J=5.2 Hz), 7.09 (d, IH, J=2.0 Hz), 6.87 (dd, 2H, J=2.0, 10.0 Hz), 6.84 (s, IH), 2.81 (p, 1H0, 2.75-2.55 (m, 4H), 2.27 (s, 3H), 2.12 (m, IH), 2.04 (m, IH), 1.95 (s, 3H), 1.9-1.7 (m, 3H), 1.6 (t, 2H), 1.5-1.4 (m, 3H) ppm.
EXAMPLE 74
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5- methyl-spiro(indoline-3,4'-piperidine)
lH NMR (CDC13, 400 MHz) δ 8.05 (d, IH), 7.38 (d, IH), 7.30 (d, IH), 7.05 (dd, IH), 7.00 (d, IH), 6.92 (s, IH), 3.79 (s, 2H), 3.01 (p, 2H), 2.9 (m, 3H), 2.52 (s, 3H), 2.5-2.1 (m, 2H), 2.29 (s, 3H), 2.20 (s, 3H), 2.1- 1.7 (m, 6H),. 1.65 (m, 2H) ppm.
EXAMPLE 75
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-5- fluoro-spiro(indoline-3,4'-piperidine)
lH NMR (CDCI3, 400 MHz) δ 8.14 (dd, IH), 7.38 (d, IH), 7.24 (s, IH), 7.05 (dd, IH), 6.88 (dt, IH), 6.82 (dd, IH). 3.96, 3.83 (rotamer singlets, 2H), 3.13 (p, IH), 3.04 (dd, 2H), 2.92 (dd, 2H), 2.69, 2.66 (rotamer singlets, 3H), 2.50 (p, IH), 2.33 (p, IH), 2.38, 2.20 (rotamer singlets, 3H), 2.13 (t, IH), 2.05 (m, IH), 1.7 (m, 4H), 1.73 (dd, 2H) ppm.
EXAMPLE 76 l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-6- fluoro-spiro(indoline-3,4'-piperidine)
lH NMR (DMSO-d6, 500 MHz) δ 7.76 (dd, IH), 7.58-7.53 (m, 2H), 7.26 (dd, IH), 7.21 (dd, IH), 6.80 (dt, IH), 3.93 (s, 2H), 2.98-2.86 (m, 3H), 2.82 (d, IH), 2.65 (d, IH), 2.38 (s, 3H), 2.19 (m, IH), 2.16 (s, 3H), 2.09 (m, IH), 2.05 (t, IH), 1.90 (t, 2H), 1.78-1.6 (m, 3H), 1.6-1.5 (m, 2H) ppm.
EXAMPLE 77
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-4- fluoro-spiro(indoline-3,4'-piperidine)
lH NMR (DMS0-d6, 500 MHz) δ 7.88 (d, IH), 7.63-7.58 (m, 2H), 7.29 (dd, IH), 7.19 (q, IH), 6.79 (t, IH), 3.86 (s, 2H), 3.23-3.13 (m, 3H), 2.97 (m, IH), 2.72 (m, IH), 2.52 (s, 3H), 2.26 (m, IH), 2.16 (s, 3H), 2.09 (t, 4H), 1.97 (p, 2H), 1.76-1.62 (m, 3H) ppm.
EXAMPLE 78
l-Acetyl-l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)- (methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 588.2 (35d + 35d isotope + H+).
EXAMPLE 79 l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)- (methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectmm (CI): m/z = 610.2 ( 5ci + 35ci isotope + H+), 612.2 (37ci + 35ci isotope + H+).
EXAMPLE 80
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)- (methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m z = 582.3 (35ci + 35ci isotope + H+).
EXAMPLE 81
l-Acetyl-l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,-dimethylbenzoyl)- (methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 610.3 (35ci + 35ci isotope + H+)
EXAMPLE 82
l-Acetyl-l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 582.2 (35ci + 35ci isotope + H+). EXAMPLE 83
l-Acetyl-l'-5-chloro-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)-(methylamino))butyl)-spiro(indoline-3,4'-piperidine)
Mass spectmm (FAB): m/z = 626.0 (35ci + 35d isotope + H+), 628.1 (37ci + 35d isotope + H+).
EXAMPLE 84
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chlorobenzoyl)- (methy lamino))butyl)-5-fluoro-spiro(indoline-3 ,4'-piperidine)
Mass spectmm (CI): m/z = 616.2 (35ci + 35ci isotope + H+).
EXAMPLE 85
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichlorobenzoyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectmm (CI): m z = 650.1 (35ci + 35d isotope + H+).
EXAMPLE 86
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-methylbenzoyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) Mass spectrum (CI): m/z = 596.2 (35ci + 35ci isotope + H+), 598.3 (37ci + 35ci isotope + H+).
EXAMPLE 87
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 610.2 (35ci + 35ci isotope + H+).
EXAMPLE 88
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-isopropoxybenzoyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 640.3 (35ci + 5ci isotope + H+), 642.3 (37ci + 35ci isotope + H+).
EXAMPLE 89
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- bis(trifluoromethyl)-(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine)
Mass spectrum (CI): m/z = 718.2 (35d + 35ci isotope + H+), 720.2 (37ci + 35ci isotope + H+). EXAMPLE 90
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))butyl)-5-methyl-spiro(indoline-3,4'-piperidine)
Mass spectmm (FAB): m/z = 606.1 (35ci + 35ci isotope + H+), 608.2 (37ci + 35d isotope + H+).
N-Napthoyl- methylamino derivatives (Examples 91 -101 ) were prepared by analogy to the benzoyl derivatives, employing commercially available 1-napthoyl chlorides in place of benzoyl chlorides:
EXAMPLE 91
1 - Acetyl- 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 650.3 (35ci + 35ci isotope + H+).
EXAMPLE 92
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(l-napthoyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 632.2 (3 ci + 35ci isotope + H+), 634.2 (37d + 35ci isotope + H+). EXAMPLE 93
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(l-napthoyl)- (methylamino))butyl)-5-fluoro-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine)
Mass spectmm (CI): m/z = 668.2 (35ci + 35ci isotope + H+).
EXAMPLE 94
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)- (methylamino))butyl)-5-fluoro- 1 -methanesulf onyl-spiro(indoline-3 ,4'- piperidine)
Mass spectrum (CI): m/z = 668.2 (3 ci + 35ci isotope + H+).
EXAMPLE 95
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)
Mass spectrum (CI): m/z = 607.2 ( ci + 35ci isotope + H+).
EXAMPLE 96 1 '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -napthoyl)-
(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine) sulfone
Mass spectrum (CI): m z = 639.1 (35ci + 35ci isotope + H+).
EXAMPLE 97
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'-piperidine)
Mass spectrum (CI): m/z = 623.1 (35ci + 35d isotope + H+).
EXAMPLE 98
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)-
(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'- piperidine)
Mass spectrum (CI): m/z = 609.3 (35ci + 35d isotope + H+), 611.3 (37ci + 35ci isotope + H+).
EXAMPLE 99
l'.(3_((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)- (methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'-piperidine) Mass spectrum (CI): m/z = 591.3 (35ci + 35ci isotope + H+), 593.3 (37ci + 35ci isotope + H+).
EXAMPLE 100
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)- (methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectmm (CI): m/z = 650.3 (35d + 35d isotope + H+).
EXAMPLE 101
l-Acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)- (methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine)
Mass spectrum (CI): m/z = 650.3 (35d + 35d isotope + H+).
Benzylamine derivatives could be synthesized by reducing the benzamide of the 1 -methanesulfony l-spiro(indoline-3,4'-piperidine) derivatives described in some of the Examples. The methanesulfonyl group could be removed by heating with HBr/acetic acid/phenol and then be replaced with an acetyl group by treating with acetic anhydride/pyridine. Representative procedures and compounds are given in Examples 102 and 103 below:
EXAMPLE 102 l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthylmethyl)- (methylamino))butyl)-5-fluoro-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine)
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthoyl)-
(methylamino))butyl)-5-fluoro-l-methanesulfonyl-spiro(indoline-3,4'- piperidine) (96 mg) was dissolved in 1M Dibal-H in toluene (160 uL). After 1/2 h, saturated aqueous sodium potassium tartrate (5 mL) and EtOAc (5 mL) were added and stirred vigorously for 2 h. The organic layer was washed with H2θ (5 mL), brine (5 mL), dried (MgS04), and concentrated to a crude oil, which was purified by column chromatography (silica gel 60, 0-10% acetone/CH2Cl2) to yield 55 mg (59%) of the title compound as a white foam; lH NMR (400 MHz, CDCI3) δ 8.09 (d, IH, J=8.5 Hz), 7.91 (d, IH, J=8.5 Hz), 7.53 (t, IH, J=7.5 Hz), 7.38 (t, IH, J=7.5 Hz), 7.33 (dd, IH, J=4.3, 8,8 Hz), 7.22 (dd, IH, J=5.8, 7.8 Hz), 7.18 (d, IH, J=8.5Hz), 7.09 (d, J=2.0 Hz), 7.04 (dd, IH, J=7.5, 10. 0 Hz), 6.92 (dt, IH, J=2.5, 8.5 Hz), 6.88 (d, IH), 6.77 (dd, IH, J=1.8, 8.3 Hz), 3.85 (dd, IH, J=8.0 Hz), 3.76 (s, 2H), 3.75 (dd, IH, J=8.0 Hz), 2.88 (s, 3H), 2.80-2.66 (m, 3H), 2.62 (dd, IH, J=8.8, 12.3 Hz), 2.51 (dd, IH, J=6.5, 12.5 Hz), 2.28 (s, 3H), 2.18-2.06 (m, 2H), 1.88-1.80 (m, 4H), 1.65 (d, 2H, J=10.5 Hz) ppm;
Mass spectrum (CI): m/z = 672.4 (35ci + 35ci isotope + H+).
EXAMPLE 103
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthylmethyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine)
l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l-napthylmethyl)- (methy lamino))buty l)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'- piperidine) (45.6 mg) and phenol (19 mg) in 30% HBr/HOAc (270 μL) were heated to 70°C for 6 h in a sealed vessel. The reaction was concentrated and partitioned between CH2CI2 (1 ml) and IN NaOH (2 mL). The organic layer was eluted through a 3x3 cm silica gel plug with 0-100% acetone/CH2Cl2 to yield 30 mg (74%) of the title compound as a yellow oil.
lH NMR (400 MHz, CDCI3) δ 8.09 (d, IH, J=8.0 Hz), 7.93 (d, IH, J=8.5 Hz), 7.52 (t, IH, J=7.5 Hz), 7.43 (t, IH, J=7.3 Hz), 7.22 (dd, IH, J=5.5, 7.5 Hz), 7.17 (d, IH, J=8.5 Hz), 7.06 (dd, IH, J=8.8, 10.3 Hz), 7.02 (d, IH, J=1.5 Hz), 6.87 (d, IH, J=3.5 Hz) 6.78 (dd, IH, J=2.3, 8.3 Hz), 6.75 (dd, IH, J=2.3, 7.8 Hz), 6.56 (dd, IH, J=4.0, 8.5 Hz) ppm;
Mass spectrum (CI): m/z = 594.3 ( 5ci + 35ci isotope + H+), 596.3 (37ci + 35ci isotope + H+).
EXAMPLE 104
l-Acetyl-l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthylmethyl)-(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine)
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-napthylmethyl)- (methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine) (10 mg) in CH2CI2 (100 μL) was treated with one drop acetic anhydride and 1 drop pyridine. After 30 min, the reaction was eluted through a 1x2 cm silica gel column using 0-100% acetone/CH2θ2 plus 1 % NH4OH to yield 10 mg (93%) of the title compound as a clear film.
lH NMR (CDCI3) δ 8.17 (dd, IH, J=4.3, 8.8 Hz), 8.09 (d, IH, J=8.5 Hz), 7.91 (d, IH, J=8.0 Hz), 7.52 (t, IH, 7.3 Hz), 7.38 (t, IH, J=7.3 Hz), 7.22 (dd IH, 6.8, 7.0 Hz), 7.18 (d, IH, J=8.8 Hz), 7.07 (d, IH, J=2.0 Hz), 7.04 (dd, IH, J=8.0, 10.5 Hz), 6.91 (dt, IH, J=2.0, 9.0 Hz), 6.86 (dd, IH, J=2.0, 7.5 Hz), 6.76 (dd, IH, J=2.0, 8.5 Hz), 3.96, 3.81 (rotamer singlets, 3H), 3.85 (d, IH, J=13 Hz), 3.75 (d, IH, J=13 Hz), 2.84 (m, 2H), 2.74 (m, IH), 2.61 (dd, IH, J=8.5, 13Hz), 2.51 (dd, IH, J=7.0, 13 Hz), 2.43, 2.35 (rotamer singlets, 3H), 2.24 (s, 3H), 2.3-2.2 (m, 3H), 2.0-1.85 (m, 4H), 1.65 (m, 2H), 1.50 (m, IH) ppm;
Mass spectrum (CI): m/z = 636.4 ( 5ci + 35ci isotope + H+), 638.4 (37ci + 35ci isotope + H+).
EXAMPLE 105
r-(5-Fluoroindolyl-3-(2-ethanoyl))-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine).
To a solution of 1 -methanesulf onyl-spiro(indoline-3,4'-piperidine) hydrochloride (373 mg, 1.23 mmol), 5-fluoroindole-3-acetic acid (500 mg, 2.59 mmol), in DMF (15 mL) at room temp, was added N-methyl morpholine (261 mg, 2.59 mmol), hyroxybenzotriazole (381 mg, 2.82 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (473 mg, 2.47 mmol). The reaction was stirred 48 h, diluted with H2θ (250 mL), extracted with EtOAc (3 x 100 mL), washed with H2O (2 x 150 mL), brine (150 mL), dried (Na2Sθ4), concentrated in vacuo and purified by column chromatography (SG 60 silica, 5% MeOH/CH2Cl2) to afford 486 mg (89%) of the title compound as a colorless oil.
lH NMR (500 MHz, CDCI3) δ 8.39 (br s, IH), 7.37 (d, IH, J = 8.2 Hz),
7.34 (dd, IH, J = 9.6, 2.3 Hz), 7.29 (dd, IH, J = 8.9, 4.4 Hz), 7.23 (dt,
IH, J = 7.8, 1.2 Hz), 7.14 (d, IH, J = 2.3 Hz), 7.03 (t, IH, J = 7.3 Hz),
6.98 (dt, IH, J = 8.9, 2.5 Hz), 6.87 (d, IH, J = 7.5 Hz), 4.73 (d, IH, J =
13.7 Hz), 3.96 (d, IH, J = 14.0 Hz), 3.82-3.92 (m, 2H), 3.72-3.78 (m,
IH), 3.13 (t, IH, J = 13.4 Hz), 2.91 (s, 3H), 2.73 (t, IH, J = 13.5 Hz), 1.83 (dt, IH, J = 13.5, 4.4 Hz), 1.65-1.75 (m, 2H), 1.52-1.58 (m, IH), 1.40 (dt, IH, J = 13.0, 4.3 Hz) ppm; Mass spec (CI) m/z 441 (M+H).
EXAMPLE 106
l'-(2-(3-(5-Fluoroindolyl))ethyl))-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine).
To a solution of 1 '-(5 -fluoroindoly 1-3 -(2-ethanoyl))-l -methanesulf onyl- spiro(indoline-3,4'-piperidine) (100 mg, .226 mmol) in CH2CI2 (8 mL) at -70°C was added Dibal-H (1M in THF, 0.91 mL, .906 mmol). After 2.5 h the mixture was quenched by addition of 1M NaOH (20 mL), diluted with CH2CI2 and stirred vigorously for 15 min. The mixmre was extracted with CH2CI2 (3 x 50 mL), washed with brine (50 mL), dried (Na2S04), concentrated in vacuo and purified by column chromatography (SG60 silica, 5% MeOH/CH2Cl2) to afford 66 mg (68%) of the title compound as a colorless solid.
lH NMR (500 MHz, CDCI3) δ 8.20 (br s, IH), 7.42 (d, IH, J = 8.0 Hz), 7.20-7.30 (m, 4H), 7.06-7.14 (m, 2H), 6.93-6.97 (m, IH), 3.84 (s, 2H), 3.08 (d, 2H, J = 11.7 Hz), 2.94-3.00 (m, 2H), 2.93 (s, 3H), 2.71-2.77 (m, 2H), 2.19 (t, 2H, J = 12.3 Hz), 2.07 (dt, 2H, J = 13.2, 3.9 Hz), 1.75 (d, 2H, J = 13.0 Hz) ppm; Mass spec (CI) m/z 428 (M+H).
EXAMPLE 107
4-Fluoro-3,5-dimethylbenzoic acid
Step 1) l-Bromo-4-fluoro-3,5-dimethylbenzene To a mixture of 4-Bromo-2,6-dimethylaniline (8.3 g, 42 mmol) at 5°C and H2θ (50 mL) was added cone H2SO4 (6.25 mL). NaNθ2 (4.1 g) was added in portions until an excess was indicated by starch iodide paper. Water (30 mL) was added to make the mixture homogeneous. After transferring to a plastic container, HBF4 (50%, 13.7 g) was added dropwise with stirring. The resultant white precipitate was collected by vacuum filtration, washed with H2θ (30 mL), MeOH (30 mL), and Et2θ (60 mL), and dried over P2O5 under vacuum for 16 h. The solid was then heated in a glass flask with an open flame until all the solid had decomposed. The remaining liquid was diluted with Et2θ (50 mL) and 0.5 M NaOH (30 mL). The organic layer was separated, washed with 0.5 M NaOH (25 mL), H2O (25 mL), brine (25 mL), dried (MgS04), and concentrated in vacuo yielding 6.06 g (72%) of 1 -bromo-4-fluoro- 3,5-dimethylbenzene as a pale yellow liquid.
lH NMR (500 MHZ, CDCI3) δ 7.17 (d, 2H, J = 6.2 Hz), 2.21 (s, 6H) ppm.
Step B) 4-Fluoro-3,5-dimethylbenzoic acid
To a mixture of magnesium shavings (120 mg, 4.92 mmol) in THF (2 mL) was added a crystal of iodine followed by slow addition of a solution of the bromide (1.0 g , 4.92 mmol) in THF (3 mL). The reaction mixture was heated to reflux for 1 h followed by cooling to room temp, and addition of Cθ2(s) (excess), stirred 1 h and quenched by addition of 1M HCI (10 mL). The mixture was extracted with Et2θ (3 x 25 mL), washed with brine (25 mL), dried (MgS04), and concentrated in vacuo to afford 0.82 g (99%) of the title compound as a pale yellow solid.
lH NMR (500 MHz, CDCI3) δ 7.81 (d, 2H, J = 6.7 Hz), 2.36 (s, 6H) ppm; Mass spec (CI) m/z 168 (M-H).
The compounds of Examples 108-120 were prepared as per Example 3 Step B utilizing the previously prepared amines and the appropriate benzoic or naphthoic acids:
EXAMPLE 108
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)- (methylamino))buty 1)- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperidine)
Mass spec (CI) 656 (37ci + 35d isotope + H+), 654 (35 d + 35ci isotope + H+).
EXAMPLE 109
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)- (methylamino))butyl)-5-fluoro- 1 -methanesulfonyl-spiro(indoline-3 ,4'- piperidine)
Mass spec (CI) 674 (37ci + 5ci isotope + H+), 672 (35ci + 35ci isotope + H+).
EXAMPLE 110
l'.(3_((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluorobenzoyl)- (methylamino))butyl)- 1 -methanesulfonyl-spiro(indoline-3 ,4'-piperidine) Mass spec (CI) 620 (37ci + 35ci isotope + H+), 618 (35ci + 35ci isotope + H+).
EXAMPLE 111
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluorobenzoyl)- (methylamino))butyl)-5-fluoro-l-acetyl-spiro(indoline-3,4'-piperidine)
Mass spec (CI) 618 (37ci + 35ci isotope + H+), 616 (35ci + 35ci isotope + H+).
EXAMPLE 112
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3-chloro-4-fluorobenzoyl)- (methylamino))butyl)-5-fluoro-l-acetyl-spiro(indoline-3,4'-piperidine)
Mass spec (CI) 636 (37ci + 35d isotope + H+), 634 (35ci + 35ci isotope + H+).
EXAMPLE 113
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)- (methylamino))butyl)-5-fluoro-l-acetyl-spiro(indoline-3,4'-piperidine)
Mass spec (CI) 630 (37ci + 35ci isotope + H+), 628 (35ci + 35ci isotope + H+). EXAMPLE 114
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)- (methylamino))butyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperidine)
Mass spec (CI) 648 (37ci + 35ci isotope + H+), 646 (35ci + 35ci isotope + H+).
EXAMPLE 115
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3- trifluoromethylbenzoyl)-(methylamino))butyl)-l -methanesulfonyl- spiro(indoline-3,4'-piperidine)
Mass spec (CI) 688 (37d + 35d isotope + H+), 686 (35ci + 5ci isotope + H+).
EXAMPLE 116
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3,5-dimethylbenzoyl)- (methy lamino))butyl)- 1 -acety l-spiro(indoline-3 ,4'-piperidine)
Mass spec (CI) 612 (37ci + 35ci isotope + H+), 610 (35ci + 35ci isotope + H+).
EXAMPLE 117 l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-3- trifluoromethylbenzoyl)-(methylamino))butyl)-l-acetyl-spiro(indoline-
3,4'-piperidine)
Mass spec (CI) 652 (3 d + 35ci isotope + H+), 650 (35 ci + 35ci isotope + H+).
EXAMPLE 118
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(4-fluoro-l-naphthoyl)- (methylamino))butyl)-l-acetyl-spiro(indoline-3,4'-piperidine)
Mass spec (CI) 634 (37ci + 35d isotope + H+), 632 (35d + 35ci isotope + H+).
EXAMPLE 119
1 -_(3_((S)-(3 ,4-Dichlorophenyl))-4-(N-(4-fluoro- 1 -naphthoyl)- (methylamino))butyl)-l-methanesulfonyl-spiro(indoline-3,4'-piperidine)
Mass spec (CI) 670 (37ci + 35ci isotope + H+), 668 (35ci + 35ci isotope + H+).
EXAMPLE 120
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(l-naphthoyl)-
(methylamino))butyl)- 1 -acetyl-spiro(indoline-3 ,4'-piperidine)
Mass spec (CI) 616 (37ci + 35d isotope + H+), 614 (35d + 35ci isotope + H+). EXAMPLE 121
l '-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5-dimethylbenzoyl)- (methylamino))-4-phenyl-butyl)-l -methanesulfony l-spiro(indoline-3, 4'- piperidine)
The title compound was prepared in 6 steps from 2-(S)- (3,4-dichlorophenyl)-4-pentenoic acid using procedures identical to those in Example 10, substituting phenyllithium for methyllithium in Example 10, Step 2.
Mass Spectmm (FAB): m/z 704 (M+H, 37C1 + 35d isotope, 100%), 706 (M+H, 37C1 + 37C1 isotope, 80%).
EXAMPLE 122
r-(4-(N-(3,5-Dimethylbenzoyl)-(methylamino))-4-(phenyl)butyl)-l* acetyl-spiro(indoline-3,4'-piperidine)
The title compound was prepared in 6 steps from 4- pentenoic acid using procedures identical to those in Example 10, substituting phenyllithium for methyllithium in Example 10, Step 2.
Mass Spectmm (FAB): m/z 524 (M+H, 37ci + 35C1 isotope, 100%), 526 (M+H, 37C1 + 37d isotope, 50%).
EXAMPLE 123
r.(3_((S)-(3,4-Dichlorophenyl))-4-(l-(2-phenylimidazolo))butyl)-l- methanesulfonyl-spiro(indoline-3,4'-piperidine) Step 1) l-(2-Phenylimidazolo)-2-((S)-(3,4-dichlorophenyl))-4-pentene
To a solution of 0.178 g (0.77 mmole) of 2-((S)-(3,4-dichlorophenyl))- 4-penten-l-ol (prepared in Example 136, Step A) and 0.099 mL (0.85 mmole) of 2,6-lutidine in 1.5 mL of methylene chloride at -53 deg C under nitrogen was added 0.136 mL (0.81 mmole) of trifluoromethanesulfonic anhydride. The solution was stirred between -30 deg C and -40 deg C for 15 min at which point 0.333 g (2.31 mmole) of 2-phenylimidazole was added. The temperature was allowed to warm to -20 deg C briefly, and the mixture was then cooled to -60 deg C, stirred at that temperature for 1 hr, stirred at -20 deg Cfor 2 hr, and then held at 4 deg C f or 16 hr. After stirring at room temperature for 8 hr, the mixmre was treated with 10 mL of saturated sodium carbonate solution and 10 mL of ethyl acetate and the layers were separated. The aqueous phase was extracted with 2x15 mL of ethyl acetate and the combined aqueous layers were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was partly purified by flash chromatography on 36 g of silica eluting with 500 mL of 3:100 methano methylene chloride then 300 mL of 5:100:0.1 methanohmethylene chloride: ammonia water. The partly purified product fractions were flash chromatographed on 66 g of silica eluting with 1.2 L of 83:17 methylene chloride:ethyl acetate to give 85 mg (31 %) of an oil.
iH-NMR (400 MHz, CDC13) δ 2.26 (app. t, 2H), 2.85 (pentet, IH), 4.08 (dd, IH), 4.27 (dd, IH), 4.9-5.0 (m, 2H), 5.45-5.55 (m, IH), 6.59 (dd, IH), 6.79 (s, IH), 6.85 (d, IH), 7.18 (d, IH), 7.23-7.30 (m, 2H), 7.35- 7.4 (m, 3H).
Mass Spectmm (FAB): m/z 359 (M+H, 65%), 357 (M+H, 100%), 145 (7%). Step 2) l'-(2-((S)-(3,4-Dichlorophenyl))-l-(l-(2-phenylimidazolo))-4- butyl)-l -methanesulfony l-spiro(indoline-3,4'-piperi dine)
The title compound was prepared by employing the chemistry outlined in Examples 1 and 2, using l-(2-phenylimidazolo)-2-((S)-(3,4- dichlorophenyl))-3-butene in place of 3-(S)-(3,4-dichlorophenyl)-4- methylamino-1-pentene, and beginning with the osmium tetroxide step.
iH-NMR (400 MHz, CDCI3) δ 1.55-2 (m, 8H), 2.08 (t, J = 7.3, 2H), 2.63 (br d, J = 11 , IH), 2.70 (br d, J = 8.3, IH), 2.86 (s, 3H), 2.9-3.0 (m, IH), 3.71 (s, 2H), 4.13 (dd, J = 14, 8.8, IH), 4.25 (dd, J = 14, 6.2, IH), 6.66 (dd, J = 6.2, 2.1, IH), 6.79 (d, J = 1.3, IH), 6.94 (d, J = 2.1, IH), 7.03 (d, J = 1.3, IH), 7.05 (d, J = 6.4, IH), 7.15 (d, J = 6.5, IH), 7.15-7.25 (m, 2H), 7.35-7.45 (m, 6H)
Mass Spectrum (FAB): m/z 609 (M+H, 25%), 279 (100%), 267 (50%), 212 (30%), 187 (35%).
EXAMPLE 124
1 '-(3-((S)-(3,4-Dichlorophenyl))-4-((N-(R or S)-(3,5-dimethylbenzoyl)- (methylamino))pentyl)-l -acetyl-spiro(indoline-3,4'-piperidine)
The title compound was prepared in 6 steps from (2S)-(3,4- dichlorophenyl)-4-pentenoic acid using procedures identical to those in Example 10, substituting l-acetyl-spiro(indoline-3,4'-piperidine) for 1- methanesulfonyl-spiro(indoline-3,4'-piperidine) in Example 10, Step 6.
Mass Spectmm (FAB): m/z 606 (M+H, 37C1 + 35d isotope, 100%), 608 (M+H, 37C1 + 37C1 isotope, 80%). EXAMPLE 125
l '-(3-((S)-(3,4-Dichlorophenyl))-4-((N-(R or S)-(4-fluoro-l-napthyl)- (methylamino))pentyl)-l-acetyl-spiro(indoline-3,4'-piperidine)
The title compound was prepared in 6 steps from (2S)-(3,4- dichlorophenyl)-4-pentenoic acid using procedures identical to those in Example 10, substituting l-acetyl-spiro(indoline-3,4'-piperidine) for 1- methanesulfonyl-spiro(indoline-3,4'-piperidine) in Example 10, Step 6, and substituting 4-fluoro-l-napthoyl chloride for benzoyl chloride.
Mass Spectrum (FAB): m/z 646 (M+H, 37C1 + 35C1 isotope, 30%), 204 (100%).
The following compounds described in Examples 126-129 were prepared by the method described in Scheme II and in Example 10, except that in step 2 ethylmagnesium chloride or propylmagnesium chloride was used at room temperature instead of methyllithium at -78°C.
EXAMPLE 126
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-(N-(3,5- dimethylbenzoyl)-(methylamino))hexyl)- 1 -acetyl-spiro(indoline- 3,4'-piperidine)
iH-NMR (400 MHz, CDCI3) δ 0.97 (t, 3H), 2.20 (s, 6H), 2.21 (s, 3H), 2.42-2.46 (s+m, 4H), 6.23 (s, 2H), 6.89 (s, IH), 7.04 (t, IH), 7.15-7.21 (m, 3H), 7.39 (t, 2H), 8.18 (d, IH).
Mass Spectrum (FAB) m/z 620 (m+). EXAMPLE 127
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-(N-(3,5- dimethylbenzoyl)-(methylamino))hexyl)- 1 -acetyl-5-fluoro- spiro(indoline-3 ,4 '-piperidine)
iH-NMR (400 MHz, CDCI3) δ 0.96 (t, 3H), 2.20 (s, 9H), 2.45 (s, 3H), 3.81 (s, 2H), 6.24 (s, 2H), 6.84-6.89 (m, 3H), 7.19 (dd, IH), 7.39 (t, 2H), 8.13 (dd, IH).
Mass Spectrum (FAB) m/z 638 (m+).
EXAMPLE 128
l'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(N-(3,5- dimethylbenzoyl)-(methylamino))heptyl)-l-acetyl-spiro(indoline- 3, 4' -piperidine)
lH-NMR (400 MHz, CDCI3) δ 0.96 (t, 3H), 2.20 (s, 6H), 2.21 (s, 3H), 2.41-2.45 (s+m, 4H), 3.78 (s, 2H), 6.22 (s, 2H). 6.89 (s, IH), 7.03 (t, IH), 7.15-7.21 (m, 3H), 7.39 (t, 2H), 8.18 (d, IH).
Mass Spectrum (FAB): m/z 634 (m+).
EXAMPLE 129
l'-(3-(S)-(3,4-Dichlorophenyl)-4-(R or S)-(N-(3,5- dimethylbenzoyl)-(methylamino))heptyl)- 1 -acetyl-5-fluoro- spiro(indoline-3,4'-piρeridine)
lH-NMR (400 MHz, CDCI3) δ 0.97 (t, 3H), 2.20 (s, 9H), 2.44 (s, 3H), 3.81 (s, 2H), 6.22 (s, 2H), 6.83-6.88 (m, 3H), 7.18 (dd, IH), 7.38 (t, 2H), 8.13 (dd, IH). Mass Spectrum (FAB) m/z 652 (m+).
EXAMPLE 130
l'-(3-((S)-(3,4-Dichlorophenyl))-4-(R or S)-hydroxy-5-(3,5- dimethylphenyl)pentyl)-l-methane-sulfonyl-spiro(indoline-3,4'- piperidine)
To a THF (3 mL) solution of 3,5- dimethylbenzylmagnesium chloride (generated from 290 mg (1.9 mmol) of 3,5-dimethylbenzyl chloride and 53 mg (2.2 mmol) of magnesium in THF) was added slowly l'-(3-((S)-(3,4- dichlorophenyl))-3-(N-methoxy-N- methy laminocarbony l)propy 1)- 1 -methanesulf onyl-spiro(indo line- 3,4'-piperidine) (100 mg, 0.19 mmol, prepared by reacting the product obtained in Example 10, Step 1 under the oxidative cleavage conditions given in Example 1 followed by the coupling procedure given in Example 2) in 1 mL of THF. The reaction mixture was stirred at 60°C for 40 min and poured into 20 mL of IN HCI. The solution was extracted with 3 x 10 mL of EtOAc. The organic extracts were combined, dried, and concentrated. The product was purified by preparative TLC (30% EtOAc in CH2CI2) to afford 20 mg of ketone. To a MeOH (3 mL) solution of ketone (19.4 mg) was added sodium borohydride (7 mg). The mixmre was stirred at 55°C for lh and concentrated. The residue was purified by preparative TLC (4% MeOH in CH2CI2) to give 15 mg of the higher Rf isomer (Isomer A) and 4 mg of a lower Rf isomer (Isomer B).
lH-NMR (400 MHz, CDCI3) , Isomer A: d 1.71 (d, 2H), 1.92- 2.12 (m, 6H), 2.23-2.29 (s+m, 9H), 2.50-2.60 (m, 2H), 2.72-2.76 (m, IH), 2.88 (s, 3H). 2.95 (d, 2H), 3.76 (s, 2H), 4.00-4.06 (m, IH), 6.69 (s, 2H), 6.83 (s, IH), 7.05 (d, IH), 7.19-7.24 (m, 3H), 7.37 (t, 2H), 7.44 (s, IH).
Mass spectmm (FAB) Isomer A, m/z 601 (m+), 603 (m++ 2).
lH-NMR (400 MHz, CDCI3) , Isomer B: d 1.69 (d, 2H), 1.74- 1.79 (m, IH), 1.83-1.90 (m, IH), 1.93-2.05 (m, 2H), 2.07-2.20 (m, 2H), 2.24-2.36 (s+m, 8H), 2.42-2.47 (m, IH), 2.55-2.58 (dd, IH), 2.66-2.72 (d+dd, 2H), 2.87 (s, 3H), 2.86-3.00 (m, 2H), 3.76 (s, 2H), 3.91-3.95 (m, IH), 6.72 (s, 2H), 6.82 (s, 2H), 7.13-7.19 (m, 2H), 7.18-7.21 (m, 2H), 7.36 (t, 2H).
Mass spectrum (FAB) Isomer B, m/z 601 (m+) 603 (m+ + 2).
EXAMPLE 131
l '-(3-(R)-(3,4-Dichlorophenyl)-5-(N-3,5-dimethylphenyl- methy lamino)-5-oxo-pentyl)-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine)
Step 1 ) Diazomethyl-(2-(S)-(3,4-dichlorophenyl)-pent-4-en-yl)-ketone.
To a solution of 2-(S)-(3,4-dichlorophenyl)-pent-4-enoic acid (5.04g, 20.6mmol) in 60mL of dichloromethane was added oxalyl chloride 2.15mL (24.6mmol) and dimethylformamide (O.lmL) upon cooling in an ice-water bath. The cooling bath was then removed and the reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure. The resulting material was diluted in ethyl acetate and concentrated in vacuo in order to remove residual HCI. The residual cmde acid chloride was dissolved in 70mL of ether and was slowly added to a lOOmL ether solution of diazomethane (77mmol). After stirring for 2hr at rt, the solvent was removed under vacuum. The resulting yellow oil was chromatographed on silica gel column eluting with a gradient of hexane : ethyl acetate = 20 : 1 to 3 : 1 to give 4.66g (84%) of diazomethyl-(2-(S)-(3,4-dichlorophenyl)-pent-4-en-yl)- ketone.
iH-NMR (CDC13 400MHz): δ 2.44(app. quint. IH), 2.82(app. qunit. IH), 3.43(br s. IH), 4.98 & 5.02 (d of AB quart., 2H), 5.16 (br s, IH), 5.63(m, IH), 7.09 (dd, J=2.2Hz, 8.3Hz, IH), 7.34(d, J=2.2Hz, IH), 7.38 (d J=8.3Hz).
Step 2) 3-(R)-(3,4-Dichlorophenyl)-hex-4-en-oic acid
To a solution of the above diazoketone 4.56g (17.0mmol) in 340mL of tetrahydrofαran was added 170mL aquous solution of silver nitrate 3.02g (17.8mmol). After stirring at rt overnight, tetrahydrofuran was removed under reduced pressure. The remaining aqueous layer was extracted with two lOOmL portions of dichloromethane. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The resulting material was purified by silica gel column chromatography. Elution with dichloromethane : methanol = 10 : 1 gave 3.94g (90%) of 3-(R)-(3,4-dichlorophenyl)-hex-4-en-oic acid.
Step 3) (N-(3,5-Dimethylphenyl)-N-methyl)-((3-(R)-(3,4- dichlorophenyl)-hex-5-en-yl)-amide
The carboxylic acid from Step 2 (300mg, l.lόmmol) was dissolved in 5mL of dichloromethane. To it was added 0.131mL (1.50mmol) of oxalyl chloride followed by the addition of a drop of dimethylformamide upon cooling in an ice-water bath. The cooling bath was then removed and the reaction mixture was stirred at rt for 2hr. The solvent and residual HCI was removed as described above. The resulting cmde acid chloride was then dissolved in 5mL of dichloromethane. To it was added N-methyl-3,5-dimethylaniline 313mg (3.32mmol) (Prepared from 3,5-Dimethylaniline following the procedure of Barluenga J., Bayon A.M., and Asensio G. J. Chem. Soc. Chem. Comm. 1984 1334.) followed by the addition of triethylamine 0.5mL (3.6mmol) upon cooling in an ice-water bath. Then the cooling bath was removed and the reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure. The residual solid material was dissolved in 15mL of ethyl acetate and 5mL of water. The organic phase was separated and aqueous phase was extracted with two 7mL portions of ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. This cmde material was chromatographed on silica gel eluting with a gradient of 10 : 1 to 3 : 1 hexane-ethyl acetate to give 386mg of (N-(3,5-dimethylphenyl)-N-methyl)-((3-(R)-(3,4- dichlorophenyl)-hex-5-en-yl)-amide (88%).
Η-NMR CDC 400MHz): δ 2.15-2.35 (m., 4H), 2.29 (s, 6H), 3.09 (s, 3H), 3.26 (quint, J=7.2Hz, IH), 4.88 (d, J=7.6Hz, IH), 4.92 (s, IH), 5.5 (m, IH), 6.45 (s, 2H), 6.91 (dd, J=2Hz, 7Hz, IH), 6.93 (s, IH), 7.30 (d, J=8.3Hz, IH).
Step 4) 3-(R)-(3,4-Dichlorophenyl)-5-(N-(3,5-dimethylphenyl)- methylamino)-5-oxo-pentanal
To 386mg (1.03mmol) of the product from the previous step was oxidized by osmium tetroxide to corresponding diol as described in Example 1 to give 413mg of cmde diol. 381mg of this material was then dissolved in lOmL of benzene. To it was added lead tetraacetate 452mg (1.02mmol). After stirring for lhr at rt, 5mL of water was added to quench the reaction. The reaction mixture was extracted with two lOmL portions of ethyl acetate. The combined organic phases were dried over anhydrous magnesium sulfate, filtered, and concentrated. The cmde material was chromatographed on silica gel eluting with hexane : ethyl acetate = 2 : 1 to give 329mg of 3-(R)-(3,4- dichlorophenyl)-5-(N-(3,5-dimethylphenyl)-methylamino)-5-oxo- pentanal (94% over two steps).
Step 5) l'-(3-(R)-(3,4-Dichlorophenyl)-5-(N-3,5-dimethylphenyl- methylamino)-5-oxo-pentyl)-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine)
Following the procedure described in Example 2, 107mg (0.287mmol) of this aldehyde was treated with 1 -methanesulf onyl - spiro(indoline-3,4'-piperidine) hydrochloride to give 103mg (58% yield) of the title compound .
Η-NMR (CDC13 400MHz) : δ 2.23 (s, 6H), 2.86 (s, 3H), 3.09 (s, 3H), 3.72 (s, 2H), 6.49 (s, 2H), 6.9-7.2 (s, 8H).
MS(CI) : 628 (M++1 : 35Clx2), 630 (M++1 : 35d & 37 1)
EXAMPLE 132
l'-(3-(R)-(3,4-Dichlorophenyl))-5-(3,5-dimethylphenyl)-5-oxo-pentyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperidine)
Step 1) (N-Methoxy-N-methyl)-(3-(R)-(3,4-dichlorophenyl)-4- hexenyl)-amide
To a solution of 3-(R)-(3,4-dichlorophenyl)-5-hexenoic acid (Example 132, Step 1) 744mg (2.87mmol) was added 1- hydroxybenzotriazole hydrate 465mg (3.44mmol), and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloroide 660mg (3.44mmol) with cooling in an ice- water bath. The cooling bath was then removed. After stirring at rt for lhr, to it was added 5mL dichloromethane suspension of N, O -dime thy lhydroxyl amine hydrochloride 840mg (8.61mmol) and triethylamine 1.2mL (8.6mmol). After stirring overnight, the solvent was removed under vacuum, diluted with ethyl acetate and water. The organic phase was separated. Aqueous phase was extracted twice with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, concentrated, chromatographed on silica gel eluting on a gradient of hexane : ethyl acetate = 5 : 1 to 2 : 1 to give 762mg (88%) of (N-methoxy-N-methyl)-(3-(R)-(3,4,-dichlorophenyl)- 4-hexenyl)-amide.
iH-NMR (CDC13 400MHz): δ 2.34(m, IH), 2.69 (App. d, 2H), 3.09 (s, 3H), 3.23 (quint. J=7.3Hz, IH), 3.56 (s, 3H), 4.95 (s, IH), 4.98 (app. d, IH), 5.6 (m, IH), 7.0 (dd, J=2.1Hz, 8.4Hz, IH), 7.28 (d, J=2.1Hz, IH), 7.32 (d, J=8.3Hz, IH).
Step 2) 3-(R)-(3,4-Dichlorophenyl)-(N-methoxy-methylamino)-5-oxo- pentanal
This above material was subjected to the osmium tetroxide oxidation to the corresponding diol as described in Example 1. The cmde product was then treated with 1.23g (2.77mmol) of lead tetraacetate as described in example 131, Step 4. Chromatographic purification on silica gel (eluant; dichloromethane : ethyl acetate = 5 : 1) afforded 618mg (81 % two steps)of 3-(R)-(3,4-dichlorophenyl)-(N- methoxy-methylamino)-5-oxo-pentanal.
Step 3) 1 '-(3-(R)-(3,4-Dichlorophenyl)-5-(N-methoxy-methylamino)-5- oxo-pentyl)- 1 -methanesulf onyl-spiro(indoline-3,4'-piperidine) A sample of 332mg (1.09mmol) of the aldehyde from Step 2 above was subjected to reductive amination with 1-methanesulfonyl- spiro(indoline-3,4'-piperidine) hydrochloride as described in Example 2 to give 369mg (61%) of l*-(3-(R)-(3,4-dichlorophenyl)-5-(N-methoxy)- N-(methyl)amino)-5-oxo-pentyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine).
Η-NMR (CDC13 400MHz): δ 2.87 (s 3H), 3.10 (s, 3H), 3.60 (s, 3H), 7.0-7.4 (m, 7H).
Step 4) 1 '-(3-(R)-(3,4-Dichlorophenyl))-5-(3,5-dimethylphenyl)-5-oxo- pentyl)- 1 -methanesulfonyl-spiro(indoline-3,4'-piperidine)
To a 1.2mL THF solution of the amide from Step 3 above (73mg, 0.13mmol) was added l.lmL of 0.7M 3,5-dimethylphenylmagnesium bromide solution in THF (prepared from 5-bromo-m-xylene and magnesium turnings in THF). Then the reaction mixture was heated to 50°C. After stirring for 1.5hr, the reaction mixmre was allowed to cool down to rt and the reaction was quenched by sat NH4CI aq solution. THF was removed under reduced pressure, diluted with ethyl acetate. The organic phase was separated and the aqueous phase was extracted twice with ethyl acetate. Combined organic phases were dried over anhydrous magnesium sulfate, filtered, concentrated, chromatographed on silica gel eluting with a gradient of dichloromethane : ethyl acetate = 10 : 1 to 1 : 1 to give 55mg (70%) of the title compound.
iH-NMR (CDCI3 400MHz): δ 2.34 (s, 6H), 2.86 (s, 3H), 3.23 (m, 2H), 3.74 (s, 2H), 7.0-7.5 (m, 10H).
MS (CI): 599 (M++1 : 35Clx2), 601 (M++1 : 35C1& 37 ).
EXAMPLE 133 l'-(3-(R)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-oxo-hexyl)-l- methanesulfonyl-spiro(indoline-3,4'-piperidine)
70mg (0.126mmol) of l'-(3-(R)-(3,4-dichlorophenyl)-5-(N- methoxy)-N-(methyl)amino)-5-oxo-pentyl)-l -methanesulf onyl- spiro(indoline-3,4'-piperidine) (Example 132, Step 3) was treated with 0.8M THF solution of 3,5-dimethyl benzylmagnesium chloride as in the case of Example 132. The cmde material was chromatographed on silica gel in the same solvent system to afford 33mg of the title compound (43%).
iH-NMR (CDC13 400MHz): δ 2.24 (s, 6H), 2.86 (s, 3H), 3.47 (s, 2H), 3.72 (s, 2H), 6.64 (s, 2H), 6.8-7.4 (m, 8H).
MS (CI): 613 (M++1: 5Clx2), 615 (M++1: 35C1& 3?d).
EXAMPLE 134
l'-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-6-oxo-hexyl)-l- methanesulfonyl-spiro(indoline-3,4'-piperidine)
3-(R)-(3,4-Dichlorophenyl)-4-hexenoic acid (Example 131, Step
2) was converted into 4-(S)-(3,4-Dichlorophenyl)-5-heptenoic acid as in Example 131 , Steps 1 and 2. 4-(S)-(3,4-dichlorophenyl)-4-heptenoic acid was converted to (N-methoxyl-N-methyl)-(4-(S)-(3,4- dichlorophenyl)-6-heptenyl)-amide followed by treatment with 3,5- dimethylphenybnagnesium bromide as described in Example 132, Step 4 to give the title compound.
iH-NMR (CDCI3 400MHz): δ 2.32 (s, 6H), 2.80 (s, 3H), 3.74 (s, 3H), 7.0-7.4 (m, 10H). MS (CI): 613 (M++1 : 35Clx2), 615 (M++1 : 35d& 37d).
EXAMPLE 135
l '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(RS)-methyl- 6-oxo-hexyl)-l-methanesulfonyl-spiro(indoline-3,4'-piperidine)
Step 1) 4-(S)-(3,4-Dichlorophenyl)-l-(3,5-dimethylphenyl)-hept-6- ene-1-one
1.42g (4.50mmol) of (N-Methoxy-N-methyl)-(4-(S)-(3,4- dichlorophenyl)-6-heptenyl)-amide (prepared in Example 134) was dissolved in 20mL of dry THF. To it added lOmL THF solution of 3,5- dimethylphenylmagnesium bromide prepared from 1 ,8g (9.6mmol) of 5-bromo-m-xylene and 463mg of magnesium turnings. After stirring for 2hr at rt, the reaction was quenched with saturated aqueous ammonium chloride solution. THF was removed under reduced pressure. The residual material was diluted with ethyl acetate. The organic phase was separated, aqueous phase was extracted twice with ethyl acetate. Combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, concentrated, chromatogrpraphed on silica gel eluting with a gradient of hexane : ethyl acetate = 10 : 1 to 5 : 1 to give 1.57g of 4-(S)-(3,4- dichlorophenyl)-l-(3,5-dimethylphenyl)-hept-6-ene-l-one (97%).
Step 2) 4-(R)-(3,4-Dichlorophenyl)-l-(3,5-dimethylphenyl)-2-(RS)- methyl-hept-6-ene- 1 -one
Hexamethyldisilazane (0.108mL, 0.512mmol), and 0.089mL of hexamethylphosphoramide were dissolved in 2mL of dry THF. To it was added 0.306mL (0.49mmol) of n-butyllithium (1.6M hexane solution) after cooling in an ice-water bath. After stirring for 20min, the ice-water bath was replaced by a dry ice-acetone bath and 2mL of a dry THF solution of 4-(S)-(3,4-dichlorophenyl)-l-(3,5- dimethylphenyl)-hept-6-ene-l-one (154mg, 0.426mmol) was added via syringe. After stirring for lhr, 0.066mL (1.06mmol) of iodomethane was added . The cooling bath was removed and the mixture stirred at rt overnight. The solvent was then removed under reduced pressure and the residual material was diluted in ethyl acetate and water. The organic phase was separated. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, filtered, concentrated, and chromatographed on silica gel eluting with a gradient of hexane : ethyl acetate = 10 : 1 to 7 : 1 to give 150mg of 4-(R)-(3,4- dichlorophenyl)-l -(3,5-dimethylphenyl)-2-(R &S)-methyl-hept-6-ene-l - one (94%). This was a 1 to 1 mixture of two diastereomers as revealed by proton NMR.
Η-NMR (CDC13 400MHz): δ 1.06 ( d, J=7Hz, 1.5H), 1.14 ( d, J=6.7Hz,
1.5H), 2.30, 2.31 (s, 6H), 2.5 (m, 0.5H), 2.6 (m, 0.5H), 3.1-3.2 (m,
IH), 4.9 (m, 2H), 5.5 (m, IH), 6.8-7.4 (m, 6H).
Step 3) 3-(S)-(3,4-Dichlorophenyl)-5-(RS)-methyl-6-(3,5- dimethylphenyl)-6-oxo-hexanal
The product from Step 2 above was subjected to osmium tetroxide oxidation followed by the treatment with sodium periodate as described in Example 1 to give 3-(S)-(3,4-dichlorophenyl)-5-(RS)- methyl-6-(3,5-dimethylphenyl)-6-oxo-hexanal.
Step 4) 1 '-(3-(S)-(3,4-Dichlorophenyl)-6-(3,5-dimethylphenyl)-5-(RS)- methyl-6-oxo-hexyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'-piperidine) This product from Step 3 above was subjected to reductive amination with l-methanesulonyl-spiro(indoline-3,4'-piperidine) as described in Example 2 to give the title compound.
Η-NMR (CDC13 400MHz): δ 1.05 (d, J=7Hz), 1.08 (d, J=6.7Hz), 2.30 & 2.32 (s, 6H), 2.89 (s, 3H), 3.72 (S, 2H), 6.8-7.0 (m, 10H).
MS (CI): 627 (M++1 : 35dχ2), 629 (M++1 : 35d& 37d).
EXAMPLE 136
l'-(3-(S)-(3,4-Dichlorophenyl)-4-(3,5-(bistrifluoromethyl)benzyloxy)- l-acetyl-spiro(indoline-3,4'-piperidine)
Step A: 2-(S)-(3,4-Dichlorophenyl)-4-penten-l-ol
To a solution of 2-(S)-(3,4-dichlorophenyl)-4-pentenoic acid (7.0 gm) (prepared as described by J. Hale et. al., Bioorganic & Medicinal Chemistry Letters 1993,5, 319-322.) in ether (50 mL) at r.t. was added portion wise over 5 min solid lithium aluminum hydride (700 mg). The reaction was heated to 40 °C for 3 hr and then stirred at r.t. for 16 hr. The reaction was poured into water containing 25 mL of 2N NaOH and extracted twice with ether. The ether layers were washed with brine, combined and dried over Na2Sθ4. Flash chromatograghy afforded the title compound (4.5 gm) as an oil. [α]D = +14 (EtOH, c = 1.5).
Step B: 2-(S)-(3,4-Dichlorophenyl)-l-(3,5-
(bistrifluoromethyl)benzyloxy)-4-pentene
To a solution of 2-(S)-(3,4-dichlorophenyl)-4-penten-l-ol (1.0 gm) in DMF (25 mL) was added sodium hydride (175 mg) while cooled in an ice bath. After 1 min, 3,5-(bistrifluoromethyl)benzyl bromide (2.0 gm) was added followed by a second portion of sodium hydride (175 mg). After 1 hr, the reaction was poured into water and extracted twice with ether. The ether layers were washed with brine, combined and dried over Na2Sθ4. Flash chromatograghy (hexanes, then 2 and 5% ethyl acetate/hexanes) afforded the title compound (2.0 gm) as an oil. NMR (CDC13): δ 2.30-2.40 and 2.50-2.60 (2 m, 2 H), 2.90-3.00 (m, 1 H), 3.55-3.65 (d of AB q, 2 H, J = 6 and 9 Hz), 4.54 (AB q, 2 H, J = 13 Hz), 4.90-5.00 (m, 2 H), 5.55-5.70 (m, 1 H), 7.04 (dd, 1 H, J = 2 and 8 Hz), 7.30 (d, 1 h, J = 2 Hz), 7.36 (d, 1 h, J = 8 Hz), 7.64 (s, 2 h), 7.76 (s, 1 H).
Step C: 3-(S)-(3,4-Dichlorophenyl)-4-(3,5-
(bistrifluoromethyl)benzy loxy)butan- 1 -ol
A solution of 2-(S)-(3,4-dichlorophenyl)-l-(3,5- 0 (bistrifluoromethyl)benzyloxy)-4-pentene (1.5 gm) in methanol (50 mL) was cooled to -70 °C in a dry ice/acetone bath and ozone bubbled thm for 15 min until a blue coloration was seen. The solution was purged with N2 for 10 min and sodium borohydride was added. The reaction was allowed to warm to r.t. and was stirred for 2 hr. The 5 volatiles were removed in vacuo and the residue was flash chromatograghed (30 then 50% ethyl acetate/hexanes) to give the title compound as a clear oil.
NMR (CDC13): δ 1.78-1.88 and 2.00-2.10 (2 m, 2 H), 3.05-3.15 (m, 1 H), 3.45-3.55 (m, 1 H), 3.55-3.68 (2 m, 3 H), 4.55 (AB q, 2 H, J = 13 0 Hz), 7.04 (dd, 1 H, J = 2 and 8 Hz), 7.32 (d, 1 h, J = 2 Hz), 7.36 (d, 1 h, J = 8 Hz), 7.65 (s, 2 h), 7.76 (s, 1 H).
Step D: 4-Bromo-2-(S)-(3,4-dichlorophenyl)-l-(3,5- (bistrifluoromethyl)benzyloxy)butane
5 3-(S)-(3,4-Dichlorophenyl)-4-(3,5-
(bistrifluoromethyl)benzyloxy)butan-l-ol from Step C (500 mg) was converted to the title compound (530 mg) with Ph3P-Br2 as described in Example 20, Step B.
Step E: l '-(3-(S)-(3,4-Dichlorophenyl)-4-(3,5- o (bistrifluoromethyl)benzyloxy)- 1 -acetyl-spiro(indoline-
3,4'-piperidine).
4-Bromo-2-(S)-(3,4-dichlorophenyl)-l -(3,5- (bistrifluoromethyl)benzyloxy)butane (30 mg) from Step D was .converted to the title compound (42 mg) as described in Example 20, Step C. NMR (CDCI3): δ 1.48-2.05 (m, 10 H), 2.14 and 2.34 (2 s, 3 H), 2.10- 2.25 (m, 2 H), 2.70-2.85 (m, 2 H), 2.90 (m, 1 H), 3.48-3.58 (m, 2 H), 3.70 and 3.84 (2 s, 2H), 4.55 (AB q, 2H, J = 13 Hz), 6.90-7.15 (m, 4 h), 7.33 (d, 1 h, J = 2 Hz), 7.37 (d, 1 h, J =8 Hz), 7.66 (s, 2h), 7.76 (s, IH), 8.18 (d, lh, 8 Hz).

Claims

WHAT IS CLAIMED IS:
1. A compound of formula I
Figure imgf000162_0001
Ri
I
or a pharmaceutically acceptable salt thereof, wherein the nitrogen expressly shown above is optionally quatemized with Ci-4alkyl or phenylCι_4alkyl or is optionally present as the N- oxide (N+O-), and wherein:
1 and m are each independently 0, 1 , 2, 3, 4, or 5, with the proviso that 1 + m is equal to 1,
2, 3, 4, or 5;
Rl is selected from a group consisting of:
(1) hydrogen,
(2) linear or branched Ci-8 alkyl, linear or branched C2-8 alkenyl, or linear or branched C2-8 alkynyl, wherein the
Cl-8 alkyl, C2-8 alkenyl or C2-8 alkynyl is di or tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy, (b) oxo,
(c) cyano,
(d) halogen which is defined to include Br, CI, I, and F,
(e) trifluoromethyl,
(f) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) phenyl,
(2) hydroxy,
(3) Cl-3alkyl,
(4) cyano,
5 (5) halogen,
(6) trifluoromethyl,
(7) -NR6COR7, wherein R6 and R7 are independently selected from:
(a) hydrogen, 10 (b) Cl -6 alkyl, or mono or disubstituted Cl-6 alkyl, the substitutents independently selected from
(1) phenyl,unsubstituted or substituted with hydroxy, Cl-3alkyl, cyano,
15 halogen, trifluoromethyl or
Ci-4alkoxy,
(2) hydroxy,
(3) oxo,
(4) cyano, 20 (5) halogen,
(6) trifluoromethyl, (c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl, pyridinyl or thiophene, the substitutents independently selected from 25 (1) hydroxy,
(2) Cl-4alkyl,
(3) cyano,
(4) halogen,
(5) trifluoromethyl, 30 (d) Cl-3alkyloxy, or
R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from (a) hydroxy, 5 (b) oxo,
(c) cyano,
(d) halogen,
(e) trifluoromethyl, (8) -NR6C02R7,
10 (9) -NR6CONHR7,
(10) -NR6S(0)jR7, wherein j is 1 or 2,
(11 ) -CONR6R7,
(12) -C0R6,
(13) -C02R6, 15 (14) -0R6,
(15) -S(0)kR6 wherein k is 0, 1 or 2,
(16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
( I ) benzimidazolyl, 20 (2) benzofuranyl,
(3) benzoxazolyl,
(4) furanyl,
(5) imidazolyl,
(6) indolyl, 25 (7) isoxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl,
(10) oxazolyl,
(I I ) pyrazinyl, 30 (12) pyrazolyl,
(13) pyridyl,
(14) pyrimidyl,
(15) pyrrolyl,
(16) quinolyl, (17) tetrazolyl,
(18) thiadiazolyl,
(19) thiazolyl,
(20) thienyl, and 5 (21) triazolyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from,
(a) hydroxy, 10 (b) oxo,
(c) cyano,
(d) halogen,
(e) trifluoromethyl, (g) -NR6R7,
15 (h) -NR6COR7,
(i) -NR6C02R7,
(j) -NR6CONHR7,
(k) -NR6S(0)jR7,
(1) -CONR6R7, 20 (m) -COR6,
(n) -CO2R6,
(o) -OR6,
(p) -S(0)kR6,
(q) heteroaryl, wherein heteroaryl is selected from the 25 group consisting of:
(1) benzimidazolyl,
(2) benzofuranyl,
(3) benzoxazolyl,
(4) furanyl,
30 (5) imidazolyl,
(6) indolyl,
(7) isoxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl, (io; ) oxazolyl,
(n; ) pyrazinyl,
(12; ) pyrazolyl,
(13; ) pyridyl,
(14; ) pyrimidyl,
(15; ) pyrrolyl,
(16; ) quinolyl,
(17; ) tetrazolyl,
(is; ) thiadiazolyl,
(19; ) thiazolyl,
(20^ ) thienyl,
(2i ; ) triazolyl, wherein tl le heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from
(1) phenyl,
(2) hydroxy,
(3) oxo,
(4) cyano,
(5) halogen,
(6) trifluoromethyl,
wherein the nitrogen of definition Rl 2(g) as defined above is optionally quatemized with Cl-4alkyl or phenylCl-4alkyl or is optionally present as the N-oxide (N+0-); W is selected from the group consisting of
(1) a covalent bond
(2) Cl-3 alkyl, unsubstituted or substituted with
(a) oxo,
(b) OR6,
(c) halogen,
(d) trifluoromethyl,
(e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from (1) hydroxy,
(2) cyano,
(3) halogen,
(4) trifluoromethyl,
(3) S(0)k,
(4) (Cl-3 alkyl)-S(0)k,
(5) S(0)k-(Cι-2 alkyl),
(6) S(0)k-NH,
(7) S(0)j-NH(Ci-2 alkyl),
(8) S(0)j-NR6,
(9) S(0)j-NR6-(Cl-2 alkyl),
(10) CONH,
(11) CONH-(Cl-2 alkyl),
(12) CONR6, (13) CONR6-(Cl-2 alkyl),
(14) C02,
(15) C02-(Cl-2 alkyl);
Q = NR2, O, S, S(O), or Sθ2, with the proviso that when W is a covalent bond and X is Cl-3alkyl, then Q must be NR2; R2 is selected from a group consisting of:
(1) hydrogen,
(2) Cl-8 linear or branched alkyl,unsubstituted, monosubstituted or multiply substituted with
(a) -OR6, (b) = O,
(c) -NHCOR6,
(d) -NR6R7,
(e) -CN,
(f) -halogen, (g) -CF3,
(i) -phenyl, unsubstituted or substituted, wherein the substitutents are selected from the group consisting of (1) hydroxy, (2) cyano,
(3) halogen,
(4) trifluoromethyl,
(3) S(0)R8, wherein R8 is Cl-6 linear or branched alkyl, unsubstituted, mono di or trisubstituted with
(a) hydroxy,
(b) oxo,
(c) cyano,
(d) -OR6,
(e) -NR6R7,
(f) -NR6COR7,
(g) -halogen, and
(h) -CF3,
(i) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from
(1) hydroxy,
(2) oxo,
(3) cyano,
(4) -NHR6,
(5) -NR6R7,
(6) -NR6COR7,
(7) -halogen,
(8) -CF3, and
(9) Cl-3 alkyl,
(4) SO2R8, or
(5) COR8,
(6) CO2R8;
(7) CONR7R8;
X is selected from the group consisting of
(1) a covalent bond
(2) Cl-3 alkyl, unsubstituted or substituted with
(a) oxo,
(b) OR6, (c) halogen,
(d) trifluoromethyl,
(e) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from
(1) hydroxy
(2) OR6,
(3) halogen, and
(4) trifluoromethyl,
(3) S(0)k,
(4) (Cl-3 alkyl)S(0)k,
(5) S(0)k(Ci-2 alkyl),
(6) NHS(0)j,
(7) NH(Cl-2 alkyl)S(0)j,
(8) S(0)jNR6,
(9) S(0)j-NR6-(Cl-2 alkyl),
(10) NHCO,
(I D NHCO-(Cl-2 alkyl),
(12) NR6CO,
(13) NR6-(Cl-2 alkyl)CO,
(14) O(CO), and
(15) (Cl-2 alkyl)O(CO),
Y-Z considered together are 2 adjoining atoms of the ring
Figure imgf000169_0001
said ring being an phenyl, naphthyl or heteroaryl group, with the heteroaryls selected from the group consisting of:
(1) benzimidazolyl,
(2) benzofuranyl,
(3) • beπzoxazolyl,
(4) furanyl,
(5) imidazolyl,
(6) indolyl, (7) isoxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl,
(io; ) oxazolyl,
(n; ) pyrazinyl,
(12; ) pyrazolyl,
(13; ) pyridyl,
(14; ) pyrimidyl,
(i5; ) pyrrolyl,
(16; ) quinolyl,
(17; ) tetrazolyl,
(is; ) thiadiazolyl,
(19; ) thiazolyl,
(2o; ) thienyl,
(2i ; ) triazolyl, and wherein the aryl or heteroaryl group is unsubstituted, mono, di or tri substituted, the substitutents selected from:
(a) hydrogen,
(b) Cl-6 alkyl, branched or unbranched, unsubstituted or mono or disubstituted, the substituents being selected from hydrogen and hydroxy,
(c) oxo
(d) OR6, wherein R6 is as defined immediately above,
(e) halogen,
(f) trifluoromethyl,
(g) nitro,
(h cyano,
(i) NR6R7,
(j) NR6COR7,
(k) NR6CO2R7,
(1) NHS(0)jR6,
(m) NR6S(0)jR7,
(n) CONR6R7,
(o) COR6, (P) C02R6,
(q) S(0)jR6,
(r) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) benzimidazolyl,
(b) benzofuranyl,
(c) benzoxazolyl,
(d) furanyl,
(e) imidazolyl,
10
(f) indolyl,
(g) isoxazolyl,
(h) isothiazolyl,
(i) oxadiazolyl,
G) oxazolyl,
15 (k) pyrazinyl,
(1) pyrazolyl,
(m) pyridyl,
(n) pyrimidyl,
(o) pyrrolyl,
20
(P) quinolyl,
(q) tetrazolyl,
(r) thiadiazolyl,
(s) thiazolyl,
(t) thienyl,
25 (u) triazolyl, and wherein the heteroaryl is unsubstituted mono or di substituted, the substitutents selected from
(1) hydrogen,
(2) Cl-6 alkyl, branched or unbranched, unsubstituted or
30 mono or disubstituted, the substituents being selected from hydrogen and hydroxy,
(3) oxo
(4) OR6,
(5) trifluoromethyl, (6) nitro,
(7) cyano,
(8) NR6R7,
(9) NR6COR7, (10) NR6C02R7,
(11) NHS(0)jR6,
(12) NR6S(0)jR7,
(18) CONR6R7,
(19) COR6, (20) CO2R6,
(21 ) S(0)jR6, and
(22) phenyl.
A compound according to Claim 1 wherein:
1 + m is equal to 2, 3, or 4;
Y and Z are each individually a carbon atom;
Rl is selected from a group consisting of:
Cl , C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, di, tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy,
(b) Cl or F,
(c) trifluoromethyl, (d) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from
(1) phenyl,
(2) hydroxy,
(3) Ci-3alkyl, (4) cyano,
(5) • halogen,
(6) trifluoromethyl,
(7) -NR6COR7, wherein R6 and R7 are independently selected from: (a) hydrogen,
(b) Cl-6 alkyl, or mono or disubstituted Cl-6 alkyl, the substitutents independently selected from
5 (1) phenyl,unsubstituted or substituted with hydroxy, Cl-3alkyl, cyano, halogen, trifluoromethyl or Cl-4alkoxy, (2) hydroxy, 10 (3) oxo,
(4) cyano,
(5) halogen,
(6) trifluoromethyl,
(c) phenyl, pyridinyl or thiophene or mono, di or 15 trisubstituted phenyl , pyridinyl or thiophene , the substitutents independently selected from
(1) hydroxy,
(2) Cl-4alkyl,
(3) cyano, 20 (4) halogen,
(5) trifluoromethyl,
(d) Cl-3alkyloxy, or
R6 and R7 are joined together to form a 5-, 6-, 25 or 7-membered monocyclic saturated ring containing
1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from 30 (a) hydroxy,
(b) oxo,
(c) cyano,
(d) halogen,
(e) trifluoromethyl, (8) -NR6C02R7,
(9) -NR6CONHR7,
(10) -NR6S(0)jR7, wherein j is 1 or 2,
(11) -CONR6R7, (12) -COR6,
(13) -CO2R6,
(14) -OR6,
(15) -S(0)kR6,
(16) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(a) pyrazinyl,
(b) pyrazolyl,
(c) pyridyl,
(d) pyrimidyl, and (e) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from,
(a) hydroxy, (b) oxo,
(c) cyano,
(d) halogen,
(e) trifluoromethyl, (e) -NR6COR7, (f) -NR6CO2R7,
(g) -NR6CONHR7,
(h) -NHS(0)jR6,
(i) -COR6,
G) -OR6, (k) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) pyrazinyl,
(2) pyrazolyl,
(3) pyridyl, (4) pyrimidyl, and
(5) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from
(a) phenyl,
(b) hydroxy,
(c) oxo,
(d) cyano, (e) halogen, and
(f) trifluoromethyl, W is selected from the group consisting of
(1) a covalent bond
(2) Cl-3 alkyl, unsubstituted or substituted with oxo, and (3) S(0)2;
Q = NR2, S, S(O) or S02, with the proviso that when W is a covalent bond and X is Cl-3alkyl, then Q must be NR2; R2 is selected from a group consisting of: (1) hydrogen, (2) Cl , C2, C3, C4, C5, C6, C7 or C8 linear or branched alkyl, unsubstituted, monosubstituted or multiply substituted with
(a) -OR6,
(b) = O, (c) -NR6R7,
(3) Sθ2R8> wherein R8 is C1-4 linear or branched alkyl, unsubstituted, mono or disubstituted with
(a) -OR6,
(b) -NHCOR6, (c) -NR6R7,
(d) -halogen,
(e) -phenyl;
(4) COR8, or
(5) C02R8; (6) CONR7R8;
X is selected from the group consisting of
(1) a covalent bond, and
(2) Cl-3 alkyl;
Y-Z considered together are 2 adjoining atoms of the ring
Figure imgf000176_0001
said ring being an phenyl, naphthyl or heter oaryl, with the heteroaryl selected from
(1) pyrazinyl,
(2) pyrazolyl,
(3) pyridyl,
(4) pyrimidyl, and
(5) thienyl.
3. A compound according to Claim 2 wherein:
1 + m is equal to 2, 3, or 4;
Rl is selected from a group consisting of:
Cl , C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from: (a) hydroxy,
(b) Cl or F,
(c) phenyl or mono, di or trisubstituted phenyl , the substitutents independently selected from
(1) phenyl, (2) hydroxy,
(3) Ci-3alkyl,
(4) cyano,
(5) halogen,
(6) trifluoromethyl, (d) -NR6COR7, wherein R6 is hydrogen or Cl-3 alkyl and R7 is phenyl, pyridinyl or thiophene, phenylCl -3alkyl, pyridinylC 1-3 alkyl or thiophenelCl-3alkyl, wherein the phenyl, pyridinyl or thiophene, phenylC 1 -3 alkyl, pyridinylCi-3alkyl or thiophenelC 1-3 alkyl, is optionally substituted with Cl, F, CF3 or Cl-3alkyl,
(e) -NHS(0)jR6,
(f) -COR6, (h) -OR6, W is selected from the group consisting of
(1) a covalent bond, and
(2) C1-3 alkyl, unsubstituted or substituted with oxo; Q is NR2, S, S(O) or S(0)2;
R2 is selected from a group consisting of: (1) hydrogen,
(2) Cl , C2, C3 or C4 linear or branched alkyl, unsubstituted, monosubstituted or disubstituted with oxo, OR6, NR6R7 or phenyl,
(3) S02R8, (4) COR8, or
(5) C02R8;
(6) CONR7R8;
X is selected from the group consisting of (1) a covalent bond, and (2) methylene or 1 -ethylene or 2-ethylene;
Y-Z considered together are 2 adjoining atoms of the ring
Figure imgf000177_0001
said ring being phenyl.
4. A compound according to Claim 3 wherein: 1 + m is equal to 2 or 3;
Rl is selected from a group consisting of:
Cl , C2, C3, C4, C5 or C6 linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy,
(b) Cl or F,
(c) phenyl or mono, di or trisubstituted phenyl , the substitutents independently selected from (1) phenyl,
(2) hydroxy,
(3) methyl or ethyl,
(4) cyano,
(5) halogen, (6) trifluoromethyl,
(d) -NR6COR7, wherein R6 is methyl and R7 is phenyl, pyridinyl or thiophene, phenylCl-3alkyl, pyridinylCl- 3alkyl or thiophenelCl-3alkyl, wherein the phenyl, pyridinyl or thiophene, phenylC l-3alkyl, pyridinylCl- 3alkyl or thiophenelCl-3alkyl, is optionally substituted with
Cl, F, CF3 or Cl-3alkyl, W is selected from the group consisting of
(1) a covalent bond, and
(2) C1-3 alkyl, unsubstituted or substituted with oxo, and Q is NR2;
R2 is selected from a group consisting of:
(1) hydrogen,
(2) Cl , C2, C3 or C4 linear or branched alkyl,unsubstituted, monosubstituted or multiply substituted with oxo, OR6, NR6R7 and phenyl
(3) S02R8,
(4) COR8, or
(5) CO2R8;
(6) CONR7R8; X is selected from the group consisting of
(1 ) a covalent bond, and
(2) methylene or 1 -ethylene or 2-ethylene; Y-Z considered together are 2 adjoining atoms of the ring
Figure imgf000179_0001
said ring being phenyl.
5. A according to Claim 4 wherein: 1 + m is 3; Rl is
Figure imgf000179_0002
0 where B is
(a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF ; 5 (b) -CH2phenyl or mono or disubstituted -CH2phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3;
(c) pyridyl or mono di or trisubstituted pyridyl wherein the substitutents are independently chloro, methyl, phenyl or ° CF3; and
(d) thiophene or mono or disubstituted thiophene wherein the substitutents are independently chloro, methyl, phenyl or CF3.
6. A according to Claim 5 wherein: where B is
(a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3.
7. A of formula I according to Claim 1
Figure imgf000180_0001
wherein the group
Figure imgf000180_0002
is an optionally mono di or trisubstituted group selected from
Figure imgf000181_0001
Figure imgf000181_0002
Figure imgf000181_0003
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000183_0002
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000193_0001
30
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Figure imgf000196_0002
Figure imgf000197_0001
Figure imgf000197_0002
Figure imgf000198_0001
Figure imgf000198_0002
the optional substitutents residing at 1 , 2, or 3 of the unsubstituted positions on the above groups, the substituents selected from the group consisting of
(a) hydroxy,
(b) oxo,
(c) cyano,
(d) -NR6R7,
(e) -NHCOR6R7,
(f) -halogen,
(g) -CF3,
(h) -phenyl or mono, di or trisubstituted phenyl, the substituents independently selected from
(1) hydroxy,
(2) oxo,
(3) cyano,
(4) -NR6R7,
(5) - HCOR6R7,
(6) -halogen,
(7) -CF3, and
(8) -Cl-3 alkyl.
8. A compound according to Claim 7 wherein:
Rl is selected from a group consisting of:
Cl , ' C2, C3, C4, C5, C6, Cγ or C8 linear or branched alky' 1, di, tri or tetra substituted, the substitutents independently selected from:
(a) hydroxy,
(b) Cl or F,
(c) trifluoromethyl,
(d) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from
(1) phenyl,
(2) hydroxy,
(3) Ci-3alkyl,
(4) cyano, (5) halogen,
(6) trifluoromethyl,
(7) -NR6COR7, wherein R6 and R7 are independently selected from:
5 (a) hydrogen,
(b) Cl-6 alkyl, or mono or disubstituted Cl-6 alkyl, the substitutents independently selected from
(1) phenyl,unsubstituted or substituted 10 with hydroxy, Cl-3alkyl, cyano, halogen, trifluoromethyl or Cl-4alkoxy,
(2) hydroxy,
(3) oxo, 15 (4) cyano,
(5) halogen,
(6) trifluoromethyl,
(c) phenyl, pyridinyl or thiophene or mono, di or trisubstituted phenyl , pyridinyl or thiophene ,
20 the substitutents independently selected from
(1) hydroxy,
(2) Cl-4alkyl,
(3) cyano,
(4) halogen,
25 (5) trifluoromethyl,
(d) Cl-3alkyloxy, or
R6 and R7 are joined together to form a 5-, 6-, or 7-membered monocyclic saturated ring containing 30 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and in which the ring is unsubstituted or mono or disubstituted, the substituents independently selected from
(a) hydroxy, (b) oxo,
(c) cyano,
(d) halogen,
(e) trifluoromethyl, (8) -NR6C02R7,
(9) -NR6CONHR7,
(10) -NR6S(0)jR7, wherein j is 1 or 2,
(11 ) -CONR6R7,
(12) -COR6, (13) -C02R6,
(14) -OR6,
(15) -S(0)kR6,
(16) heteroaryl, wherein heteroaryl is selected from the group consisting of: (a) pyrazinyl,
(b) pyrazolyl,
(c) pyridyl,
(d) pyrimidyl, and
(e) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from,
(a) hydroxy,
(b) oxo, 5 (c) cyano,
(d) halogen,
(e) trifluoromethyl,
(e) -NR6COR7,
(f) -NR6CO2R7, ° (g) -NR6CONHR7,
(h) -NHS(0)jR6, (i) -COR6, G) -OR6, (k) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) pyrazinyl,
(2) pyrazolyl, (3) pyridyl,
(4) pyrimidyl, and
(5) thienyl, wherein the heteroaryl is unsubstituted or mono di or trisubstituted, the substituents independently selected from
(a) phenyl,
(b) hydroxy,
(c) oxo,
(d) cyano, (e) halogen, and
(f) trifluoromethyl.
9. A compound according to Claim 8 wherein: Rl is selected from a group consisting of: Cl , C2, C3, C4, C5 or Cβ linear or branched alkyl, di or tri substituted, the substitutents independently selected from:
(a) hydroxy,
(b) Cl or F, (c) phenyl or mono, di or trisubstituted phenyl , the substitutents independently selected from
(1) phenyl,
(2) hydroxy,
(3) Cl-3alkyl, (4) cyano,
(5) halogen,
(6) trifluoromethyl,
(d) -NR6COR7, wherein R6 is hydrogen or Cl-3 alkyl and R7 is phenyl, pyridinyl or thiophene, phenylC 1-3 alkyl, pyridinylC 1-3 alkyl or thiophenelCl -3alkyl, wherein the phenyl, pyridinyl or thiophene, phenylC 1-3 alkyl, pyridinylCl-3alkyl or thiophenelCl-3alkyl, is optionally substituted with Cl, F, CF3 or Ci-3alkyl, (e) -NHS(0)jR6,
(f) -COR6, (h) -OR6.
10. A compound according to Claim 9 wherein wherein the group
Figure imgf000203_0001
is an optionally mono di or trisubstituted group selected from
Figure imgf000204_0001
Figure imgf000204_0002
the substitutents residing at 1, 2, or 3 of the positions 1, 2, 3, 4, 5, 6 or 7 of the above groups, the substituents selected from the group consisting of (a) hydroxy,
(b) oxo,
(c) cyano,
(d) -NHR6,
(e) -NR6R7,
(f) -NHCOR6R7,
(g) -halogen,
(h) -CF3,
(i) -phenyl or mono, di or trisubstituted phenyl, the
10 substituents independently selected from
(1) hydroxy,
(2) oxo,
(3) cyano,
(4) -NHR6,
15 (5) -NR6R7,
(6) -NHCOR6R7,
(7) -halogen,
(8) -CF3, and
(9) -Cl-3 alkyl.
20 11. A compound according to Claim 10 wherein:
Rl is selected from a group consisting of:
C2, C3, C4 or C5 linear or branched alkyl, di or tri substituted, the substitutents independently selected from
25 (a) hydroxy,
(b) Cl or F,
(c) phenyl or mono, di or trisubstituted phenyl, the substitutents independently selected from
(1) phenyl,
30 (2) hydroxy,
(3) methyl or ethyl,
(4) cyano,
(5) halogen,
(6) trifluoromethyl, (d) -NR6COR7, wherein R is methyl and R7 is phenyl, pyridinyl or thiophene, phenylCi-3alkyl, pyridinylCl- 3alkyl or thiophenelCl-3alkyl, wherein the phenyl, pyridinyl or thiophene, phenylCl-3alkyl, pyridinylCl- 3alkyl or thiophenelCl-3alkyl, is optionally substituted with Cl, F, CF3 or Cl-3alkyl.
12. A according to Claim 11 wherein:
Rl is
Figure imgf000206_0001
where B is
(a) phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or
CF3;
(b) -CH2phenyl or mono or disubstituted -CH2phenyl wherein the substitutents are independently chloro, methyl, phenyl or
CF ; (c) pyridyl or mono di or trisubstituted pyridyl wherein the substitutents are independently chloro, methyl, phenyl or
CF3; or (d) thiophene or mono or disubstituted thiophene wherein the substitutents are independently chloro, methyl, phenyl or CF3.
13. A compound according to Claim 12 wherein B is phenyl or mono di or trisubstituted phenyl wherein the substitutents are independently chloro, methyl, phenyl or CF3.
14. A compound according to Claim 1 selected from the group consisting of
(a) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-t- butoxycarbonyl)(methylamino))butyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine);
(b) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'- piperidine);
(c) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N- ° (benzoyl)(methyl-amino))butyl)- 1 -methanesulfonyl-spiro(indoline-3,4'- piperidine);
(d) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- bistrifluoro-methylbenzoyl)(methylamino))butyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine); 5 (e) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- methylbenzoyl)(methylamino))butyl)-l-methanesulfonyl-spiro(indoline- 3, 4' -piperidine);
(f) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- chlorobenzoyl)(methylamino))butyl)- 1 -methanesulf onyl-spiro(indoline- 0 3,4'-piperidine);
(g) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- trifluoromethyl-benzoyl)(methylamino))butyl)- 1 -methanesulfony 1- spiro(indoline-3 ,4'-piperidine) ;
(h) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dichloro- 5 benzoyl)(methylamino))butyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'- piperidine);
(i) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- trifluoromethyl-phenylacetyl)(methylamino))butyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine); 0 (j) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- isopropyloxy-phenylacetyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine); (k) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N- (benzenesulfonyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine);
(1) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-benzyoxycarbonyl-spiro(indoline-3,4'- piperidine);
(m) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-spiro(indoline-3,4'-piperidine);
(n) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)- 1 -propionyl-spiro(indoline-3 ,4'- piperidine);
(o) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino)) butyl)-l-formyl-spiro(indoline-3,4'- piperidine); (p) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-f-butylcarbonyl-spiro(indoline-3,4'- piperidine);
(q) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)- 1 -methylaminocarbonyl-spiro(indoline- 3,4'-piperidine);
(r) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-ethoxycarbonyl-spiro(indoline-3,4'- piperidine);
(s) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-ethanesulfonyl-spiro(indoline-3,4'- piperidine);
(t) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-l-t'-propanesulfonyl-spiro(indoline-3,4'- piperidine); (u) l'(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5-dimethyl- benzoyl)(methylamino))butyl)-r-methyl-l-methanesulfonyl-spiro- indoline-3 ,4'-piperidinium iodide; (v) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3- methylbenzoyl)(methylamino))pentyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine);
(w) l '-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5- bis(trifluoromethyl)benzoyl)(methylamino))pentyl)- 1 -methanesulf onyl- spiro(indoline-3 ,4'-piperidine) ;
(x) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5- dimethylbenzoy l)(methylamino))pentyl)- 1 -methanesulfony 1-spiro-
(indoline-3,4'-piperidine); (y) l'-(3-(S)-(3,4-dichlorophenyl)-4-(N-(R or S)-(3,5- dichlorobenzoyl)(methylamino))pentyl)-l -methanesulf onyl-spiro-
(indoline-3,4'-piperidine); xs (aa) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- difluorobenzoyl)(methylamino))butyl)- 1 -methanesulfony 1- spiro(indoline-3,4'-piperidine);
(ab) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5- (trifluoromethyl)benzoyl)(methylamino))butyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine);
(ac) l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(l- naphthoyl)(methy lamino))butyl)- 1 -methanesulf onyl-spiro(indoline-3 ,4'- piperidine);
(ad) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(2- chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulf onyl- spiro(indoline-3,4'-piperidine); (ae) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- chlorophenylsulf onyl)-(methylamino))butyl)- 1 -methy lsulf onyl - spiro(indoline-3,4'-piperidine);
(af) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4- chlorophenylsulfonyl)-(methylamino))butyl)- 1 -methylsulf onyl- spiro(indoline-3,4'-piperidine);
(ag) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichloropheny lsulf onyl)-(methylamino))butyl)-l -methy lsulf onyl- spiro(indoline-3,4'-piperidine); (ah) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-fluoro-5- (trifluoromethyl)benzoyl)(methylamino))butyl)-l-acetyl-spiro(indoline- 3, 4' -piperidine);
(ai) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-l-acetyl-spiro(indoline-3,4'- piperidine).
(aj) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-bromo-5- methylbenzoyl)(methylamino))butyl)-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine); (ak) l'-(3-((S)-(3,4-Dichlorophenyl))-4-(N-(3,5- dimethylbenzoy l)(methylamino))butyl)- 1 -(2-aminoacetyl)- spiro(indoline-3,4'-piperidine);
(al) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-l-methyl-spiro(indol-2-one- 3,4'-piperidine);
(am) l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(isoindol- 1 -one- 3,4'-piperidine);
(an) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2-oxo- tetrahydroquinoline-4,4'-piperidine); and
(ao) l*-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichlorobenzoyl)(methylamino))butyl)- 1 -methyl-spiro(2-oxo- tetrahydroquinoline-4,4'-piperidine).
15. A compound according to Claim 1 selected from
(a) l'-(3-(S)-(4-fluorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl- spiro(indoline-3,4'-piperidine),
(b) l'-(3-(S)-(3-chlorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoy l)(methylamino))butyl)- 1 -acetyl- spiro(indoline-3,4'-piperidine), (c) l'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))buty 1)- 1 -acetyl- spiro(indoline-3 ,4'-piperidine),
(d) l'-(3-(S)-(3,4-difluorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -acetyl - spiro(indoline-3,4'-piperidine),
(e) 1 '-(3-(S)-(3,4-methylenedioxyphenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine), (f) l'-(3-(RS)-(3,5-dichlorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine),
(g) l'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine),
(h) l'-(3-(RS)-(4-pyridyl)-4-(N-(3,5- bistrifluoromethylbenzoy l)(methylamino))buty 1)- 1 -acetyl- spiro(indoline-3,4'-piperidine),
(i) 1 '-(3-(S)-(3,4-dichlorophenyl)-4-(N-(3,5- dimethylbenzoyl)(ethylamino))butyl)-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine),
(j) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3- dihydrobenzofuran-3,4'-piperidine),
(k) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- chlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3- dihydrobenzofuran-3,4'-piperidine),
(1) l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3- dihydrobenzofuran-3,4'-piperidine),
(m) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- methylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(2,3- dihydrobenzofuran-3,4'-piperidine), (n) l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(benzoyl)- (methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran-3,4'- piperidine),
(o) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N- (benzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'- piperidine),
(p) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- methylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'- piperidine), (q) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran- 3,4'-piperidine),
(r) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- chlorobenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'- piperidine),
(s) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichlorobenzoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran- 3,4'-piperidine),
(t) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'- piperidine),
(u) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t- butoxycarbonyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine), (v) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine),
(w) l'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine),
(x) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t- butoxycarbonyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine)-l -oxide, (y) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthylmethyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene- 3,4'-piperidine)-l -oxide,
(z) l '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(t- butoxy carbony l)(methy lamino))buty 1) -spiro (2,3- dihydrobenzothiophene-3,4'-piperidine)- 1 ,1 -dioxide,
(aa) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine)-l ,1 -dioxide, (ab) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine)- 1 , 1 -dioxide,
(ac) l'-(3-((S)-(4-chlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine)-l ,l-dioxide,
(ad) l*-(3-((S)-(4-chlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihy drobenzothiophene-3 ,4'-piperidine)- 1 -oxide,
(ae) 1 '-(3-(S)-(4-chlorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylammo))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine), 1 -oxide,
(af) l'-(3-(S)-(4-chlorophenyl)-4-(N-(3,5- bistrifluoromethylbenzoyl)(methylamino))butyl)-spiro(2,3- dihydrobenzothiophene-3,4'-piperidine), 1 , 1 -dioxide, (ag) 1 '-benzyloxy carbony 1-5-fluoro- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine),
(ah) l'-(3-((S)-(3,4-dichlorophenyl))-4- (methy lamino)butyl)- 1 -methanesulf onyl-5-methoxy-spiro(indoline-3 ,4'- piperidine), (ai) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-
(methylamino)butyl)- 1 -methanesulfonyl-5-methyl-spiro(indoline-3 ,4'- piperidine),
5-chloro-l'-(3-((S)-(3,4-dichlorophenyl))-4-(methylamino)butyl)-l- • methanesulfonyl-spiro(indoline-3,4'-piperidine), (ak) l'-(3-((S)-(3,4-dichlorophenyl))-4- (methylamino)butyl)-5-fluoro- 1 -methanesulfonyl-sρiro(indoline-3 ,4'- piperidine),
(al) l'-(3-((S)-(3,4-dichlorophenyl))-4- (methylamino)butyl)-7-fluoro-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine),
(am) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl-5-methyl- spiro(indoline-3,4'-piperidine), (an) 5-chloro-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- methylbenzoyl)(methylamino))butyl)-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine),
(ao) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulf onyl-5-methoxy- spiro(indoline-3,4'-piperidine),
(ap) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- methylbenzoyl)(methylamino))butyl)-5-fluoro- 1 -methanesulf onyl- spiro(indoline-3,4'-piperidine),
(aq) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichlorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine),
(ar) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl- spiro(indoline-3 ,4'-piperidine),
(as) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- chlorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -methanesulfony 1- spiro(indoline-3,4'-piperidine),
(at) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- bis(trifluoromethyl)benzoyl)-(methylamino))butyl)-5-fluoro- 1 - methanesulfonyl-spiro(indoline-3,4'-piperidine),
(au) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethy lbenzoy l)(methylamino))butyl)-7-fluoro- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine), (av) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-t- butoxycarbonyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine),
(aw) l -acetyl-5-chloro-l'-(3-((S)-(3,4-dichlorophenyl))-4- (methylamino)butyl)-spiro(indoline-3,4'-piperidine),
(ax) l-acetyl-l '-(3-((S)-(3,4-dichlorophenyl))-4- (methylamino)butyl)-5-methyl-spiro(indoline-3,4'-piperidine),
(ay) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4- (methylamino)butyl)-5-fluoro-spiro(indoline-3,4'-piperidine), (az) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-
(methylamino)butyl)-6-fluoro-spiro(indoline-3,4'-piperidine),
(ba) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4- (methylamino)butyl)-4-fluoro-spiro(indoline-3,4,-piperidine),
(bb) 1 -acetyl- l'-(3-((S)-(3,4-dichlorophenyl))-4-(N- (benzoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'-piperidine),
(be) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,- dimethylbenzoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'- piperidine),
(bd) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N- (benzoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'-piperidine),
(be) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5,- dimethylbenzoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3,4'- piperidine),
(bf) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N- (benzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine),
(bg) 1 -acetyl- l'-5-chloro-(3-((S)-(3 ,4-dichlorophenyl))-4- (N-(3,5,-dimethylbenzoyl)(methylamino))butyl)-spiro(indoline-3,4'- piperidine),
(bh) l -acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- chlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine),
(bi) l -acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dichlorobenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4,- piperidine), (bj) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- methylbenzoyl)(met_hylamino))butyl)-5-fluoro-spiro(indoline-3,4,- piperidine),
(bk) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine),
(bl) l-acetyl-l"-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3- isopropoxybenzoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine), (bm) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- bis(trifluoromethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine),
(bn) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))butyl)-5-methyl-spiro(indoline-3,4'- piperidine),
(bo) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4- fluoro-l-napthoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'- piperidine),
(bp) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(l- napthoyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3,4'-piperidine),
(bq) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(l-napthoyl)- (methylamino))butyl)-5-fluoro-l-methanesulfonyl-spiro(indoline-3,4'- piperidine),
(br) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthoyl) (methy lamino))butyl)-5-fluoro- 1 -methanesulfony 1- spiro(indoline-3 ,4'-piperidine),
(bs) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine),
(bt) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l - napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine) sulfone, (bu) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthoyl)(methylamino))butyl)-spiro(2,3-dihydrobenzothiophene-3,4'- piperidine),
(bv) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthyl)(methylamino))butyl)-5-fluoro-spiro(2,3-dihydrobenzofuran- 3,4'-piperidine),
(bw) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthyl)(methylamino))butyl)-spiro(2,3-dihydrobenzofuran-3,4'- piperidine), ° (bx) l-acetyl-r-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4- fluoro-l-napthoyl)(methylamino))butyl)-6-fluoro-spiro(indoline-3,4'- piperidine),
(by) 1 -acetyl- l*-(3-((S)-(3, 4-dichlorophenyl))-4-(N-(4- fluoro- 1 -napthoyl)(methylamino))butyl)-4-fluoro-spiro(indoline-3 ,4'- 5 piperidine),
(bz) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- napthylmethyl)(methylamino))butyl)-5-fluoro- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine),
(ca) 1 '-(3-((S)-(3 ,4-dichlorophenyl))-4-(N-(4-fluoro- 1 - ° napthylmethyl)(methylamino))butyl)-5-fluoro-spiro(indoline-3 ,4'- piperidine),
(cb) l-acetyl-l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4- fluoro-l-napthylmethyl)(methylamino))butyl)-5-fluoro-spiro(indoline- 3,4'-piperidine), 5 (cd) l'-(5-fluoroindolyl-3-(2-ethanoyl))-l- methanesulfonyl-spiro(indoline-3,4'-piperidine),
(ce) r-(2-(3-(5-fluoroindolyl))ethyl))-l-methanesulfonyl- spiro(indoline-3,4'-piperidine),
(cf) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4- ° fluorobenzoyl)(methylamino))butyl)- 1 -methanesulfony l-spiro(indo line-
3,4'-piperidine),
(eg) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4- fluorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -methanesulf onyl- spiro(indoline-3 ,4'-piperidine), (ch) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4- fluorobenzoyl)(methylamino))butyl)-l-methanesulfonyl-spiro(indoline- 3,4'-piperidine),
(ci) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4- fluorobenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl-spiro(indoline- 3,4'-piperidine),
(cj) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3-chloro-4- fluorobenzoyl)(methylamino))butyl)-5-fluoro-l-acetyl-spiro(indoline- 3,4'-piperidine), (ck) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5- dimethylbenzoyl)(methylamino))butyl)-5-fluoro- 1 -acetyl- spiro(indoline-3 ,4'-piperidine),
(cl) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5- dimethylbenzoyl)(methylamino))butyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine),
(cm) 1 '-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3- trifluoromethylbenzoyl)(methylamino))butyl)- 1 -methanesulf onyl- spiro(indoline-3 ,4'-piperidine),
(cn) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3,5- dimethylbenzoyl)(methylamino))butyl)-l-acetyl-spiro(indoline-3,4'- piperidine),
(co) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-3- trifluoromethylbenzoyl)(methylamino))butyl)-l-acetyl-spiro(indoline- 3,4'-piperidine), (cp) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l- naphthoyl)(methylamino))butyl)-l-acetyl-spiro(indoline-3,4'- piperidine),
(cq) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(4-fluoro-l - naphthoyl)(methylamino))butyl)-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine),
(cr) . l'-(3--((S)-(3,4-dichlorophenyl))-4-(N-(l- naphthoyl)(methylamino))butyl)-l-acetyl-spiro(indoline-3,4'- piperidine), (cs) l'-(3-((S)-(3,4-dichlorophenyl))-4-(N-(3,5- dimethylbenzoyl)(methylamino))-4-phenyl-butyl)-l-methanesulfonyl- spiro(indoline-3,4'-piperidine),
(ct) 1 '-(4-(N-(3,5-dimethylbenzoyl)(methylamino))-4- (phenyl)butyl)-l-acetyl-spiro(indoline-3,4'-piperidine),
(cu) l'-(3-((S)-(3,4-dichlorophenyl))-4-(l-(2- phenylimidazolo))butyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine),
(cv) l'-(3-((S)-(3,4-dichlorophenyl))-4-((N-(3,5- dimethylbenzoyl)(methylamino))-4-(methyl)butyl)- 1 -acetyl- spiro(indoline-3,4'-piperidine),
(cw) l'-(3-((S)-(3,4-dichlorophenyl))-4-((N-(4-fluoro-l- napthyl)(methylamino))-4-(methyl)butyl)-l-acetyl-spiro(indoline-3,4'- piperidine),
(ex) l'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-(N- (3,5-dimethylbenzoyl)(methylamino))hexyl)-l-acetyl-spiro(indoline- 3,4'-piperidine),
(cy) l'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)-(N- (3,5-dimethylbenzoyl)(methylamino))hexyl)-l-acetyl-5-fluoro- spiro(indoline-3,4'-piperidine),
(cz) l'-(3-(S)-(3,4-dichlorophenyl)-4-(R and S)-(N-(3,5- dimethy Ibenzoy l)(methylamino))heptyl)- 1 -acetyl-spiro(indoline-3 ,4'- piperidine),
(da) l'-(3-(S)-(3,4-dichlorophenyl)-4-(R and S)-(N-(3,5- dimethylbenzoyl)(methylamino))heptyl)- 1 -acetyl-5-fluoro- spiro(indoline-3,4'-piperidine),
(db) l'-(3-((S)-(3,4-dichlorophenyl))-4-(R and S)- hydroxy-5-(3 ,5 -dimethy lphenyl)pentyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine),
(dc) l'-(3-(R)-(3,4-dichlorophenyl)-5-(N-(3,5- dimethylphenyl)(methylamino))-5-oxo-pentyl)- 1 -methanesulfony 1- spiro(indoline-3,4'-piperidine), (dd) l'-(3-(R)-(3,4-dichlorophenyl))-5-(3,5- dimethylphenyl)-5-oxo-pentyl)-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine),
(de) l'-(3-(R)-(3,4-dichlorophenyl)-6-(3,5- dimethylphenyl)-5-oxo-hexyl)-l-methanesulfonyl-spiro(indoline-3,4'- piperidine),
(df) l'-(3-(S)-(3,4-dichlorophenyl)-6-(3,5- dimethylphenyl)-6-oxo-hexyl)-l -methanesulf onyl-spiro(indoline-3, 4'- piperidine), and (dg) l'-(3-(S)-(3,4-dichlorophenyl)-6-(3,5- dimethy lphenyl)-5-(R&S)-methyl-6-oxo-hexyl)- 1 -methanesulfonyl- spiro(indoline-3,4'-piperidine).
(dh) l'-(3-(S)-(3,4-dichlorophenyl)-4-(3,5- (bistrifluoromethy l)benzyloxy )- 1 -acety l-spiro(indoline-3 ,4'-piperidine)
15. A pharmaceutical composition for antagonizing the effect of substance P in a patient in need of such treatment comprising a pharmaceutically acceptable carrier and a non-toxic threapeutically effective amount of the compound of Claim 1.
16. A pharmaceutical composition for the antagonizing the effect of neurokinin A, in a patient in need of such treatment comprising a pharmaceutically acceptable carrier and a non-toxic threapeutically effective amount of the compound of Claim 1.
17. A method for antagonizing the effect of substance P in a patient in need of such antagonizing which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound according to Claim 1.
18. A method for antagonizing the effect of neurokinin A in a patient in need of such antagonizing which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound according to Claim 1.
19. A method of treating or preventing asthma in a pateint in need thereof which comprises the administration to the patient of a non-toxic therapeutically effective amount of the compound of Claim 1.
20. A process of making compounds of formula I according to Claims 1 to 14
Figure imgf000221_0001
I comprising the steps of: (a) reacting a compound of formula A
Figure imgf000221_0002
H
in a suitable solvent with a compound of formula Rl-Xl wherein Xl is a leaving group optionally in the presence of a suitable base such as trialkylamine; or
(b) reacting a compound of formula A in a second suitable solvent with a compound of the formula R-CH(O), wherein R-CH2 is Rl as defined above, in the presence of a reducing agent; or (c) reacting a compound of formula A in a halocarbon solvent with a compound of the formula R-C(0)X2 wherein X2 is a suitable leaving group such as bromo or chloro in the presence of a suitable base; to yield a compound of formula I.
PCT/US1994/005545 1993-06-07 1994-05-17 Spiro-substituted azacycles as neurokinin antagonists WO1994029309A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7501802A JPH08511522A (en) 1993-06-07 1994-05-17 Spiro-Substituted Aza Rings as Neurokinin Antagonists
AU72011/94A AU680020B2 (en) 1993-06-07 1994-05-17 Spiro-substituted azacycles as neurokinin antagonists
EP95901979A EP0702681A1 (en) 1993-06-07 1994-05-17 Spiro-substituted azacycles as neurokinin antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7290493A 1993-06-07 1993-06-07
US072,904 1993-06-07

Publications (1)

Publication Number Publication Date
WO1994029309A1 true WO1994029309A1 (en) 1994-12-22

Family

ID=22110458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/005545 WO1994029309A1 (en) 1993-06-07 1994-05-17 Spiro-substituted azacycles as neurokinin antagonists

Country Status (8)

Country Link
EP (1) EP0702681A1 (en)
JP (1) JPH08511522A (en)
AU (1) AU680020B2 (en)
CA (1) CA2163995A1 (en)
HR (1) HRP940337A2 (en)
IL (1) IL109836A0 (en)
WO (1) WO1994029309A1 (en)
ZA (1) ZA943946B (en)

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005203A1 (en) * 1994-08-08 1996-02-22 Merck Sharp & Dohme Limited Spiro-substituted azacyclic derivatives and their use as therapeutic agents
WO1996024582A1 (en) * 1995-02-10 1996-08-15 Zeneca Limited 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
WO1996033189A1 (en) * 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
WO1996039386A1 (en) * 1995-06-06 1996-12-12 Schering Corporation Piperidine derivatives as neurokinin antagonists
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
EP0758238A1 (en) * 1994-04-26 1997-02-19 Merck & Co. Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
WO1997019084A1 (en) * 1995-11-23 1997-05-29 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists
US5635509A (en) * 1994-05-03 1997-06-03 Zeneca Limited Piperidine derivatives useful as neurokinin antagonists
EP0776893A1 (en) 1995-12-01 1997-06-04 Sankyo Company Limited Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2
WO1997030056A1 (en) * 1996-02-15 1997-08-21 Merck Sharp & Dohme Limited Spiro-ketal derivatives and their use as therapeutic agents
WO1997030055A1 (en) * 1996-02-15 1997-08-21 Merck Sharp & Dohme Limited Spiro-ketal derivatives and their use as therapeutic agents
US5691362A (en) * 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
WO1997049710A1 (en) * 1996-06-21 1997-12-31 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as therapeutic agents
US5710169A (en) * 1994-10-25 1998-01-20 Zeneca Limited Therapeutic heterocycles
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5723616A (en) * 1995-10-27 1998-03-03 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
WO1998018761A1 (en) * 1996-10-28 1998-05-07 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
WO1998028297A1 (en) * 1996-12-20 1998-07-02 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5840725A (en) * 1995-05-02 1998-11-24 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5885999A (en) * 1996-01-29 1999-03-23 Merck Sharp & Dohme Ltd. Serine derivatives and their use as therapeutic agents
US5889024A (en) * 1995-04-29 1999-03-30 Zeneca Limited Substituted heterocycles
US5892039A (en) * 1995-08-31 1999-04-06 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5945428A (en) * 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5968923A (en) * 1994-08-09 1999-10-19 Pfizer Inc. (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6063926A (en) * 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
US6090824A (en) * 1995-11-17 2000-07-18 Zeneca Limited Therapeutic neurokinin receptor antagonist compounds
WO2000059873A1 (en) * 1999-04-06 2000-10-12 Astrazeneca Ab N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
US6362179B1 (en) 1997-05-30 2002-03-26 Sankyo Company, Limited Salts of an optically-active sulfoxide derivative
US6569872B1 (en) 2001-05-08 2003-05-27 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6903102B2 (en) 2001-09-06 2005-06-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6969718B2 (en) 2001-10-17 2005-11-29 Schering Corporation 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7091211B2 (en) 2003-07-31 2006-08-15 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2006094948A1 (en) * 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7247725B2 (en) * 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
US7276511B2 (en) 2003-07-31 2007-10-02 Zeria Pharmaceutical Co., Ltd. Benzylamine derivative
US7279486B2 (en) 2004-03-29 2007-10-09 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
EP1880996A1 (en) 2002-06-14 2008-01-23 Syngenta Limited Spiroindolinepiperidine derivatives
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
WO2009133135A1 (en) 2008-05-01 2009-11-05 Glaxo Wellcome Manufacturing Pte Ltd Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists
WO2010000073A1 (en) 2008-07-03 2010-01-07 Neuraxon, Inc. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2011095581A1 (en) 2010-02-05 2011-08-11 Intervet International B.V. S piroindoline compounds for use as anthelminthi cs
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
US8299058B2 (en) 2003-12-12 2012-10-30 Syngenta Crop Protection Llc Spiro-condensed indoline derivatives as pesticides
US8309567B2 (en) 2003-12-12 2012-11-13 Syngenta Crop Protection Llc Spiroindoline derivatives having insecticidal properties
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
US9085531B2 (en) 2004-07-15 2015-07-21 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2016078770A1 (en) * 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US10076510B2 (en) 2012-05-18 2018-09-18 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10328055B2 (en) 2012-05-18 2019-06-25 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indo]-4-amine and antidepressants
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11096950B2 (en) 2006-11-01 2021-08-24 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US11311504B2 (en) 2012-05-18 2022-04-26 Park Therapeutics, Inc. Pharmaceutical composition comprising (1R,4R)-6′- fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) * 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
US4233307A (en) * 1978-02-13 1980-11-11 Sumitomo Chemical Company, Limited Spiro-4'-piperidine compounds and their pharmaceutical compositions
EP0360390A1 (en) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
EP0431943A2 (en) * 1989-12-08 1991-06-12 Merck & Co. Inc. Nitrogen-containing spirocycles
EP0450761A1 (en) * 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclic oxytocin antagonists
EP0518805A1 (en) * 1991-06-13 1992-12-16 H. Lundbeck A/S Piperidine derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) * 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
US4233307A (en) * 1978-02-13 1980-11-11 Sumitomo Chemical Company, Limited Spiro-4'-piperidine compounds and their pharmaceutical compositions
EP0360390A1 (en) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
EP0431943A2 (en) * 1989-12-08 1991-06-12 Merck & Co. Inc. Nitrogen-containing spirocycles
EP0450761A1 (en) * 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclic oxytocin antagonists
EP0518805A1 (en) * 1991-06-13 1992-12-16 H. Lundbeck A/S Piperidine derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 110, no. 21, 1989, Columbus, Ohio, US; abstract no. 193172d, S. MISZTAL ET AL.: "Synthesis of 1-spiropiperidino-1,2,3,4-tetrahydro-beta-carbolines and their transformation into new systems" page 786; *
CHEMICAL ABSTRACTS, vol. 90, no. 17, 1979, Columbus, Ohio, US; abstract no. 137699n, HOECHST: "Spiro[indoline-3,4-piperidine] compounds" page 503; *
F.E.C.S. INT. CONF. CHEM. BIOTECHNOL. BIOL. ACT. NAT. PROD., [PROC.], 3RD 1985 (PUB. 1987) 4, 145-7 *
H.H. ONG ET AL.: "Novel tetracyclic spiropiperidines", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 18, 1981, PROVO US, pages 815 - 820 *

Cited By (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
US5705505A (en) * 1993-12-15 1998-01-06 Zeneca Limited Cyclic amide derivatives for treating asthma
EP0758238A4 (en) * 1994-04-26 1997-09-03 Merck & Co Inc Spiro-substituted azacycles as neurokinin-3 antagonists
EP0758238A1 (en) * 1994-04-26 1997-02-19 Merck & Co. Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
US5635509A (en) * 1994-05-03 1997-06-03 Zeneca Limited Piperidine derivatives useful as neurokinin antagonists
US5739149A (en) * 1994-05-03 1998-04-14 Zeneca Limited Substituted piperidinobutyl nitrogen-containing heterocyclic compounds and analogues thereof as neurokinin antagonists
WO1996005203A1 (en) * 1994-08-08 1996-02-22 Merck Sharp & Dohme Limited Spiro-substituted azacyclic derivatives and their use as therapeutic agents
US5968923A (en) * 1994-08-09 1999-10-19 Pfizer Inc. (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
US5710169A (en) * 1994-10-25 1998-01-20 Zeneca Limited Therapeutic heterocycles
US6147083A (en) * 1994-10-25 2000-11-14 Zeneca Limited Azospiro compounds as NK1 or NK2 antagonists
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
JP2008138007A (en) * 1995-02-10 2008-06-19 Astrazeneca Uk Ltd 5-(4-substituted-piperidinyl-1)-3-aryl-pentanoic acid derivative as tachykinin receptor antagonist
WO1996024582A1 (en) * 1995-02-10 1996-08-15 Zeneca Limited 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
WO1996033189A1 (en) * 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
US6235757B1 (en) 1995-04-29 2001-05-22 Zeneca Limited Substituted heterocycles
US6355695B1 (en) 1995-04-29 2002-03-12 Zeneca Limited Substituted heterocycles
US5889024A (en) * 1995-04-29 1999-03-30 Zeneca Limited Substituted heterocycles
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5840725A (en) * 1995-05-02 1998-11-24 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5798359A (en) * 1995-05-02 1998-08-25 Schering Corporation Piperazino derivatives as neurokinin antagonists
CN1085661C (en) * 1995-06-06 2002-05-29 先灵公司 Piperidine derivatives as neurokinin antagonists
WO1996039386A1 (en) * 1995-06-06 1996-12-12 Schering Corporation Piperidine derivatives as neurokinin antagonists
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US5892039A (en) * 1995-08-31 1999-04-06 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
US5723616A (en) * 1995-10-27 1998-03-03 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US6090824A (en) * 1995-11-17 2000-07-18 Zeneca Limited Therapeutic neurokinin receptor antagonist compounds
WO1997019084A1 (en) * 1995-11-23 1997-05-29 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists
US6060469A (en) * 1995-11-23 2000-05-09 Merck Sharp & Dohme Ltd. Spiro-piperidine derivatives and their use as tachykinin antagonists
EP0776893A1 (en) 1995-12-01 1997-06-04 Sankyo Company Limited Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2
US6448247B1 (en) 1995-12-01 2002-09-10 Sankyo Company, Limited Method for treating an inflammatory disease
US6159967A (en) * 1995-12-01 2000-12-12 Sankyo Company, Limited Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use
US5885999A (en) * 1996-01-29 1999-03-23 Merck Sharp & Dohme Ltd. Serine derivatives and their use as therapeutic agents
WO1997030055A1 (en) * 1996-02-15 1997-08-21 Merck Sharp & Dohme Limited Spiro-ketal derivatives and their use as therapeutic agents
WO1997030056A1 (en) * 1996-02-15 1997-08-21 Merck Sharp & Dohme Limited Spiro-ketal derivatives and their use as therapeutic agents
US6127365A (en) * 1996-02-15 2000-10-03 Merck Sharp & Dohme Ltd. Spiro-ketal derivatives and their use as therapeutic agents
US6080740A (en) * 1996-02-15 2000-06-27 Merck Sharp & Dohme Ltd. Spiro-ketal derivatives and their use as therapeutic agents
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5691362A (en) * 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
WO1997049710A1 (en) * 1996-06-21 1997-12-31 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as therapeutic agents
US6071927A (en) * 1996-06-21 2000-06-06 Merck Sharp & Dohme Ltd. Spiro-piperidine derivatives and their use as therapeutic agents
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
WO1998018761A1 (en) * 1996-10-28 1998-05-07 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5945428A (en) * 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5783579A (en) * 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
WO1998028297A1 (en) * 1996-12-20 1998-07-02 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
US6362179B1 (en) 1997-05-30 2002-03-26 Sankyo Company, Limited Salts of an optically-active sulfoxide derivative
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6063926A (en) * 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
WO2000059873A1 (en) * 1999-04-06 2000-10-12 Astrazeneca Ab N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
US6476077B1 (en) 1999-04-06 2002-11-05 Astrazeneca Ab N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
US6586432B2 (en) 1999-04-06 2003-07-01 Astrazenela Ab Neurokinin-1 receptor antagonists
US6821973B2 (en) 1999-04-06 2004-11-23 Astrazeneca Ab Compounds
US6569872B1 (en) 2001-05-08 2003-05-27 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7138396B2 (en) 2001-09-06 2006-11-21 Schering Corporation 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7432268B2 (en) 2001-09-06 2008-10-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6903102B2 (en) 2001-09-06 2005-06-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6969718B2 (en) 2001-10-17 2005-11-29 Schering Corporation 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1880996A1 (en) 2002-06-14 2008-01-23 Syngenta Limited Spiroindolinepiperidine derivatives
US7247725B2 (en) * 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
US7091211B2 (en) 2003-07-31 2006-08-15 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US7276511B2 (en) 2003-07-31 2007-10-02 Zeria Pharmaceutical Co., Ltd. Benzylamine derivative
US8846907B2 (en) 2003-12-12 2014-09-30 Syngenta Crop Protection Llc Spiro-condensed indoline derivatives as pesticides
US8309567B2 (en) 2003-12-12 2012-11-13 Syngenta Crop Protection Llc Spiroindoline derivatives having insecticidal properties
US8299058B2 (en) 2003-12-12 2012-10-30 Syngenta Crop Protection Llc Spiro-condensed indoline derivatives as pesticides
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7279486B2 (en) 2004-03-29 2007-10-09 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
US7354925B2 (en) 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
US9085531B2 (en) 2004-07-15 2015-07-21 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8604200B2 (en) 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
KR101388453B1 (en) 2005-03-08 2014-04-23 얀센 파마슈티카 엔.브이. Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
JP2008532976A (en) * 2005-03-08 2008-08-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Diaza-spiro- [4.4] -nonane derivatives as neurokinin (NK1) antagonists
WO2006094948A1 (en) * 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
AU2006221984B2 (en) * 2005-03-08 2011-04-21 Janssen Pharmaceutica N.V. Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
EA014239B1 (en) * 2005-03-08 2010-10-29 Янссен Фармацевтика Н.В. Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
WO2007011820A2 (en) 2005-07-15 2007-01-25 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9403776B2 (en) 2005-07-15 2016-08-02 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007093827A1 (en) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US11096950B2 (en) 2006-11-01 2021-08-24 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945A1 (en) 2007-01-10 2014-11-26 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2336120A1 (en) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP3103791A1 (en) 2007-06-27 2016-12-14 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
KR20110015421A (en) * 2008-05-01 2011-02-15 글락소 웰컴 매뉴팩쳐링 피티이 엘티디 Spiro(piperidine-4,2'-pyrrolidine)-1-(3,5-trifluoromethylphenyl)methylcarboxamides as nk1 tachykinin receptor antagonists
US8633214B2 (en) 2008-05-01 2014-01-21 Nerre Therapeutics Limited Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as NK1 tachikynin receptor antagonists
WO2009133135A1 (en) 2008-05-01 2009-11-05 Glaxo Wellcome Manufacturing Pte Ltd Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists
AU2009242120B2 (en) * 2008-05-01 2012-05-24 Nerre Therapeutics Limited Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonists
US8367692B2 (en) 2008-05-01 2013-02-05 Glaxo Wellcome Manufacturing Pte Ltd Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonists
EA017960B1 (en) * 2008-05-01 2013-04-30 Глэксо Уэлкам Мэньюфэкчуринг Пте Лтд. 1,8-diazospiro[4,5]decane-8-carboxamide derivatives having antagonist activity against nk1 receptor
KR101645743B1 (en) 2008-05-01 2016-08-04 네르 쎄라퓨틱스 리미티드 Spiro(piperidine-4,2'-pyrrolidine)-1-(3,5-trifluoromethylphenyl)methylcarboxamides as nk1 tachykinin receptor antagonists
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010000073A1 (en) 2008-07-03 2010-01-07 Neuraxon, Inc. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
US9173879B2 (en) 2009-05-12 2015-11-03 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9604960B2 (en) 2009-05-12 2017-03-28 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US9598412B2 (en) 2010-02-05 2017-03-21 Intervet Inc. Spiroindoline compounds for use as anthelminthics
WO2011095581A1 (en) 2010-02-05 2011-08-11 Intervet International B.V. S piroindoline compounds for use as anthelminthi cs
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3327125A1 (en) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US10076510B2 (en) 2012-05-18 2018-09-18 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US11311504B2 (en) 2012-05-18 2022-04-26 Park Therapeutics, Inc. Pharmaceutical composition comprising (1R,4R)-6′- fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro [cyclohexane-1,1′-pyrano- [3,4,b ]indol] -4-amine and paracetamol or propacetamol
US10328055B2 (en) 2012-05-18 2019-06-25 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indo]-4-amine and antidepressants
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
CN107001369A (en) * 2014-11-21 2017-08-01 埃斯蒂文博士实验室股份有限公司 There are the piperidine compounds of spiral shell isoquinolin 1,4 ' of multi-mode activity for pain
US10407428B2 (en) 2014-11-21 2019-09-10 Esteve Pharmaceuticals, S.A. Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain
WO2016078770A1 (en) * 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Also Published As

Publication number Publication date
ZA943946B (en) 1995-01-20
IL109836A0 (en) 1994-08-26
EP0702681A1 (en) 1996-03-27
HRP940337A2 (en) 1997-04-30
JPH08511522A (en) 1996-12-03
AU7201194A (en) 1995-01-03
CA2163995A1 (en) 1994-12-22
AU680020B2 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
AU680020B2 (en) Spiro-substituted azacycles as neurokinin antagonists
US6013652A (en) Spiro-substituted azacycles as neurokinin antagonists
US5869496A (en) Spiro-substituted azacycles as tachykinin receptor antagonists
US5434158A (en) Spiro-substituted azacycles as neurokinin-3 antagonists
US5962462A (en) Spiro-substituted azacycles as modulators of chemokine receptor activity
US5604252A (en) Azanorbornane derivatives
EP1626958B1 (en) (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht 1f agonists
JP5328349B2 (en) Beta-lactamphenylalanine, cysteine, and serine vasopressin antagonist
JP4212112B2 (en) Non-peptidyl vasopressin V1a antagonist
WO1998025605A1 (en) Spiro-substituted azacycles as modulators of chemokine receptor activity
NZ551997A (en) Pyrrolidine and piperidine derivates as NK1 antagonists suitable for treating emesis and cough
KR20060127927A (en) Hydroisoindoline tachykinin receptor antagonists
JP2006522835A (en) Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
US5869489A (en) Trypthophan ureas as neurokinnin antagonists
CA2562138A1 (en) Fused ring nk1 antagonists
US11155538B2 (en) Bicyclic CX3CR1 receptor agonists
GB2311523A (en) Tryptophan urea tachykinin receptor antagonists
KR20030036834A (en) 5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis
CHENG et al. PYRROLIDINE AND PIPERIDINE DERIVATES AS NK1 ANTAGONISTS
Paliwal et al. NK 1 antagonists
CA2370241A1 (en) Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
MXPA06011715A (en) Fused ring nk1 antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CN CZ FI HU JP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SI SK TT UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995901979

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 553454

Country of ref document: US

Date of ref document: 19951127

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2163995

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1995901979

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1995901979

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995901979

Country of ref document: EP